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Non-melanoma skin cancers (NMSC) are the most common human malignancy. They 
can be divided into basal cell carcinomas (BCC) and cutaneous squamous cell 
carcinomas (cSCC), with the latter being responsible for the majority of NMSC 
deaths. Incidence rates for NMSC are rising due to increased exposure to UV 
radiation, caused by active sun-seeking behaviour and increased cumulative sun-
exposure in aging population. In addition to the general populations, there are high 
risk groups, such as organ transplant recipients, who are in urgent need for strategies 
to treat aggressive cSCC. 
Most animal models only partly reflect the complex genetic landscape of cSCC or 
leave out important parts of the carcinogenic process. We have developed a 
preclinical mouse model for cSCC by irradiating SKH-1 mice with low chronic doses 
of solar simulated UVR. The resulting tumors are remarkably similar to human cSCC 
in terms of histopathology and genetics. In this study, we provide a comprehensive 
analysis of global DNA methylation of this murine model and compare it to the 
methylome of human cSCC. We found that methylation changes in the murine cSCC 
tumors occur predominantly at regions of potential regulatory function, such as 
enhancers, promoters and intergenic regions of tumor suppressor genes that may be 
involved in regulation of gene expression or alternative splicing. Deactivation of 
tumor suppressor genes is an important feature for cancer, especially cSCC and our 
data suggest, that silencing of tumor suppressor genes by DNA methylation could be 
important in cSCC. Furthermore, we discovered differential methylation in the 
tumor suppressor gene Filamin A interacting protein 1 like (Filip1l). Down-regulation 
of the FILIP1L gene has been linked to ovarian, prostate and pancreatic cancer 
aggressiveness and metastatic potential and is an independent prognostic marker in 
ovarian cancer patients. The levels of Filip1l protein were significantly down-
regulated in murine cSCC as well as in 9 out of 15 tested human cSCC cell lines. 
Although the exact function of the FILIP1L protein is incompletely understood, the 
strongest evidence points to its regulation of β-catenin stability and therefore WNT 
signalling activity. We found evidence that FILIP1L may regulate WNT signalling in 
skin, although FILIP1L did not regulate proliferation of the human cSCC cell lines 
that we tested.     
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When we compared the methylome of human cSCC patients to the methylome of 
mouse cSCC, the general features of the DNA methylation were similar. For example, 
average methylation levels increased in a subset of human cSCC cases and the mouse 
tumors, an effect that has been previously reported for UV irradiated skin (both human 
and mouse). We identified 214 genes that have at least one differentially methylated 
CpG in our dataset. Using R and the Ensemble gene annotation, we identified 153 of 
these genes that had a human orthologue. Of these 153 genes, 150 (93%) were also 
differentially methylated in human cSCC. 
The remarkable similarities in histopathology, genetics and DNA methylation between 
human cSCC and the solar simulated UV induced mouse cSCC model suggest that 
this model could be advantageous over existing models and may provide new 
possibilities to investigate cSCC and develop new treatment strategies, especially for 
high risk groups. Furthermore, extending previous observations that most mutations 
in this tumor type occur not within oncogenes, but within tumor suppressor genes, our 
findings highlight the importance of inactivation of tumor suppressors (by both genetic 
















The primary energy source on earth is the sun. Despite some forms of life at deep sea 
vents that receive their energy by chemosynthesis from inorganic sources, all life on 
earth, directly or indirectly, depends on energy produced by plants or other 
photosynthetic organisms. Furthermore, most processes on our planet, e.g. wind, 
weather or oceanic streams, also are fuelled by the sun’s energy. 
Despite our dependence on solar energy and the beneficial effects of ultraviolet 
radiation (UVR) for e.g. vitamin D production and the mobilisation of nitric oxide 
from nitrate stores in skin, with consequent reduction in blood pressure [1,2], the sun’s 
UVR also possesses a major health risk. UVR that reaches the earth comprises of 95% 
UVA (315-400 nm) and 5% UVB (290-315 nm), while UVC wavelengths (100-
280 nm) are completely blocked by the ozone layer. Due to depletion of the 
stratospheric ozone, changes in our lifestyle that lead to increased exposure to UVR 
and longer life expectancy, skin cancer cases are increasing [3]. Since the early 90s, 
the incidence of melanoma has increased by 134% [4] and non-melanoma skin cancer 
cases have increased by 163% [5] in the UK. Although adequate protection against 
UVR, e.g. sunscreen or responsible habits when it comes to time spent in the sun, is 
undoubtedly the best protection against skin cancers, studies have shown that even in 
high-risk groups, awareness for these preventive measures is limited and programs to 
raise awareness do not have sufficient success [6]. 
Therefore, developing new strategies to prevent and treat skin cancers are urgently 
needed. To achieve this, it is necessary to fully understand all aspects of skin cancer 
biology and develop adequate animal models or other means to study this 
heterogeneous disease. The work described in this thesis, aims to analyse the global 
DNA methylation landscape of cutaneous squamous cell carcinoma (cSCC) in 




1.1 Structure of the human skin 
With 1.5 to 2 m2 in adults, the skin is one of  the largest human organs and covers the 
whole body [7,8]. Its primary function is to protect the underlying structures from 
injury, dehydration, chemicals and invasion by harmful organisms. The skin also has 
an important role as a sensory organ, as it is covered with sensory nerve ends and is 
the part of our body that is in contact with our surrounding. Furthermore, the skin is 
responsible for thermoregulation by both, protecting the body from heat and heat loss, 
as well as regulating the body temperature by producing sweat.  
The skin also serves as protection against ultraviolet radiation. Structural aberrations 
that are sometimes precursors for cancer, can therefore often be found at areas of high 
sun exposure. These areas include the face, hands, neck, forearms, forehead and the 
scalp [9,10].  
The skin structure can be broken down into the epidermis, the most superficial layer, 
the dermis, and subcutaneous tissue.  
The subcutaneous tissue, or hypodermis, is the deepest layer of the skin, dividing the 
dermis and the underlaying muscle tissue. It mostly consists of adipocytes, that not 
only serve as an energy reservoir, but also as a protective layer against heat loss and 
mechanical injury [11]. 
The dermis gives the skin its elastic and tough features. The main cells are fibroblasts, 
which extracellular matrices contain collagen fibres that bind water. Other structures 
in the dermis include blood vessels, sensory nerve endings, hairs and arrector pili 
muscles and sweat glands. 
The most outer layer of the skin is the epidermis (Figure 1). It mainly consists of 
keratinocytes and melanocytes. It can be subdivided into for layers: the basal layer, 
the spinal layer, the stratum granulosum and the stratum corneum. The epidermis does 
not harbour any blood vessels. Instead, its layers are constantly supplied with oxygen 
and nutrients by intestinal fluid from the dermis, that drains away as lymph. The basal 
germinative layer consists of undifferentiated basal keratinocytes and constantly 
spawns epithelial cells that gradually undergo differentiation as they move up as 
epidermal layers or strata. When basal keratinocytes differentiate, they move upwards 
to the spinal layer. Here, they change shape and begin producing their defining 
proteins, the keratins. When keratinocytes move further up to the stratum granulosum, 
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they become granulated as they produce keratohyalin granules. These keratohyalin 
granules are filled with proteins that are rich in histidine and cysteine and bind keratin 
filaments together [12,13]. Reaching their final differentiation stage in the stratum 
corneum, keratinocytes become flat and thin. At this point, they are dead, have lost 
their nuclei and are called squames. Their cytoplasm has been replaced with keratin. 
These cells are constantly rubbed off by wear and tear. Within a month, humans 
completely renew their epidermis [9,14].  
 
Figure 1: Structure of the epidermis. The basal layer is formed of the basal keratinocytes, which 
have stem cell like properties and give rise to all keratinocytes. When basal keratinocytes divide, the 
daughter cells move upwards in the spinous cell layer and begin to differentiate. As they move 
upwards, their maturation continues, and they adapt a flattened shape and form keratohyalin granules 
in the stratum granulosum. Keratinocytes end their maturation process in the stratum corneum. 
Here, cells are dead, have lost their nuclei and their cytoplasm is substituted with keratin fibres. 
Constant wear and tear sheds of the stratum corneum and new keratinocytes move upwards to replace 
it. The basal cell layer also contains melanocytes. These cells produce the pigment melanin, which 
protects the skin from UV radiation and gives hair its colour. Langerhans cells are dendritic cells in 
the spinous cell layer that phagocytose pathogens that invade the skin. They then travel to nearby lymph 




As all keratinocytes are derived from the basal layer of the epidermis, the proliferative 
potential of these basal cells must be maintained throughout life. Furthermore, 
keratinocytes must express a distinct set of keratins during their differentiation process 
to ensure normal skin formation. In basal keratinocytes, expression of Keratin 5 and 
14 (K5, K14) as well as their proliferative potential is maintained by Tp63 gene 
expression. This member of the p53 family inhibits expression of cyclin-dependant 
kinase inhibitor 1 (p21) and therefore allows proliferation [15]. When keratinocytes 
move up to the spinous cell layer, the activation of Notch signalling represses p63 
activity and keratinocyte differentiation and cell cycle arrest are initiated [16–18]. 
Additionally, Notch regulates expression of specific keratins (e.g. K14) as well as 
loricrin and filaggrin.  
The progressing differentiation stages of keratinocytes define the layers of the 
epidermis. Basal keratinocytes express K5 and K14, while keratinocytes in the spinal 
layer express K1 and K10. When they further differentiate, keratohyalin granules are 
formed and cells adopt a flattened shape, a characteristic feature of the corneocytes. 
These cells are filled with keratins and eventually lose their nucleus to form the 
stratum coronium. Aberrant regulation of this process can lead to abnormal growth of 




1.2 Cancers of the human skin 
Cancers of the human skin can be divided into two general types: melanoma and non-
melanoma  skin cancer (NMSC, also called keratinocyte cancers). Skin cancers are 
the most common malignancy in Caucasians and their incidence is steadily rising. 
Over the past 50 years, melanoma cases in adults have risen by 0.6% annually, while 
the average rise of NMSC cases is 3-8% per year since the 1960s [21].  
The GLOBOCAN Global Cancer Statistics 2018 reported 1,042,056 new cases of 
NMSC worldwide (5.8% of all cancers) and 287,723 new cases of melanoma (1.6% 
of all cancers). While NMSC related deaths contributed to 0.7% of all cancer related 
deaths (65,155 deaths), the much rarer melanoma lead to almost the same number of 
deaths (60,712 deaths, 0.6% of all cancer related deaths). It is worth noting, that skin 
cancers, both melanoma and NMSC are over-represented in Oceania, where 
melanoma contributes to 6.9% of the new cancer cases (compared with 1.6% 
worldwide) and NMSC accounts for 28.1% of new cancer cases (compared with 5.8% 
worldwide). But NMSC are also very common in North America (20.3% of new 
cancer cases) and Europe (7.5% of new cancer cases) [22,23]. However, these 
statistics may be biased, as some cancer registries, the basis for the GLOBOCAN 
statistics, do not adequately register NMSC [21,24,25].  
1.2.1 Skin cancer risk factors 
The risk for certain types of cancer is influenced by lifestyle factors. In 1761 the 
English physician John Hill discovered a correlation between excessive tobacco snuff 
and nasal cancer (despite this, tobacco companies denied a connection between 
tobacco consumption and cancer for another 200 years). A few years later, the London 
surgeon Percivall Pott noticed that there was a substantial number of skin cancers of 
the scrotum in men, who in their youth had been working as chimney sweeps. The 
evidence that certain cancers were more prevalent in certain groups of workers became 
more apparent and gave rise to occupational medicine. Examples include lung cancer 
in miners (later found to be caused by radiation from ores), breast cancer in nuns or 
increased rates of cancer in physicians and others, exposed to X-rays. The most 
compelling studies came in 1949 and 1950, when two groups of epidemiologists 




Solar radiation, especially UVR, is the most ubiquitous carcinogen in the world. For 
skin cancers, UVR is the main risk factor. UVR directly damages DNA, when 
energetic UVB (280-315 nm) give rise to pyrimidine dimers and other photoproducts, 
which cannot be appropriately repaired, leading to mutations [27]. Furthermore, UVR 
causes the formation of reactive oxygen species (ROS) as well as reactive nitrogen 
species (RNS) thus causing oxidative DNA damage, e.g. 8-hydroxy-
2’deoxyguanosine [28].  Additionally, UVR leads to immunosuppression, a known 
risk factor for NMSC [21]. The skin has a build-in defence against UVR. The 
melanocytes produce a dark pigment, melanin, which is synthesised from the amino 
acid tyrosine. Melanin absorbs UVR and protects against its harmful effects [14]. 
Risk factors for cutaneous squamous cell carcinoma will be discussed in more detail 
in Section 1.2.3.2. 
1.2.2 Melanoma 
While the majority of skin cancers are NMSCs, melanomas have a much higher 
mortality rate. In 2018, worldwide there were 5 times more NMSC than melanoma 
cases, while the deaths related to both skin cancer types were almost the same [22]. 
Melanoma’s cells of origin are melanocytes, cells that can be found in the basal 
epidermis, hair follicles, in the choroidal layer of the eye and at mucosal surfaces. 
They express melanocortin receptor 1 (MC1R) and produce and release melanin after 
stimulation by melanocyte stimulating hormone (MSH). MSH is produced by 
keratinocytes in response to UVR and subsequent DNA damage [29,30].  
As for all types of skin cancer, UVR is the primary carcinogen contributing to 
melanoma development. In Caucasians, melanoma arising at chronically sun-exposed 
areas (e.g. the head and neck), are often diagnosed in middle age and older patients 
(>55 years of age). The main genetic drivers in melanoma are B-Raf proto-oncogene 
(BRAF), neurofibromin (NF1) and NRAS mutations, but melanomas also bear a high 
mutation burden. Melanoma in younger patients (<55 years of age), often arise at 
intermediately sun-exposed areas (e.g. the trunk and proximal extremities) and usually 
bear the BRAFV600E mutation and a lower overall mutation load [31–33]. 
Interestingly, 80% of benign melanoma precursors, have a BRAF mutation, that only 
results in limited melanocyte proliferation, pointing towards the need for additional 
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driver mutations (usually CDKN2A or TERT). Melanoma development clearly does 
not follow a singular evolutionary pattern [34–40]. 
Melanomas are one of the most aggressive types of skin cancer. In contrast to most 
NMSCs, melanoma often possess a high metastatic potential. This is due to gene 
mutations, that favour the invasion of adjacent tissues and a tumor microenvironment, 
which facilitates such infiltration. A key player in melanoma invasion are matrix 
metalloproteases (MMPs), particularly MMP-9 and MMP-2. These MMPs cleave 
proteins of the extracellular matrix and therefore allow tumor cells to enter the 
bloodstream [41–43].  
The majority of melanoma (up to 90%) harbour mutations that lead to aberrant 
mitogen-activated protein kinase (MAPK) activation and subsequent cell cycle 
deregulation and limited apoptotic potential. This common feature has led to new 
treatment options: tyrosine kinase inhibitors and immune checkpoint inhibitors. In 
fact, melanoma survival has increased by 22% in England and Wales over the past 40 
years (from 75% to 97%) [44]. 
Biomarkers for melanoma therapy response or detection of tumor-derived circulating 
cell-free DNA (ctDNA) specific to melanoma (liquid biopsy) are being developed, but 
the best “treatment” for melanoma certainly is prevention. Cancer Research UK states, 
that 86% of melanoma in the UK are caused by overexposure to UVR and therefore 
are preventable [45].  
1.2.3 Non-melanoma skin cancers 
Non-melanoma skin cancers (NMSC), also known as keratinocyte skin cancers, 
represent the most common type of skin cancer in humans. As their name suggests, 
the progenitor cells for keratinocyte skin cancer are keratinocytes. NMSCs are the 
most common human malignancy, with the highest incidence in Australia, where there 
are more than 1000 cases per 100,000 person-years [3]. Depletion of stratospheric 
ozone, increased exposure to solar radiation and longer life expectancy has led to an 
increase in NMSC incidence. Cancer Research UK states, that NMSC incidence has 
increased by 147% since the early 1990s and by 59% in the past decade alone. 
Although NMSCs have a relatively low mortality rate, accounting for less than 1% of 
cancer-related deaths, in 2016 there were around 950 NMSC-related deaths in the UK 
and NMSC is among the 20 most common causes of death from cancer [46].  
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In general, NMSC are treatable and mostly, lesions can be easily removed by various 
techniques (curettage, electrodisection, cryotherapy, Mohs surgery of standard 
surgical excision) with cure rates as high as 96%. However, most of these therapies 
are associated with high morbidity and reduced quality of life. Treatments for NMSC 
are discussed in Section 1.2.3.5. 
The vast majority (99%) of NMSC can be further divided into two subgroups: basal 
cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), with a ratio of 
80:20 between BCC and cSCC. 
1.2.3.1 Basal Cell Carcinoma 
While Basal Cell Carcinoma (BCC) typically is slow growing and has a low rate of 
metastasis and seldom causes death but can be destructive and disfiguring locally. 
BCC is most common in Caucasians and elderly people [47–49], but incidences are 
on the rise, especially among younger females (likely due to increased tanning 
behaviours, both naturally and in tanning salons) [50,51]. 
The main pathological event in BCC genetics is upregulation of hedgehog (HH) 
signaling, a pathway involved in development, stem cell maintenance as well as tissue 
repair and regeneration. Inactivation or loss of Protein patched homolog 1 (PTCH1) 
function is a feature of over 90% of BCCs as well as activating Smoothened (SMO) 
mutations. Other relevant mutations in BCC include TP53, Ras family members, 
NOTCH 1 and 2 as well as mutations in the telomerase reverse transcriptase (TERT) 
promoter (summarized in [49]). 
As this thesis is focussing on the other form of NMSC, cutaneous squamous cell 
carcinoma, BCC will not be discussed further. 
1.2.3.2 Cutaneous Squamous Cell Carcinoma 
The precursor lesion of cutaneous Squamous Cell Carcinoma (cSCC) is actinic 
keratosis (AK). AKs appear as single or multiple lesions on sun exposed skin, 
especially the forehead, hairless scalp areas, the nose and ears, cheeks, bottom lip as 
well as forearms and the back of the hand. Men are more likely to get AK than women, 
and incidences are higher in elderly people [52]. People that are highly exposed to 
sunlight, are more likely to develop AK (e.g. people working outdoors). Chronically 
immunosuppressed individuals are also at high risk. AKs greatly vary in size (between 
1 mm and 2.5 cm) and can either be the same colour as the skin (in these cases they 
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are easier felt than seen), reddish or brownish and can have white keratosis or yellow 
encrustation. Histologically characteristic for AK are atypical (sometimes mitotic) 
keratinocytes with enlarged, hyperchromatic or pleomorphic nuclei. In contrast to 
cSCC, AK is clearly demarcated from normal epidermis [53,54]. 
Cutaneous SCC is a malignant epithelial tumor with keratinocytic diffentiation. 
Premalignant forms often only present as hyperkaratinic plaques but if they proliferate 
unchecked, the plaques become thicker, erode and can ulcerate. Ulcerating cSCC also 
tend to have bacterial superinfections. Especially for elderly people, returning 
bleeding or secretion rather than the, often slowly growing, tumors are the reason to 
consult a dermatologist. Although cSCC is mostly known as a disease of elderly 
people, genetic prepositions or extensive exposure to UVR can lead to the 
development of these tumors in younger individuals (for risk factors see Section 
1.2.3.2.1). For people that are highly sensitive to UVR (e.g. Xeroderma pigmentosum 
or albinism), cSCC even may develop in childhood [53,54].  
Cutaneous SCC accounts for roughly 20% of all NMSC cases. In contrast to BCC, 
cSCC carry a substantial risk for metastasis with an annual incidence of 4% and 
accounts for the majority of metastasis related deaths [21].  
While cure rates for localized cSCC are as high as 96% when appropriately treated 
(mostly by excision of the affected area), locoregional and metastatic cSCC have a 
dismal prognosis at more advanced stages, with 5-year survival rates below 30%. 
Metastasis of cSCC occurs in 85% of cases in regional lymph nodes and 15% of cases 
in more distant locations (e.g. lungs, liver, brain, skin or bone). The ten-year survival 
chances for patients with lymph node metastases are 20% and only 10% for patients 
with distant metastasis [21]. 
1.2.3.2.1 Risk factors for cutaneous squamous cell carcinoma 
The main risk factor for cSCC is exposure to UVR. This leads to a very high mutation 
burden with as much as 1 mutation per 30 kb of coding sequence, making cSCC the 
most mutated cancer type [55]. The vast majority of these mutations are “UV-
signature mutations”, i.e., G to A or C to T transitions, which makes G- and C-rich 
genes more likely to become mutated [56]. Known driver mutations in cSCC are TP53 
(90% of cSCC, early event), NOTCH (75%), CDKN2A (50% with additional 
epigenetic inactivation) and TGF-β. Interestingly, Ras mutations are relatively 
40 
 
uncommon [57,58]. This is particularly notable when considering that the most 
commonly used chemically- and genetically-induced mouse models for cSCC are 
often Ras driven [59,60]. 
Although UVR is the main carcinogen leading to development of NMSC, other risk 
factors include exposure to arsenic, tar or certain polycyclic aromatic substances. 
Cutaneous SCCs may also develop in areas of radiodermatitis and on keratoses caused 
by X-rays or arsenic [54]. 
Furthermore, infection with human papilloma viruses (HPV) is associated with cSCC 
[54] and HPV DNA can be detected in 30%-60% of cSCC of immunocompetent 
patients. Interestingly, the prevalence of HPV infections is even higher in AK (up to 
93%) and can reach 100% in immunosuppressed individuals, which indicates the 
crucial role of the immune system in preventing cSCC [61–65]. It has been proposed, 
that vaccination against HPV types associated with cSCC may be an efficient 
prevention strategy, as it has been demonstrated for HPV types causing cervical cancer 
[66–68]. 
Especially for high risk groups, cSCC represents a significant problem. Individuals, 
who are genetically predisposed, immunosuppressed patients and/or those receiving 
thiopurine therapies or people living in high-risk areas (e.g. Oceania) are all more 
likely to develop cSCC. Solid organ transplant recipients (SOTRs) for example, have 
a greatly increased risk (60 to 200-fold compared to the general population) to develop 
cSCC [69]. This risk increases with the duration of immunosuppression and decreases 
if immunosuppression is terminated. Conventional means of treating cSCC are also 
only partially successful as lesions are multiple, span large areas and frequently 
relapse [70,71]. In a single patient, more than 100 lesions may develop in one year 
and are likely to metastasize [3,72,73]. 
In the US, the incidence ratios of cSCC are estimated at 1,355 per 100,000 person-
years in SOTRs, while this number is only 38 per 100,000 person-years in the general 
population. The National Cancer Institute states that the incidence rate for cSCC in 
SOTRs is nearly 5 times that of all other cancers combined and that additional risk 
factors include age at transplantation, duration of immunosuppressive therapy, skin 
type, gender and the transplanted organ [74]. Other diseases, which are treated with 
immunosuppressive drugs, such as inflammatory bowel disease, autoimmune diseases 
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or rheumatic arthritis, carry an increased risk for development of cSCC [75–77]. 
Diseases associated with acquired immunodeficiency, like HIV/AIDS or leukaemia, 
also show higher incidence rates of cSCC. For HIV infected individuals, adequate 
therapy with antiretroviral medication may reduce cSCC risk [78], but in chronic 
lymphatic leukaemia (CLL), cSCC prognosis is worse with increased rates of 
metastasis and recurrence [79,80].  
How exactly the innate and acquired immunodeficiency causes such a massive 
increase in cSCC risk is not entirely clear. It is likely, that in immunosuppressed 
individuals, tumor surveillance is impaired and these individuals are more susceptible 
to HPV infection. Furthermore, certain immunosuppressive drugs themselves can 
have carcinogenic effects and are likely to add to the already elevated risk [3]. 
Thiopurines, especially azathioprine, cause enhanced UVA sensitivity and UVA-
induced DNA damage as well as an increase in mutations caused by UVB due to 
reduced UVB-induced DNA damage repair [81,82]. Interestingly, there is a specific 
azathioprine-associated mutation signature in cSCC [83]. Another 
immunosuppressant, cyclosporin, reduces UVR-induced DNA damage repair and 
apoptosis, as well as ATF3 induction and suppression of senescence via p53 [84,85]. 
Other drugs used in transplantation or treatment of immune diseases may also 
contribute to cSCC risk, but due to limited data available, the evidence is not 
conclusive [86–88]. 
In addition to mutations, epigenetic alterations are considered one of the hallmarks of 






Figure 2: The effect of UV radiation (UVR) on the human skin. UVR can damage the DNA of skin 
cells. In cells with p53 wild type (WT), DNA damage is repaired, or cells undergo apoptosis if the 
damage is too severe to be repaired. Cells with p53 mutations do not undergo apoptosis and allow 
damaged cells to grow abnormally leading to the development of cancer. Figure adapted from Alam 




1.2.3.3 Cutaneous squamous cell carcinoma genetics 
As mentioned previously, cSCC is the most mutated human cancer. The sheer amount 
of mutations makes is challenging to identify driver mutations of cSCC. Chromosomal 
aberrations and copy number alterations show cSCC’s genomic instability and create 
a complex molecular landscape. Furthermore, a mutation burden similar to the one 
seen in many cancers and genes that are considered driver mutations in cSCC are also 
present in keratinocyte clones in skin that appears to be completely normal [56]. 
The vast majority of mutations in cSCC are “UV-signature mutations”, i.e., G to A or 
C to T transitions, which makes G and C rich genes more likely to undergo mutations 
[56,57,59]. The tumor suppressor gene TP53, encoding the protein p53, is frequently 
mutated in human cSCC. TP53 mutations are considered and early event in cSCC 
development and interestingly, these mutations do also exist in normal-appearing skin 
[95,96]. Furthermore, TP53 mutations are  more frequent in metastatic cSCC (85%) 
compared to non-metastatic cSCC (54%) [97]. Up to 70% of TP53 mutations in cSCC 
can be attributed to UVR. Normally, UV induced DNA damage is repaired or, if the 
damage is too severe, cells enter apoptosis through p53 induced pathways. Cells with 
TP53 mutations not only have a proliferative advantage [98], they furthermore cannot 
enter these apoptotic pathways and may give rise to cSCC [99] (see Figure 2).  
The KMT2D encodes for the Lysine Methyltransferase 2D and is one of the most 
frequently mutated genes in cancer, especially epithelial cancers [100] including cSCC 
where KMT2D is mutated in 69.2% of cases [101]. KMT2D has been shown to with 
p63 and loss of KMT2D is associated with reduced p63 target gene expression, likely 
due to a global loss of enhancer histone marks [100]. 
In skin, NOTCH receptors are important for stemness and promote epidermal 
differentiation, thereby inhibiting skin tumorigenesis. NOTCH1 and NOTCH2 are 
mutated in 75% of human cSCCs [57,58,96]. In the canonical NOTCH signalling 
pathway, NOTCH ligand binds to the NOTCH receptor on the cell surface. Binding 
leads to cleavage of the NOTCH intracellular domain (NICD) from the receptor by 
ADAM protease. The NICD then translocate to the nucleus and activates transcription. 
Inhibition of NOTCH signalling promotes keratinocyte-dependant cSCC formation 
and NOTCH signalling is down-regulated in cSCC [102,103].  
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The CDKN2A locus encodes for the p16INK4a and p14ARF tumor suppressor genes. 
UVR can lead to mutations in sporadic cSCC and BCC, as well as cSCCs that develop 
in patients with xeroderma pigmentosa (these patient have severe defects in nucleotide 
excision repair (NER) proteins and are extremely sensitive to UVR) [104–107]. 
Additionally, CDKN2A genes are frequently silenced by promoter hypermethylation 
in cSCC [108]. Transforming growth factor beta (TGF-β) possesses a tumor 
suppressor role in skin and can also be mutated in cSCC [109,110]. Ras mutations are 
relatively uncommon in cSCC [57,58]. This is particularly interesting when 
considering that chemically and genetically induced models for cSCC are often Ras 
driven [59,60] (models for cSCC will be further discussed in  Section 1.2.3.6). 
 
Table 1: Mutation rates of genes in aggressive cSCC according to Pickering et al. 2014 [101]. 
Mutations in TP53 are present in the majority of cSCCs. KMT2D, NOTCH 1 and 2 and CDKN2A are 
also frequently mutated. Activating RAS mutations are relatively uncommon. 
 
Pickering et al. 2014 [n=39] 
 
n % 
TP53 37 94.90% 
KMT2D 27 69.20% 
NOTCH1 23 59.00% 
NOTCH2 20 51.30% 
CDKN2A 17 43.60% 
HRAS 8 20.50% 
NRAS 2 5.10% 
 
Depending on the type and frequency of genomic aberrations, cancer genomes can be 
classified into different mutation signatures. These signatures can help to identify 
cancers into different subtypes (see https://cancer.sanger.ac.uk/cosmic/signatures) 
[111,112]. Interestingly, a novel mutation signature has been identified in human 
cSCC from patients, that received the immunosuppressive drug azathioprine [83]. This 
again highlights the profound effect of azathioprine on cSCC development and the 





1.2.3.4 Cutaneous squamous cell carcinoma pathology 
Commonly, cSCCs begin as asymptomatic small plaques or nodules. They can enlarge 
over time and become keratoachantoma-like, ulcerate, become necrotic or 
botryomycotic (a chronic granulomatous bacterial infection) [113,114]. cSCCs can be 
subdivided into the following subtypes: 
Verrucous cSCC [113,114]:  
• Well-defined, exophytic, cauliflower like growth 
• Locally invasive 
• Low metastatic potential 
Spindle cSCC [113–115]: 
• Relatively rare but highly aggressive 
• Arising from sun-exposed sites 
• Not always keratinocyte differentiation 
• Positive staining for cytokeratins and epithelial membrane antigen 
Desmoplastic cSCC [113,114,116]: 
• High infiltrative growth 
• Often perineural or perivascular  
• High amounts of stroma and narrow cord cells 
• High risk for perineural invasion, metastasis and recurrence 
Acantholytic cSCC [114,117]: 
• Intramural pseudo gland structures 
• Greater metastatic risk compared to common cSCC 
Adenosquamous cSCC [114,117]: 
• Expression of Keratin 7 
• Mucosecretory tubular structures 
46 
 
According to the TNM (Tumor, Nodes, Metastasis) system of the American Joint 
Committee of Cancer (AJCC), cSCC can be classified into four clinical stages (see 
Table 2 and Table 3) [114].  
Table 2: TNM classification of cSCC according to AJCC. 
 TUMOR 
TX  Primary tumour cannot be assessed  
TIS  Carcinoma in situ  
T1  Tumour <2 cm at largest horizontal width +0–1 high-risk feature  
T2  Tumour ≥2 cm but ≤ 4 cm at largest horizontal width +2–5 high-risk 
features or tumour >2 cm at largest horizontal width  
T3  Tumour ≥4 cm or minor bone erosion or perineural invasion or deep invasion   
T4A  Tumour with gross cortical bone/marrow invasion  
T4B  Tumour skull base invasion and/or skull base foramen involvement  
 Lymph nodes metastasis  
NX  Regional lymph nodes cannot be assessed  
N0  No regional lymph node metastases  
N1  Metastasis in a single ipsilateral lymph node, ⩽3 cm in greatest dimension and 
ENE  
(-)  
N2A  Metastasis ipsilateral lymph node larger than 3 cm but no larger than 6 cm in 
greatest dimension and ENE (-)   
N2B  Metastases in multiple ipsilateral lymph node, none larger than 6 cm in greatest 
dimension and ENE (-)  
N2C  Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in 
greatest dimension and ENE (-)  
N3A  Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-)  
N3B  Metastasis in any node(s) and ENE (+)  
 Distant metastasis  
M0  No distant metastases  





Table 3: Clinical stages of cSCC according to AJCC. 
 CLINICAL STAGES   
STAGE 0 Tis  N0  M0  
STAGE I T1  N0  M0  
STAGE II T2  N0  M0  
 
STAGE III  
T3  N0  M0  
T1  N1  M0  
T2  N1  M0  
T3  N1  M0  
 
 
STAGE IV  
T1  N2  M0  
T2  N2  M0  
T3  N2  M0  
Every T  N3  M0  
T4  Every N  M0  
Every T  Every N  M1  
 
1.2.3.5 Cutaneous squamous cell carcinoma treatment 
Treatment of locally confined cSCCs normally involves surgical excision of the 
affected area. The vast majority (approximately 96%) of cSCCs are curable by this 
method. However, the remaining 4% can metastasize and have 3-year survival rate of 
56% and a 5-year survival rate of just 25-35% [118]. 
Normally, complete excision is performed, and methods have been developed (such 
as Mohs microscopical surgery) to allow histopathological control of the tumor type 
and complete excision. Excision margins should be adapted to the tumor size and 
aggressiveness [119]. Surgery can also be combined with plastic reconstruction [120]. 
Surgery has a lower chance of cSCC recurrence than other techniques, including 
curettage, cryotherapy, radiotherapy or photodynamic therapy [120]. Radiotherapy 
can be used as a complementation therapy to surgery, especially when complete 
excision of the affected area is unsuccessful or not possible [121]. However, especially 
in immunosuppressed patients, radiotherapy can lead to the formation of new tumors 
and should therefore only be applied in immunosuppressed patients with short life 
expectancy [114]. Furthermore, a higher rate of metastasis has been observed for 
verrucous cSCCs treated by radiotherapy [114]. If cSCC has spread to lymph nodes, 




Advanced cSCCs can be treated with chemotherapy. Especially platinum-based drugs, 
5-floururacil, gemcitabine and methotrexate show good initial responses in 
approximately 80% of cases. However, very few tumors respond to these drugs for 
longer periods of time, so that chemotherapy is mostly palliative [122–125]. 
Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR) 
in recent years has been used for treatment of advanced cSCCs. Although efficacy is 
good, severe side-effects limit cetuximab’s potential [126,127]. EGFR inhibitors have 
response rates that vary from 31 to 69% and are an additional option for advanced 
cSCC treatment [3,128]. 
A combination therapy with 13-cis-retinoic acid, Interferon-α (IFN-α) and cisplatin 
shows a response rate of 34% for patients with advanced cSCC, with 17% of patients 
showing complete and 17% showing partial remission [129]. Furthermore, 90% of 
advanced local, but, inoperable, cSCCs and 23% of patients with distant metastasis 
respond positively to the combination of 13-cis-retinoic acid and IFN-α [130]. 
1.2.3.6 Modelling Cutaneous squamous cell carcinoma 
cSCC is a common malignancy, and therefore it is crucial to have adequate models to 
investigate this type of cancer. Patient samples are readily available, but intervention 
studies in humans are not feasible, as cSCCs can take decades to develop. Animal 
models are essential to test candidate agents for prevention in a manageable timespan. 
Because of the high mutation burden, modelling cSCC is challenging. 
A commonly used skin carcinogenesis model is Harvey-Ras (HrasQ61L) driven 
formation of papilloma. This is induced by topical administration of the carcinogen 
7,12-dimethylbenz[a]anthracene (DMBA), followed by chronic application of the 
tumor promoter 12-O-tetradecanoylphorbal-13-acetate (TPA). The resulting mouse 
tumors (90%) have driver mutations in Hras, Kras or Rras2, with the characteristic 
DMBA/TPA mutation signature (A>T and G>T transversions) [131,132]. Other 
mutations in those tumors have a different mutation signature, suggesting that these 
mutations occur at later time points during tumor development [131]. The 
DMBA/TPA model is an excellent model for Ras driven tumors, but in contrast to 
human cSCC, skin tumors produced by the DMBA/TPA model, do not carry the broad 
spectrum of mutated genes or the extraordinarily high number of mutations, with an 
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average of 5.2 mutations per Mb [132] compared to 30 to 50 mutations per Mb [58] 
for the human tumours  and therefore do not adequately reflect the human disease.  
 
Figure 3: Emission spectrum of UVA-340 lamps. A: Emission spectrum of UVA-340 lamps 
compared to sunlight according to the lamp manufacturer (Q-Labs). B: Emission spectrum of UVA-
340 lamps as measured in our lab [60]. UVA-340 lamps are the best available simulation of sunlight 
in the critical UV region. 
Another way to reliably produce skin tumors in mice is exposure to UVB radiation. 
UVB however, only comprises 5% of the solar UVR that reaches the surface of the 
earth. Undoubtedly, UVB is more carcinogenic, but 95% of the solar UVR is UVA 
and is not accounted for in this model. Especially for high risk populations, the UVA 
component is highly relevant. This includes patients that receive life-long 
immunosuppressive or anti-inflammatory therapy (e.g. SOTRs or patients with 
inflammatory bowel disease). Thiopurine (administered as immunosuppressive drugs) 
metabolites are incorporated in the DNA of proliferating skin cells and sensitize these 
cells particularly to UVA radiation damage [71,82,133,134]. These high-risk groups 
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are in dire need for strategies to prevent cSCC, as their risk to develop cSCC is 
approximately 100-fold higher compared to the general population. Models that solely 
use UVB may not fully display the molecular mechanisms that lead to tumor formation 
in these individuals. 
We previously developed a preclinical mouse model to overcome the limitation of the 
existing models for cSCC. The principal aim was to mimic human cSCC 
carcinogenesis and development. The hope was, that by subjecting mice to a very 
similar carcinogen (a combination of UVA and UVB) the resulting murine tumors 
would resemble the human disease. 
We therefore chose immunocompetent SKH-1 hairless mice and chronically and 
intermittently (2 times a week for 15 weeks) subjected them to suberythermal doses 
of solar-simulated UVR (ssUVR), consisting of both, UVA and UVB wavelengths 
with a similar spectrum compared to solar UVR (see Figure 3) [60]. UV irradiation is 
then discontinued, and mice are monitored. Essentially all mice develop skin tumors 
in the subsequent 15 to 20 weeks. Histological examination of the murine tumors 
revealed a spectrum of mouse cSCCs (mcSCCs) that is very similar to the spectrum 
of human cSCCs (hcSCCs), ranging from AK with no invasion, to AK with early 
dermal invasion and both, moderately to well differentiated cSCCs [60,135]. Tumors 
were also microdisected and isolated DNA was used for whole exome sequencing. 
With a median single nucleotide polymorphism (SNP) rate of 155 mutations per Mb, 
mutation burden was higher than in hcSCC. The majority (>78%) of mutations were 
C.G>T.A transitions, consistent with a UVR signature. Also consistent with hcSCCs, 
the most frequently mutated genes were Trp53 (83% of mcSCCs) as well as Notch 
(~55%) receptor family genes. Furthermore, the mutations in key driver genes were in 
similar positions in ssUV cSCC compared to human cSCC [59]. The similarities 
between mcSCC arising in our model and hcSCC in histology and genetics suggest, 
that this model is superior to the DMBA/TPA model, that produces papilloma, and 
may have advantages over models that only use UVB as the carcinogen. 
In this thesis, we aimed to further validate our ssUVR induced mouse model by 
investigating changes in global DNA methylation and comparing it to DNA 




1.3 Epigenetic regulation of gene expression and genome stability in 
normal and cancer cells 
In addition to mutations leading to constitutively active oncogenes or inactive tumor 
suppressor genes, epigenetic alterations have been demonstrated to play a crucial role 
in cancer development and progression. Epigenetic regulations are defined as 
heritable, but potentially reversible alterations that, in contrast to mutations, do not 
result in changes in the DNA sequence. Epigenetic mechanisms include: 
• DNA methylation, that can inactivate promoters, enhancers or other regulatory 
elements 
• histone tail modifications, packing the chromatin more or less tightly, therefore 
influencing DNA accessibility for transcription factors and the translational 
machinery 
• expression of micro RNAs (miRNAs) that control gene expression by RNA 
interference as well as long non-coding RNAs (lncRNAs) that can bind 
mRNAs and even carry out enzymatic functions 
The epigenetic regulation of gene expression is briefly summarized in Figure 4. DNA 
methylation, especially at promoter regions is recognised by methyl-CpG-binding 
domain containing proteins (MeCP). This class of proteins, depending on the cellular 
context and structure of the CpG island, can recruit DNA methyltransferases 
(DNMTs) and histone modifiers like histone deacetylases (HDAC) and histone 
methyltransferases (HMT). This in turn can further modify the epigenetic landscape 
of the region. Normally, CpG-dense promoter regions are unmethylated, while 
intragenic and repetitive elements are silenced by high methylation. Unmethylated 
promoters can bind transcription factors (TF) and activate transcription via RNA 
polymerase and co-activators. If these regions are methylated, TF binding is inhibited, 
and transcription of the gene is prohibited. Genes that are silenced by DNA 
methylation can be re-activated by ten-eleven-translocases (TET) that remove 
methyl-groups from DNA. DNA methylation and TET proteins will be discussed in 
greater detail in Sections 1.3.1 and 1.3.2. Gene expression is highly regulated by 
dynamic positioning of active (histone acetylation, H3K4me3) and repressive 
(H3K27me3) histone marks at promoter regions and regulatory elements. HDACs 
deacetylate, while HATs acetylate histone tails. Histone methyltransferases (HMTs) 
and their counterpart enhancer of zeste homolog 2 (EZH2) add or remove methylation 
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marks from histone tails. In cancer, EZH2 is often overexpressed and silences 
expression by H3K27 tri-methylation. Furthermore, micro RNAs (miRNA) genes 
underlay the same regulatory processes as other genes. miRNAs can inhibit gene 
expression by destroying mRNA transcripts via the RNA-induced silencing complex 
(RISC). miRNAs are further regulated by expression of the proteins that are 
responsible for their maturation and function. These components often are also 
regulated by epigenetic mechanisms (summarized in [89,90,136]). 
 
Figure 4:  Epigenetic regulation of gene expression. Further explanations are given in the text. 
Abbreviations: TF (Transcription factor), HDAC (histone deacetylase), HAT (histone acetyl 
transferase), HMT (Histone methyl transferase), HDM (Histone demethylase), DNMT (DNA methyl 
transferase), TET (ten-eleven-translocase), MeCP (methyl-CpG-binding domain containing protein), 
PRC2 (polycomb remodelling complex 2), EZH2 (enhancer of zeste homolog 2), Figure modified from 
Pudenz et al. 2014 [89]. 
1.3.1 DNA methylation 
DNA methylation was first discovered and therefore is the best studied of the three 
type of epigenetic modifications. DNA methylation occurs at the 5C position of 
cytosine (5-methyl-cytosine, 5mC) in the context of CG dinucleotides (CpG) but can 
also be observed outside of CpGs in a CHH or CHG context (where H is either an A, 
C or T) in embryonic stem cells and plants. The key writers of DNA methylation are 
DNA methyltransferases (DNMTs) 1, 3a and 3b as well as ten-eleven translocases 
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(TETs) 1, 2 and 3 (Figure 5).  While DMNT1 is responsible for maintaining the 
existing DNA methylation pattern after DNA replication, DNMT3a and 3b are 
involved in the de novo methylation of previously unmethylated regions. TET proteins 
convert 5mC to 5-hydroxomethyl cytosine (5hmC) and even further oxidize 5hmC to 
5-formyl cytosine (5fC) and 5-carboxy cytosine (5caC). TET proteins are responsible 
for DNA demethylation by either passive or active mechanisms [137–142]. 
In normal cells CpG dense regions (CpG islands) are often located at gene promoters 
as well as the untranslated region and exon 1 of genes. These CpG islands are often 
unmethylated and therefore allow active transcription. Approximately 6-8% of genes 
have hypermethylated promoter regions that silence these genes and maintain tissue-
specific gene expression. In contrast, hypomethylated promoters allow active gene 
transcription. Regions with low CpG contend are often found in repetitive sequences 
and are normally highly methylated. This contributes to genome stability by silencing 
endoparasitic sequences and transposons and therefore prevents chromosomal 
instability, translocations and gene disruption. Furthermore, methyl-CpG-binding 
domain containing proteins (MeCPs) can specifically bind to methylated DNA 
sequences and recruit co-repressors such as histone lysine methyl transferases (HMTs) 
and histone deacetylases (HDACs). If DNA methylation occurs at transcription factor 
(TF) binding sites, these sites may be protected from TF binding, therefore preventing 
or down-regulating transcription of certain genes [89–92]. 
In addition to their mutation profile, tumors have a distinct DNA methylation pattern 
that is different from the DNA methylation landscape in normal cells [90,143,144]. 
Global DNA hypomethylation in cancer cells contributes to genome instability and 
the expression of aberrant transcripts from repetitive sequences that contribute to 
chromosomal rearrangements, mitotic recombination and aneuploidy. Furthermore, 
loss of DNA methylation at gene promoter regions can activate expression of 
oncogenes, genes involved in DNA repair, cell proliferation, angiogenesis or 
migration associated genes that may contribute to metastasis [89,91,145]. Despite the 
general global DNA hypomethylation found in cancer, promoters of tumor suppressor 
genes are often hypermethylated and therefore silenced in cancer. Prominent tumor 
suppressors like retinoblastoma (Rb) [146,147], p16INK4a and Breast cancer type 1 
susceptibility protein (BRCA1) [148] have been shown to be silenced by promoter 
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hypermethylation in cancer and just like a mutation profile, different cancer types have 
a specific DNA methylation profile [91]. 
Interestingly, normally ubiquitously expressed housekeeping genes, can be silenced 
by promoter hypermethylation. Furthermore, promoters of tissue-specific genes can 
lose their hypermethylated state in cancer, therefore re-activating these previously 
silenced genes and contributing to cell de-diffentiation [90,91,149]. 
1.3.2 Mechanisms of DNA demethylation: Ten-eleven-translocases 
As discussed before, DNA methylation is a dynamic and reversible process. This 
means that cells need a mechanism by which they can convert methylated cytosines 
back to an unmethylated state. Although there is evidence that DNMT3a and 3b are 
able to convert 5hmC back to 5mC in vitro, it is still unknown if this occurs in vivo 
[150,151]. In 2009 the first member of the TET enzyme family, Tet1, was 
demonstrated to hydroxylate 5mC to 5hmC and shortly after, Tet2 and Tet3 were 
discovered and shown to carry out similar reactions [152–154].  
The three TET proteins contain a C-terminal catalytic domain with a cysteine rich 
region and a double-stranded β-helix. This catalytic domain is characteristic for the 
family of Fe(II) and 2-oxoglutarate (2-OG)-dependent dioxygenase superfamily and 
is responsible for binding two Fe(II)-ions and 2-OG that are required as co-factors for 
the reaction. Tet1 and Tet3 further contain an N-terminal CXXC zinc finger domain 
(~ 60 AA) that has high affinity for clusters of unmethylated CpGs. Tet2 has lost its 
CXXC domain but interestingly the domain still exists as the separate gene CXXC4, 
suggesting that Tet2 lost this part of the gene during evolution. CXXC4 negatively 
regulates Tet2 by caspase-mediated cleavage and is also a reported inhibitor of WNT 





Figure 5: Conversion reactions carried out by DNMTs and TETs as well as mechanisms of DNA 
demethylation. Cytosine is methylated at the 5C position by DNMT enzymes. Methylated Cytosines 
can be demethylated by various mechanisms. TET proteins oxidize methylated Cytosines in multiple 
steps from 5hmC to 5fC to 5caC. These oxidize methyl Cytosines are not recognised by DNMTs during 
cell division leading to passive DNA demethylation. Active forms of DNA demethylation include 
removal of 5fC and 5caC by TDG and the BER as well as proposed mechanisms (dotted lines). 5mC: 
5-methyl-Cytosine, 5hmC: 5-hydroxymethyl-Cytosine, 5fC: 5-formyl-Cytosine, 5caC: 5-carboxyl-
Cytosine, 5hmU: 5-hydroxymethyl-Uracile. DNMT: DNA methyl transferase, TET: Ten-eleven 
translocase, TDG: thymine DNA glycosylase, BER: base excision repair, AID: activation induced 
deaminase, APOBEC: apolipoprotein B mRNA editing enzyme complex, SMUG1: Single-strand 
selective monofunctional uracil DNA glycosylase. Figure adapted from Pastor et al. 2013 [141]. 
The TET proteins are the counterparts of DNMTs. First, 5hmC is not recognized by 
some MeCPs, therefore reversing the normally inhibitory effect of DNA methylation. 
Other DNA binding proteins on the other hand are specifically recruited by 5hmC and 
recruit chromatin remodelling factors, suggesting that 5hmC might be an epigenetic 
mark on its own. Furthermore, the maintenance DNA methylase DNMT1, that 
methylates the newly synthesized DNA strand after DNA replication, does not 
recognize 5hmC as methylated cytosine, therefore leading to passive DNA 
demethylation in proliferating cells. The content of 5hmC is highest in the brain, where 
the number of proliferating cells is relatively low. The process of passive DNA 
methylation is relatively slow but energy conserving, suggesting a role for 
demethylation on a larger scale. Active DNA demethylation would provide a faster 
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and more precise mechanism. Besides being demonstrated, the importance and 
contribution of active DNA demethylation is still controversial. Active DNA 
demethylation mechanisms require further oxidation of 5hmC to 5fC and 5caC. 
Indeed, thymine DNA glycosylase (TDG) is able to excise 5fC and 5caC, therefore 
creating an abasic site that will be repaired, resulting in unmodified cytosine. 
Interestingly, TDG is faster in removing 5fC from 5fC:T base pairs that removing G:T 
mismatches and has virtually no activity on 5mC:T base pairs (reviewed in [138–
141]).  
Another active demethylation mechanism involves AID/APOBEC (activation induced 
deaminase, apolipoprotein B mRNA editing enzyme complex) mediated deamination 
of 5hmC that would produce 5-hydromexyl uracil (5hmU). This would result in a 
5hmU:T mismatch that could be repaired by base excision repair mechanisms, 
therefore restoring the normal, unmethylated C:T base pair. Indeed, DNA glycosylases 
(e.g. TDG and SMUG1) have robust activity for 5hmU:T mismatches and low activity 
for 5hmC:T base pairs [155]. In mammalian cells, 5hmU is not accumulating to 
detectable levels, suggesting that either the repair of 5hmU:T mismatches is extremely 
fast, or this pathway is only demethylating a minority of the methylated CpGs in 
mammals [156,157].  
The DNA demethylating mechanisms mentioned above are too complex to account 
for the large-scale demethylation that can be observed during certain stages of 
development. Wu and Zhang [158] proposed a simple mechanism that would require 
TET proteins to oxidize 5hmC further to 5fC or 5caC followed by decarboxylation, 
therefore restoring unmethylated cytosine. This would allow simple and fast, active 
large scale DNA demethylation, but the putative carboxylase has not yet been 
discovered [158].  
1.3.3 Studying DNA methylation 
Methods to study the DNA sequence are well established. Polymerase chain reaction 
(PCR) techniques are now being performed even at the school level. They are fast, 
inexpensive and easy, although they can be tricky for regions with a high degree of 
secondary structures. Sequencing has become fast, relatively inexpensive and reliable 
and is an integral part of biological research. However, conventional PCR and 
sequencing techniques are unable to distinguish between methylated and 
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unmethylated cytosine. A simple way to solve this problem is the use of sodium 
bisulfite (BS), a reagent that deaminates cytosine, therefore converting it into uracil 
that become thymines in subsequent PCR amplification. In contrast, 5mC (as well as 
the much rarer 5hmC) is resistant to bisulfite conversion. Bisulfite conversion-based 
methods are considered the gold standard of analysing DNA methylation [159]. 
By using bisulfite-treated DNA (btDNA) and btDNA-specific primers in PCR 
methods, one can determine if methylation at certain loci is present. By using 
quantitative PCR, a semi-quantitative estimation of the percentage of DNA 
methylation can be made. By sequencing both, a bisulfite-treated DNA sample and an 
untreated one, the two sequences can be compared, and position specific methylation 
data may be generated. The approach may even be expanded, to not only analyse 
methylated cytosines, but also hydroximethylated cytosines. In order to achieve this, 
the input DNA has to be subjected to a special oxidization step that converts 5hmC to 
5fC, which in contrast to 5hmC is not protected from bisulfite conversion. After the 
oxidation step, bisulfite conversion and sequencing can be carried out. By comparing 
results to sequences from normal DNA and btDNA, information on the positions of 
5hmC may be obtained [160]. 
Utilizing next generation sequencing (NGS) methods, the whole methylome (the DNA 
methylation across the entire genome) can be analysed. For these methods, it is critical 
to ensure full conversion of the DNA in the samples, as the results directly depend on 
it. It is also worth noting, that when analysing data from bisulfite sequencing, the 
sample degree of heterogeneity should be considered, as analysing samples from 
mixed cell populations (including heterogenic tumors) can “dilute” the obtained 
results. 
In the following section, a few selected methods to analyse DNA methylation will be 
discussed. 
1.3.3.1 PCR-based methods 
The simplest way to investigate DNA methylation at a given site is by using btDNA 
in a simple PCR reaction. By designing primers, which only bind to the specific 
sequence if the input DNA (prior to bisulfite conversion) is methylated, one can 
determine if methylation in present at a given locus. The disadvantage of this method 
is, that the throughput is low, and the obtained results are not quantitative. It is possible 
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to obtain semi-quantitative data from this method, if instead of conventional PCR, 
quantitative PCR (qPCR) is used. 
1.3.3.2 Whole genome bisulfite sequencing 
Whole genome bisulfite sequencing (WGBS) is the most comprehensive of all 
methods, as it theoretically provides data on all potential methylation sites in a given 
sample. WGBS is similar to whole genome sequencing with only one additional step: 
bisulfite conversion of the input DNA. However, WGBS data analysis can be 
challenging, as bisulfite conversion reduces the genomic complexity to essentially 
three nucleotides (compared to cytosine, 5mC, that remains cytosine after conversion, 
is relatively rare). This makes alignment of the sequences more challenging. 
Furthermore, btDNA is more fragmented, thus amplification of longer reads is 
difficult and can lead to chimeric products. The data analysis also requires a 
considerable amount of bioinformatic expertise and resources because of the 
difficulties in sequence alignment and the huge amounts of data produced. 
Because only a small fraction of the genome has the potential to be differentially 
methylated, WGBS may not be required for some, if not most, studies. There are other 
methods that enrich the methylated DNA fraction of the genome that are cheaper and 
may be sufficient for the specific research question. 
1.3.3.3 Reduced Representation Bisulfite Sequencing 
Reduced Representation Bisulfite Sequencing (RRBS) in principle follows the same 
protocol as WGBS, the difference is in the input DNA. Before library preparation, the 
CpG rich fraction of the genome is enriched by isolating short fragments that are 
generated by digestion with the restriction enzyme MspI (recognizing CCGG sites). 
RRBS allows for isolation of about 85% of CpG islands (CGIs) in the human genome 
and enriches such sequences, that have moderate or high CpG density and allows for 
analysis of mostly CGIs, promoters and enhancer sites. 
Data processing and analysis is very similar to WGBS, although not as intensive as 
the amount of generated data is smaller. Lastly, when interpreting the data, the fact 




In this study, I used oxidative RRBS (oxRRBS) to analyse the methylomes in a 
preclinical mouse model of cSCC. Figure 6 shows an overview of the oxRRBS 
method. 
 
Figure 6: Principle of the oxRRBS method. Input DNA is either directly bisulphite (BS) converted 
or oxidized and then BS converted. Following amplification and sequencing, the sequences can be 
compared and positions of 5mC and 5hmC can be analysed. 
1.3.3.4 Affinity enrichment-based methods 
Another way to enrich input DNA for CpG rich sequences, is immunoprecipitation of 
methylated DNA (MeDIP) with monoclonal antibodies against 5mC [161] or affinity 
capture of methylated sequences by members of the methyl-CpG binding domain 
(MBD) family proteins (collectively termed MBDCap) [162]. Different MBDCap 
methods use different MBD proteins (e.g. MeCP2 in the case of MethylCap assay or 
MBD2 and MBD3L1 in the case of methylated-CpG island recovery assay (MIRA)). 
[163,164].  
Although MeDIP and MBSCap methods are in principle very similar, the choice of 
method has a huge influence on the results. The antibodies used in MeDIP bind to 
DNA fragments that contain a small number of methylated cytosines, while MBD 
proteins capture DNA fragments with multiple methylated cytosines with increasing 
affinity [165]. This can be turned into an advantage: By serially eluting methylated 
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DNA sequences with increasing salt concentrations, one can generate different 
fractions with increasing CpG density. This can allow to get an overview on the 
methylation changes at regions with different CpG density or, if the fraction eluded 
by the highest salt concentration is being analysed, an enrichment for CGIs can be 
achieved [166]. When interpreting the results, it is crucial to take into account which 
fraction of the genome is being analysed [165]. 
1.3.3.5 Illumina Beadchip arrays 
Illumina 27k and 450k beadchip arrays provide an alternative to sequencing-based 
methods but are only available for human samples. While the 27k array covers 27,578 
CpGs  and over 14,475 annotated genes, the 450k array covers 99% of all annotated 
genes with an average of 17 CpGs per gene. With probes for more than 450,000 CpGs 
on the chip, 96% of all CGIs can be analysed [167]. 
The principle of both arrays is simple: Bisulfite treated DNA is being hybridized to 
bead-bound probes on the chip. While one probe is designed to bind the methylated 
CpG, the other probe binds the unmethylated CpG. After hybridization, single base 
extension with fluorescently labelled nucleotides is used for means of detection. 
Illumina 450k arrays are used in large international projects like TCGA (The Cancer 
Genome Atlas, see https://cancergenome.nih.gov/). 
Illumina 27k and 450k arrays allow for a fast and cost-efficient quantitative analysis 
of genome-wide DNA methylation. Furthermore, these arrays allow usage of DNA, 
isolated from archival samples such as FFPE embedded tissues, that can be 
problematical in sequencing-based methods. It is worth mentioning, that the Illumina 
arrays, as hybridization-based methods, are susceptible to small nucleotide 
polymorphisms (SNPs) in the input DNA, as they may affect hybridization efficiency 
[168]. 
1.3.3.6 EpiTYPER MassARRAY 
The EpiTYPER MassARRAY system (Agena Bioscience, San Diego USA) provides 
a method to get quantitative DNA methylation data at specific loci with high 
throughput. The locus of interest is amplified from btDNA and a T7 promoter is added. 
In the next step, the amplicon is in vitro transcribed into a single stranded RNA 
molecule. Depending on the methodology used, the in vitro transcription mixes use 
either deoxyribose cytosines or uracils. In the next step, RNase A is used to cleave the 
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RNA molecules and because RNase A is not able to cleave after deoxyribose 
nucleotides, cleavage only happens after cytosines or uracils (again, depending on the 
methodology used). The cleaved RNA can then be analysed using a MALDI-TOF 
mass spectrometer. Because of the previous steps, unmethylated cytosines will appear 
as adenines in the mass spectrometry, while methylated cytosines will appear as 
guanines. As there is a mass difference of 16 Daltons between the two bases, 
methylated and unmethylated cytosines will appear as separate peaks in the 
spectrogram that can be quantified. 
 
Figure 7: Schematic overview of the EpiTYPER MassARRAY technology. Figure adapted from 
Busó and Iborra 2016 [169]. 
One advantages of MassARRAY is that, in contrast to other methods that analyse 
DNA methylation at specific loci, the method is high throughput. After MassARRAY 
primers have been established, the required PCRs and following reactions are all 
performed in a 386 well format. This allows for analysis of a high number of samples 
and loci in a relatively short amount of time.  
During method development, it has been realized that calibration for peaks of 
fragments below 1700 Da is not ideal and those fragments often produce non-reliable 
data. The same is true for high mass fragments and therefore, it is recommended that 
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data from these fragments is not included in analysis. Furthermore, it is possible that 
different fragments have the exact same mass. In this case, one has to carefully analyse 
the results from those fragments and if multiple fragments have the same mass, these 
results also have to be excluded [169].  
In this study, I used MassARRAY to validate differentially methylated regions 
(DMRs) that were identified by RRBS. 
1.3.4 DNA methylation in cutaneous squamous cell carcinoma 
UV radiation is known to influence DNA methylation and UV-induced changes in the 
methylome of normal skin cells may contribute to skin carcinogenesis [170–173]. On 
the other hand, CpG methylation itself changes the absorption spectrum of cytosine 
(non-methylated C: max at 270 nm, methylated C: max 280 nm) and therefore makes 
hypermethylated DNA sequences prone to UV-induced DNA damage. This 
phenomenon has been demonstrated for the coding sequence of p53 [173–175]. 
In most cases, cancer is associated with global hypomethylation and locus specific 
hypo- or hypermethylation [90]. A few studies have demonstrated an increase in DNA 
methylation in human cSCC, murine skin exposed to UVB radiation and skin cancer 
cell lines, such as A431 and SCC13 [170,172,176], and Lin et al. suggested a link of 
this increase in global DNA methylation with TET proteins [170]. Interestingly, TET 
proteins have been found to be mutated in human cSCCs (see supplemental 
information in South et al. 2014 [58]). TET proteins also appeared as frequent 
mutations in murine ssUVR induced cSCCs [59].  
Several studies have focused on differentially methylated regions (DMRs) in promoter 
regions of genes. However, the multitude of different models and methods used makes 
it difficult to compare the results from those studies. Early investigations used 
methylation specific PCR (MSP). MSP utilizes bisulfite treated genomic DNA, where 
unmethylated cytosines are converted to thymines whereas methylated cytosines are 
protected from this conversion. This allows the design of specific primers for 
methylated and unmethylated DNA regions. While this method is highly specific for 
methylated CpGs, it remains a qualitative method that is not able to provide 
quantitative methylation data. With next generation sequencing techniques becoming 
more advanced and the cost for these techniques getting lower, more recent studies 
have utilized genome-wide methods that will be discussed below. 
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Takeuchi et al. used MSP to investigate promoter methylation of the T-cadherin gene 
in human primary tumors. T-cadherin is involved in cell adhesion and may play a role 
in intracellular signalling. Takeuchi et al. demonstrated that the T-cadherin promoter 
is methylated in invasive human cSCCs as well as in the A431 skin cancer cell line. 
Treatment with the demethylating agent 5’-aza-2’-deoxycytidine (DAC), a DMNT 
inhibitor, restored T-cadherin expression in A431 cells [177]. 
Similar to T-cadherin, E-cadherin is involved in cell adhesion. E-cadherin is a major 
marker for epithelial cells and is down-regulated when cells undergo epithelial-
mesenchymal transition (EMT), a mechanism important for tumor metastasis [178–
182]. In their 2003 study, Chiles et al. from the Smoller lab (Department of Pathology 
and Dermatology, University of Arkansas) utilized MSP to investigate methylation at 
the E-cadherin promoter in human non-neoplastic skin, actinic keratosis, an early pre-
stage of cSCC, cSCC in situ and invasive cSCC. Despite relatively small sample 
cohorts, they found that the E-cadherin promoter is un-methylated, and therefore 
active, in 7 out of 9 cases in non-neoplastic skin samples. In actinic keratosis as well 
as cSCC in situ, the E-cadherin promoter is methylated in approximately 50% of cases 
(actinic keratosis: 5 un-methylated, 4 methylated; cSCC in situ: 4 un-methylated, 4 
methylated). For 6 of 7 cases of invasive cSCC the E-cadherin promoter was 
methylated, suggesting silencing of the E-cadherin gene and up-regulated EMT 
mechanisms [183]. Both studies by Takeuchi et al. and Chiles et al. suggest that in 
invasive human cSCC, cell-adhesion proteins may be down-regulated by promoter 
methylation, therefore contributing to increased metastatic potential.  
In a publication by Tyler et al., Smoller and co-workers analysed promoter 
methylation of death-associated protein kinase (DAPK) and the tumor suppressor p16, 
again using MSP and the same sample cohort as in their E-cadherin study. They found 
that both promoter regions are mostly un-methylated in nonneoplastic skin samples, 
actinic keratosis, cSCC in situ and invasive cSCC, suggesting that these genes are 
regulated by different mechanisms in cSCC [184].  
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Table 4: Overview of differentially methylated genes and global methylation in cSCC. Further explanation is given in Section 1.3.462. 
GENE GENE REGION METHYLATION EXPRESSION SAMPLE ORIGIN TECHNIQUE SOURCE 
T-cadherin Promoter hyper down invasive human cSCC MSP Takeuchi 2002 [185] 
T-cadherin Promoter hyper down A431 MSP Takeuchi 2002 [185] 
E-cadherin Promoter hypo 7/9 (78%) 
 
non-neoplastic skin MSP Chiles 2003 [183] 
E-cadherin Promoter hypo 5/9 (56%) 
 
AK MSP Chiles 2003 [183] 
E-cadherin Promoter hypo 4/8 (50%) 
 
cSCC in situ MSP Chiles 2003 [183] 
E-cadherin Promoter hyper 6/7 (86%) 
 
invasive human cSCC MSP Chiles 2003 [183] 
p14ARF Promoter hyper 16/38 (42%) 
 
human cSCC MSP Brown 2004 [108] 
p16INK4a Promoter hyper 13/36 (36%) 
 
human cSCC MSP Brown 2004 [108] 
p16INK4a Promoter hyper 2/8 (25%) 
 
human cSCC MSP Arbiser 2004 [186] 
E-cadherin Promoter hyper 4/10 (40%) 
 
TPA/DMBA mouse btDNA seq Fraga 2004 [187] 
Snail Promoter hyper 6/10 (60%) 
 
murine skin cancer cells btDNA seq Fraga 2004 [187] 
global 
 
250% of normal skin 
 
UVB irradiated mouse skin Methylamp Nandakumar 2011 [172] 
global 
 
300% of normal skin 
 
UVB induced mouse skin tumors Methylamp Nandakumar 2011 [172] 
global 
 
350% of normal skin 
 
human cSCC Methylamp Nandakumar 2011 [172] 
global 
 
325% of NHEK 
 
A431 Methylamp Nandakumar 2011 (2) [176] 
p16INK4a Promoter hyper down UVB induced mouse skin tumors MSP Nandakumar 2011 [172] 
RASSF1A Promoter hyper down UVB induced mouse skin tumors MSP Nandakumar 2011 [172] 
Cip1/p21  Promoter hyper down UVB induced mouse skin tumors MSP Nandakumar 2011 (2) [176] 
p16INK4a Promoter hyper down 13 human cSCC cell lines MSP Nandakumar 2011 [172] 
RASSF1A Promoter hyper down 13 human cSCC cell lines MSP Nandakumar 2011 [172] 
Cip1/p21  Promoter hyper down 13 human cSCC cell lines MSP Nandakumar 2011 (2) [176] 
p16INK4a Promoter hyper down A431 MSP Lin 2014 [170] 
Cip1/p21  Promoter hyper down A431 MSP Lin 2014 [170] 
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The CDKN2A locus encodes for the p16INK4a and p14ARF tumor suppressor genes. The 
CDKN2A gene, as previously mentioned, is also frequently mutated in cSCCs. Brown 
et al. found promoter methylation of the p16INK4a promoter in 13 of 36 (36%) and 
p14ARF promoter in 16 of 38 cases of human cSCC, again using MSP [108].  
Another study that investigated promoter methylation at the p16INK4a promoter was 
conducted by Arbiser et al. 2004, again using the MSP method. They found p16INK4a 
promoter methylation in 2 of 8 primary human cSCC samples [186], which is 
consistent with the data from Brown et al [108]. 
Fraga et al. compared methylation of various gene promoters in human primary 
tumors, tumors that form in the DMBA/TPA mouse multistage skin carcinogenesis 
model [188,189] as well as human and murine skin cancer cell lines. Most notably, 
the promoter of E-cadherin was only methylated in 4 out of 10 murine skin cancer cell 
lines, whereas Chiles et al., as previously discussed, found the E-cadherin promoter 
to be methylated in 67% of cases in human primary tumors. Concordantly, the 
promoter of Snail, an EMT promoting transcription factor and negative regulator of 
E-cadherin, was methylated in 6 out of 10 murine skin cancer cell lines [186], 
suggesting that regarding to regulation of EMT by DNA methylation, murine cancer 
cell lines and human primary tumors are different, likely because of differences in 
cancer drivers (reviewed in [173]). Other gene promoters show similar methylation 
when comparing human primary tumors and human or murine cancer cell lines. For 
example, the cysteine and glycine-rich protein 2, involved in the JAK/STAT signalling 
pathway shows similar methylation patterns. The same is true for the chemokine 
receptor CXCR4 and the antioxidant enzyme peroxiredoxin 1. In contrast insulin-like 
growth factor binding protein 3 is mostly unmethylated in human primary tumors but 
mostly methylated in human and murine skin cancer cell lines [187]. The differences 
between human primary tumors, human skin cancer cells and murine skin cancer cells 
highlights the importance of choosing the right and most accurate model system. 
In a more recent study from 2011, Nandakumar et al. used a variety of methods to 
address methylation changes in UVB-exposed skin and UVB-induced skin tumors of 
SKH-1 hairless mice. First, they demonstrated, using Methylamp global methylation 
quantification kit, that global DNA methylation levels are significantly higher in 
UVB-irradiated skin and UVB-induced skin tumors. This was also observed in 
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13 human cSCC samples. This is likely to be caused by elevated expression and 
activity of DNMTs. Nandakumar et al. also found transcriptional silencing of p16INK4a 
and RASSF1A by promoter methylation and histone deacetylation using a 
combination of MSP, methylated DNA immunoprecipitation (MeDIP), methyl-CpG-
binding domain capture (MCDCap) and western blotting [172]. 
The methylation specific PCR method used in the studies described so far is an easy 
and specific method to analyse DNA methylation at small regions. However, this 
method does not provide any insight in the grade of DNA methylation. An advanced 
version of MSP was used in a second publication by Nandakumar et al. 2011. By using 
qPCR instead of regular PCR, they created semi-quantitative data for methylation 
changes in the p16INK4a and Cip1/p21 promoters in A431 skin cancer cells. First 
Nandakumar et al. showed that global methylation levels are higher in A431 cells 
compared to NHEK keratinocyte cells, and that EGCG, a green tea polyphenol, 
reduces global methylation levels in a time- and dose-dependent manner. Again, the 
effect was linked to decreased expression and activity of DNMTs. The effects of 
EGCG on global DNA methylation levels was also observed in the human SCC 13 
cell line, but unfortunately, global methylation levels of A431 and SCC 13 cells were 
not compared. Furthermore, EGCG was able to up-regulate expression of the silenced 
tumor suppressor genes p16INK4a and Cip1/p21 by reduced methylation levels at their 
promoters [176]. 
More recent techniques make use of next generation sequencing (NGS) to produce 
quantitative or semi-quantitative genome-wide methylation data. Tony Kong and co-
workers (Yang et al. 2014 [171]) used methylated DNA immunoprecipitation 
(MeDIP) coupled with NGS to screen for differentially methylated genes in UVB- or 
DMBA/TPA-induced murine skin cancers. This approach utilizes monoclonal 
antibodies specific for 5mC, followed by crosslinking and pulldown of the methylated 
DNA fragments, followed by NGS. MeDIP is a biased method because it 
preferentially enriches regions with low and intermediate 5mC contend [167]. Yang 
et al. found 6003 genes to be differentially methylated (≥ 2-fold change in 
methylation) in the UVB-induced tumors, 4140 of which were hyper- and 1863 were 
hypomethylated. Regarding the DMBA/TPA-induced mouse skin tumors, 5424 genes 
showed an at least 2-fold change in DNA methylation levels. The methylation 
percentage was higher for 3781 and lower for 1643 genes compared to the control. 
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Unfortunately, there is no comprehensive data for all differentially methylated genes 
available. But comparing the 50 most hyper- or hypomethylated genes from both 
models, only TSN1 (tensin1) is hypermethylated and GRIA1 (Glutamate receptor, 
ionotropic, AMPA 1) is hypomethylated in both models, suggesting that regarding 
DNA methylation, the two models are not comparable. Yang et al. performed 
Ingenuity Pathway Analysis (IPA) with differentially methylated genes from UVB- 
and DMBA/TPA-induced murine tumors. Results shows that the differentially 
methylated genes are enriched in different pathways, with only “molecular 
mechanisms of cancer” showing up as a pathway enriched in both models. This 
however is not surprising as Yang et al. compared skin tumors with other skin tumors. 
The lack of shared pathways further suggests that DNA methylation patterns are not 
comparable between the models [171] and also increases doubts, that the DMBA/TPA 
model is suitable to investigate cSCC (as discussed in Section 1.2.3.6).  
While Nandakumar et al. 2011 demonstrated that silencing of the p16 and p21 genes 
in A431 cells can be reversed with EGCG through inhibition of DNMTs, Lin et al. 
2014 showed that the p16 and p21 are also re-expressed in A431 cells after treatment 
with vitamin C. Similar to EGCG treatment, vitamin C is able to reduce DNA 
methylation at the p16 and p21 promoters, therefore up-regulating the expression of 
both genes. Interestingly, although 5mC levels at the promoters drop, 5hmC levels 
significantly increase after vitamin C treatment. This suggests a TET-dependant 
mechanism, as the conversion of 5mC to 5hmC is carried out by TET proteins. 
Although Lin et al. had established shRNA knockdown of Tet1 and Tet2 in A431 
cells, they did not test if the accumulation of 5hmC at the p16 and/or p21 promoters 
is impaired in Tet1/2 knockdown A431 cells after vitamin C treatment, and therefore 
did not provide direct evidence for a TET-dependant mechanism [170].  
The most comprehensible data for DNA methylation in cSCC comes from a recent 
paper by Rodríguez-Paredes et al. [190]. They performed global methylation analysis 
of 12 normal epidermis samples (taken from healthy volunteers), 16 AK samples and 
18 cSCCs using Infinium MethylationEPIC 850k methylation array. Great care was 
taken to ensure tissue homogeneity by separating the epidermis from the dermis. When 
principal component analysis (PCA) was performed, normal epidermis samples 
clearly separated from AK and cSCC samples, and a high overlap between AK and 
cSCC was observed. Interestingly, methylation between normal epidermis samples 
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showed high homogeneity, while AK and cSCC samples distributed with greater 
heterogeneity. Between normal epidermis and AK, pairwise comparison resulted in 
identification of 372,213 significantly differentially methylated probes, and 310,102 
probes were significantly differentially methylated between normal epidermis and 
cSCC. Between AK and cSCC, no significantly differentially methylated probes were 
detected (in agreement with PCA). This suggests, that there are profound methylation 
changes when normal epidermis becomes diseased (AK and cSCC) but also high 
similarity in methylation between AK and cSCC. When Rodríguez-Paredes et al. 
analysed cancer specific features, they found that AK samples already display these 
cancer specific features, and that this is conserved in cSCC [191]. These cancer 
associated features included hypomethylation of open sea regions (CpGs not 
associated with a CGI), hypermethylation of CGIs and their shores (CpGs in proximity 
to CGIs) and hypermethylation at lamina-associated domains (LADs) in both, AK and 
cSCC [192].  
Furthermore, when predicting the chronological age of AK and cSCC samples, the 
calculated methylation age was significantly lower than the chronological age of the 
patient from whom the sample originated, an effect similar to the one observed for 
stem cells [193]. In mammalian stem cells, DNA methylation can also be observed 
outside of a CpG context [194,195]. Rodríguez-Paredes et al. were able to detect 
significantly increased non-CpG methylation in AK and cSCC samples, reminiscent 
of features observed in stem cells. Furthermore, they showed that expression of the 
DNA methyltransferase enzyme associated with non-CpG methylation, DNMT3b 
which is also an important epidermal stem cell gene [196], was increased in AK and 
cSCC samples compared to controls.  
Expression of keratins correlates with the differentiation stage of keratinocytes and 
the keratin genes are located in gene clusters on chromosomes 12 and 17 [197]. 
Rodríguez-Paredes et al. observed major DNA methylation changes at these clusters 
between AK, cSCC and healthy samples. Moreover, inspection of DNA methylation 
at the individual keratin genes (while also confirming their previous findings), 
indicated that there were two separate keratin gene methylation patterns in AK and 
cSCC samples. When they performed a similar analysis of keratin gene methylation 
patterns in datasets from The Cancer Genome Atlas (TCGA, 7824 cancer data sets, 26 
different tumor entities), PCA revealed the presence of two subgroups in AK and 
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cSCC samples. Interestingly, while one group clustered together with the cancer 
samples, the other one was closely related to healthy epidermis. The Infinium 
MethylationEPIC also allows for analysis of enhancer regions, a particularly important 
target of DNA methylation [198]. When analysing over 75,000 enhancers of H1 
embryonic stem cells (ESC) line and normal human keratinocytes and clustering 
samples in a PCA, they identified the same two subclasses, one related to ESCs and 
one related to keratinocytes. Together, this strongly suggest that cSCC in humans 
arises from distinct progenitor cell types, undifferentiated epidermal stem cells and 
more differentiated keratinocytes. 
I will compare the data from Rodríguez-Paredes et al. with the findings obtained by 





When I was analysing DNA methylation in mouse cSCC, Filip1l was the most 
differentially methylated gene, as an intronic region of the gene showed a highly 
significant difference in methylation in tumors compared to matched healthy skin. 
In humans, the FILIP1L gene lies on chromosome 3. The gene has 6 exons of varying 
length (118 bp to 2776 bp) with exon 5 being the longest. In mouse, the Filip1l gene 
has a similar structure compared to humans. It only has 5 exons, but exon and intron 
lengths are similar. Interestingly, the intron harbouring the differentially methylated 
region (DMR) identified during my study is extraordinarily long (human: 183,022 bp, 
mouse: 153,140 bp). FILIP1L has 8 known isoforms. The full-length isoform is 
isoform 202 (1135 bp, 130 kDa) but isoform 201 has the same molecular weight and 
only misses the short exon 6 (1133 bp, 130 kDa). Alternative transcription start sites 
(TSSs) and splicing of exon 6 allow for different N- and C-termini of the different 
isoforms. Currently, it is not known if FILIP1L isoforms have different biochemical 
functions or display tissue specific expression. There are only 3 known mouse 
isoforms of Filip1l. An overview of the FILIP1L isoforms in mouse and human are 
depicted in Figure 8. Information on the FILIP1l gene and isoforms is available at 
Ensemble (http://www.ensembl.org) [199]. The nomenclature to name the FILIP1L 
isoforms is confusing. I will use the isoform names from Ensemble during this thesis. 
 
Figure 8: FILIP1L isoform structure in mouse and human. Exons are depicted in blue, alternative 
TSSs and 3’ untranslated regions (UTRs) are depicted in light blue. Size correlates with sequence length 
but is not scaled. aa = amino acids, kDa= kilo Dalton. 
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The FILIP1L protein consists of a coiled-coil region (residues 3-542), two leucin 
zipper motifs (83-111 and 218-253) and a potential nuclear localization sequence 
(NLS) domain (168-183). Using NCBI conserved domain search 
(https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) Kwon et al. also found other 
conserved domains of FILIP1L are: CortBP2 (cortactin-binding protein 2, residues 
57-249), SbcC (an ATPase involved in chromosome segregation, residues 15-576), 
ApoLP-III like (apolipophorin-III and similar insect proteins, residues 383-507) and 
DHC-N1 (dynein heavy chain N-terminal region 1, residues 392-665). The C-terminus 
is an unstructured region with a Herpes-BLLF1 (Herpes virus major outer envelope 
glycoprotein, residues 875-1115) conserved domain (the FILIP1L protein structure is 
also reviewed in [200]). 
Alignment of the human FILIP1L isoform 202 and mouse isoform 203 using NCBI 
protein Blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi) shows that proteins are very 
similar between human and mouse (Query cover 99%, percentage identity 88.40%).  
1.4.1 Discovery of FILIP1L 
Before we were able to perform screens of entire genomes, epigenomes, 
transcriptomes or proteomes, scientists had to go through great struggles to identify 
differentially expressed genes, especially when comparing multiple samples. One 
technique used for this purpose was RNA-based arbitrary primed PCR (RAP). In 
principle, this technique uses one or two arbitrary primers to amplify multiple 
sequences from total RNA. By separation of the PCR products on an acrylamide gel, 
differences in expression between individuals can be observed [201,202]. Using RAP, 
Mok et al. were able to identify two transcripts, which were expressed in human 
ovarian surface epithelial (HOSE) primary cell cultures but absent in nine ovarian 
carcinoma cell lines. They termed those transcripts down-regulated in ovarian cancer 
1 and 2 (DOC-1 and -2), with DOC-1 later being renamed filamin A interacting protein 
1 like (FILIP1L, I will be using this name through this thesis) [203], but the function 
of the gene remained unknown. In 2002, the down-regulation of FILIP1L was 
confirmed in primary cell lines, derived from epithelial ovarian carcinomas using an 
Affymetrix genechip expression array [204]. Although mutations in FILIP1L are 
common in ovarian cancer, in their 2011 study, Notaridou et al. found, that SNPs in 
FILIP1L most likely do not contribute to ovarian cancer risk [205], other means of 
gene regulation (for example DNA methylation) were not investigated.  
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Since then, multiple studies have linked FILIP1L to different cellular processes in 
both, normal and cancer cells and tissues. For example, Schwarze et al. demonstrated, 
that FILIP1L expression is up-regulated in human prostate epithelial cells (HPECs) 
when they become senescent, but expression then is down-regulated once the cells are 
immortalized (using HPV15 E6 and E7 genes) [206]. They also showed, that FILIP1L 
expression is induced when HPECs as well as the prostate cancer cell lines DU145 
and LNCaP are forced into a senescent-like phenotype using doxorubicin, Docetaxel 
or the DNMT inhibitor 5-aza-2’-deoxycitidine (DAC) [207]. It is however unclear, if 
FILIP1L expression is involved in inducing or maintaining a senescent phenotype, or 
simply is a result of cells becoming senescent. 
Mazzanti et al. found that treatment of human endothelial cells with the angiogenesis 
inhibitors endostatin or fumagillin, induced expression of FILIP1L after only 1h of 
treatment using human cDNA 10k array in human umbilical vein endothelial cells 
(HUVECs). They speculated, that FILIP1L could be involved in cytoskeleton 
organisation as it shares similarities with the mouse myosin heavy-chain smooth 
muscle isoform, and that FILIP1L could have a tumor suppressor role [208]. In a 
similar study, Tandle et al. from the same lab reported similar results in HUVECs 
using the tumor derived cytokine endothelial monocyte activating polypeptide-II 
(EMAP-II) [209]. In both studies, the authors used siRNA mediated knock-down of 
FILIP1L to show, that FILIP1L is involved in early signaling in response to 
angiogenesis inhibitors and that FILIP1L lies upstream of other genes with altered 
expression. 
Stangeland et al. found by microarray analysis, that FILIP1L is expressed in 
glioblastoma stem cells (GSCs) but not in neuronal stem cells (NSCs) from adult 
brains [210,211]. However, they were not able to validate differential expression of 
FILIP1L in an independent sample set, but upon closer inspection found, that 
expression is low in the glioblastoma neural subtype, but consistently up-regulated in 
mesenchymal tumors. It is interesting to note, that in an earlier study using the same 
initial microarray data, Sandberg et al. noticed that compared to NSCs, GSCs have 
dysregulate WNT-signaling [211], a pathway FILIP1L has been linked to (data on the 
function of FILIP1L will be discussed later in this chapter). 
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1.4.2 Characterization of function and expression of FILIP1L 
In two studies, Mazzanti et al. [208] and Tandle et al. [209] from the Steven K. Libutti 
group found that FILIP1L expression is upregulated in HUVECs after treatment with 
angiogenic inhibitors. Kwon et al. from the same lab aimed to functionally 
characterize FILIP1L. First, they made a monoclonal FILIP1L antibody using mice. 
This antibody was then used to confirm that in HUVECs within two hours, FILIP1L 
protein is up-regulated after treatment with endostatin. FILIP1L predominantly was 
localized in the cytoplasm, with lower levels in the membrane and nucleus. 
Furthermore, Kwon et al. used immunohistochemistry to show, that in normal colon 
tissue, FILIP1L is expressed in the vasculature and muscularis mucosa, while in colon 
cancer, FILIP1L was strongly expressed in the vasculature as well as the stroma. When 
trey transfected HUVECs with FILIP1L expressing plasmid, HUVECs displayed 
decreased proliferation (measured by BrdUrd ELISA after 24 h) and increased 
apoptosis (increased Caspase-3 and -7 activity). Kwon et al. created different 
truncation mutants of FILIP1L and expressed them in HUVECs in order to determine 
which part of FILIP1L mediates the antiproliferative effect in those cells. All 
truncation mutants, except the three shortest ones (residues 1-369, 369-893, 512-893) 
significantly inhibited cell proliferation and apoptosis, with FILIP1LΔC103 (residues 
1-790) being more potent than the full-length protein. When they over-expressed the 
FILIP1LΔC103 truncation mutant in HUVECs, migration was significantly slower. 
Using DU145 prostate cancer cells, that have low FILIP1L expression, doxorubicin 
induced FILIP1L expression had significantly slower migration. Finally, they showed 
that targeted expression of FILIP1LΔC103 in tumor vasculature in an M21 xenograft 
model significantly reduced tumor growth and tumors showed extensive apoptosis. 
Using a yeast two-hybrid system, Yangzhou and Mivechi discovered FILIP1L 
isoform 203 (termed version 2 in their publication) as an interaction partner of heat 
shock factor 1 (HSF1). This interaction was also observed in H1299 (human small cell 
lung carcinoma) cells using immunoprecipitation. Interestingly, in heat treated (43°C 
for 1 h) HEK293 (human embryonic kidney epithelial) cells the interaction was 
weakened. Furthermore, the N-terminal region of FILIP1L (residues 1-230) alone also 
was able to bind HSF1, suggesting that the N-terminus of FILIP1L that contains the 
two leucine zipper domains is essential for HSF1 binding. Under physiological 
conditions, HSF1 exists as a heterodimer with HSP72. Using a series of GST pulldown 
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assays, Yangzhou and Mivechi also were able to show that full-length HSF1 interacts 
with both, FILIP1L and HSP72. Furthermore, GST pull-down using FILIP1L residues 
1-288 (containing the leucine zipper domains) were able to co-immunoprecipitate 
FILIP1L, suggesting that FILIP1L exists as a dimer or oligomer. Overexpression of 
fluorescently labelled FILIP1L reduced expression of endogenous HSF1 in both, 
physiological conditions and after heat shock, reduced HSF1 nuclear granules 
following heat shock and reduces HSF1 transcriptional activity. Using overexpression 
of HA-ubiquitin and HA-HSF1, Yangzhou and Mivechi tested if FLAG-FILIP1L 
influences HSF1 ubiquitination. Indeed, using proteasome inhibitor MG132, FILIP1L 
overexpression lead to a significant increase in HSF1 polyubiquitination. They also 
tested the if the ubiquitin adapter protein HhR23A interacts with FILIP1L. The 
FILIP1L leucine zipper domains interacted with the ubiquitin associated domains 
(UBA) of HhR23A and both, FILIP1L and HSF1 can be pulled down together with 
GST-HhR23A, while HSF1 alone could not. This indicates, that FILIP1L could be an 
adapter protein for ubiquitinated HSF1 [212]. 
Following up on the initial discovery, that FILIP1L is not expressed in ovarian cancer, 
Xie et al. investigated, if delivery of FILIP1LΔC103 by biodegradable cationic 
heparin-polyethyleneimine (HPEI) nanogels is able to inhibit ovarian cancer growth 
[213]. They established, that delivery of FILIP1L by the HPEI nanogel to an 
intraperitoneal ovarian carcinoma xenograft model (using SKOV3 human ovarian 
carcinoma cells) was possible. FILIP1L expression reduced tumor weight by almost 
72% and while control group tumors spread to the liver and mice developed ascites, 
none of the mice harbouring FILIP1L expressing tumors developed ascites and all 
tumors were in the pelvis area. Staining frozen tumor section with CD31 antibody 
revealed, that microvessel density (MVD) was significantly reduced in FILIP1L 
expressing tumors, suggesting that angiogenesis is inhibited in these tumors. This was 
supported by alginate-encapsulated tumor cell assay and FITC-dextran uptake. 
Furthermore, FILIP1L expression reduced tumor proliferation by at least 50% 
(measured by Ki-67 staining) and TUNEL-assay revealed a significant increase in 
apoptosis. The findings of this study suggest, FILIP1L is a valid therapeutic target in 
ovarian cancer [213]. In a follow-up study, Xie et al. [214] combined delivery of 
FILIP1L via HPEI nanogels with low-dose cisplatin (3 mg/kg). FILIP1L HPEI 
nanogels were approximately as effective in inhibiting tumor growth, proliferation and 
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angiogenesis as cisplatin treatment and induced apoptosis at similar rates. 
Combination treatment was more effective than either of the treatments alone [214]. 
As mentioned before, Notaridou et al. [205] found, that SNPs in FILIP1L most likely 
does not contribute to ovarian cancer risk however, Xie et al. [214] found that re-
expressing FILIP1L in an ovarian cancer xenograft model slowed tumor growth 
significantly. Taken together, it appears that in ovarian cancer, FILIP1L is repressed 
on a transcriptional level, but the mechanism was unknown. Using a series of ovarian 
cancer cell lines as well as both, immortalized and primary human ovarian surface 
epithelial cells (IOSE and HOSE), Burton et al. [215] from the Libutti lab first 
determined, that FILIP1L expression is high in HOSE cells, but low or absent in all 
tested ovarian carcinoma cell line (OVCAR8, OV90, SKOV3, OVCA429, OCC1 and 
ES2). Interestingly, FILIP1L expression was also significantly lower in IOSE cells 
compared to HOSE cells, but higher than in ovarian carcinoma cell lines. Using 
immunoblotting, these findings were confirmed on a protein level. Expression levels 
of FILIP1L were shown to inversely correlate with the invasive potential of the 
different cell lines. Furthermore, transfecting ES2 and SKVO3 cells, that express no 
FILIP1L, with the truncation mutant FILIP1LΔC103 reduced invasion significantly. 
To test if FILIP1L expression inversely correlates with invasiveness in vivo, Burton 
et al. tested FILIP1L mRNA levels in FFPE imbedded clinical ovarian carcinoma 
specimen. Indeed, FILIP1L expression and protein levels were significantly lower in 
invasive serous carcinomas compared to serous borderline tumors (low malignant 
potential tumors).  
There is a 407 base pair (59 individual CpGs) CpG island at the promoter controlling 
FILIP1L isoform 203 expression [215]. The 29 CpGs in the core of the CpG island 
were highly methylated in ES2 and OCC1 cells (that have no FILIP1L expression) 
and partially methylated in OVCA429 and SKOV3 cells (having medium and low 
FILIP1L expression). Interestingly, in HOSE and IOSE the CpG island was almost 
unmethylated (<10%) and the percentage of methylation inversely correlated with 
FILIP1L expression. Treatment of cell lines with the DNMT inhibitor DAC resulted 
in decrease methylation levels at the FILIP1L promoter and an increase in FILIP1L 
expression [215]. The histone deacetylase inhibitor TSA had no effect on FILIP1L 
expression and treatment of OVCAR8 cells (having medium FILIP1L expression) 
with DAC did not increase FILIP1L expression significantly. A similar effect was 
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observed in clinical ovarian carcinoma specimen, where methylation was lower in 
non-invasive and increased in invasive samples, and FILIP1L expression inversely 
correlated with percentage methylation of the promoter region, however, the inverse 
correlation was not as significant as it was in cell lines. Taken together, these findings 
suggest that promoter methylation mediates FILIP1L expression in ovarian cancer 
[215].  
In an attempt to identify genes, involved in mediating doxorubicin resistance, Lu and 
Hallstrom [216] used a pooled shRNA screening approach in U2OS human 
osteosarcoma cells. They found, that shRNA mediated knock-down of FILIP1L 
significantly decreased doxorubicin induced apoptosis in U2OS cells. Furthermore, 
doxorubicin treatment increased FILIP1L expression 150-fold and inhibition of ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) with 
caffeine reduced FILIP1L induction by 90%, suggesting ATM or ATR induction or 
both by doxorubicin induced DNA damage mediates FILIP1L induction. Because 
U2OS cells carry a wild type Trp53 gene, Lu and Hallstrom tested if in mutant p53 
SAOS-2 cells induction of FILIP1L could also be observed. Interestingly, FILIP1L 
was not induced in SAOS-2 cells, suggesting ATM/ATR and p53 are required for 
FILIP1L induction following DNA damage. Doxorubicin is a so-called DNA 
topoisomerase 2 (TOP2) poison. Agents of this class increase TOP2-DNA complexes 
and eventually lead to DNA strand breaks and cell death. In contrast, TOP2 catalytic 
inhibitors do not elevate TOP2-DNA complex levels. FILIP1L expression was only 
increased after treatment with TOP2 poisons, but not by TOP2 catalytic inhibitors or 
UV damage, suggesting that up-regulation of FILIP1L is specific to DNA damage 
cause by TOP2 poisons. It is worth noting, that the results from experiments by Lu 
and Hallstrom testing the effect on UVR on FILIP1L expression were performed with 
UV-C radiation and may not produce reliable data (check methods section of Lu and 
Hallstrom [216]). To test if FILIP1L alone is able to induce apoptosis, Lu and 
Hallstrom ectopically expressed FILIP1L in U2OS cells and observed that apoptosis 
was increase 5-fold compared to controls. Similarly, in SAOS-2 cells (that do not 
upregulate FILIP1L in response to doxorubicin, FILIP1L expression also led to a 4-
fold increase in apoptosis. The FILIP1L promoter harbours three potential OCT1 
(POUF2F1) binding sites, OCT1 is known to mediate DNA induced cellular stress. 
Knock-down of OCT1 with shRNA in U2OS cells, while only 60% effective, did not 
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affect baseline expression of FILIP1L. However, when cells were treated with 
doxorubicin, FILIP1L induction was reduce by 65% and apoptosis was reduced by 
45%. Furthermore, doxorubicin treatment lead tom increased binding of OCT1 to the 
FILIP1L promoter. Taken together these findings suggest, that doxorubicin induces 
DNA damage, which then induces OCT1 and subsequently up-regulates FILIP1L 
expression and apoptosis [216].  
In order to elucidate the role of FILIP1L in various human cancers, Kwon et al. [217] 
investigated FILIP1L expression in human cell lines of different tumor origin, namely 
colon cancer (HT-29, HCT116, HCT-15, SW620, T84, Caco-2, SW480), lung cancer 
(H23, H322, H1299, H460, A549, H661), pancreas cancer (MIA Paca-2, PANC-1, 
Hs766T, HPAC, HPAF-II, SU.86.86, Panc 02.03, Capan-1) and breast cancer (BT-
549, Hs578T, MDA-MB-468, BT-474, ZR-75-1,MDA-MB-231, MCF7). As controls, 
they used immortalized colon cell line NCM460, primary small airway epithelial cells 
(SAEC) and mammary epithelial cells (HMEC). FILIP1L mRNA and protein levels 
correlated well, except for HMEC and SAEC cell line, that both showed robust 
FILIP1L expression, but no FILIP1L protein. In general, FILIP1L expression and 
protein were high in normal cells, nut low in most cancer cell lines. Interestingly in 
the breast cell line panel, non-invasive MCF7 cancer cells highly expressed FILIP1L. 
Methylation at the FILIP1L promoter inversely correlated with FILIP1L expression 
in all four cancer entities and treatment of BT549, HT29, H1299 and MIA PaCa2 cells 
with DAC restored FILIP1L expression. Taken together, this further suggests 
promoter methylation mediates FILIP1L expression. 
When Kwon et al. tested the invasive potential of the cell lines using Matrigel, they 
demonstrated that FILIP1L expression inversely corelates with Matrigel invasion. Re-
expression of FILIP1L (or truncation mutant FILIP1LΔC103) in low expressing cells 
significantly reduced invasion, while siRNA mediated knock-down in high expressing 
cells significantly increased invasive potential. These data suggest, that FILIP1L 
expression inversely correlates with invasive potential and the invasive phenotype can 




Figure 9: Regulation of FILIP1L expression: Left: An intronic CGI in the mouse Filip1l gene could 
potentially be involved in Filip1l expression. Right: Methylation at the human FILIP1L promoter has 
been shown to inversely correlate with FILIP1L expression.  
As previously discussed, the FILIP1L gene encodes 8 known isoforms (see Figure 8). 
Desostelle et al. [218] used isoform specific primers to determine which isoforms are 
expressed in prostate cancer and normal prostate. They used primers that are able to 
distinguish between isoforms 202 (full length, termed isoform 1 in their publication) 
and 203 (termed isoform 2 in their publication). Since their study was published, more 
FILIP1L isoforms were reported. The primers used to amplify isoform 202 also 
amplify isoforms 206 and 209 and the primers used to amplify isoform 203 also 
amplify isoform 206. In human prostate epithelial cells (HPECs) FILIP1L isoform 203 
was predominantly expressed, with isoform 202 only showing very low expression. 
FILIP1L was not expressed in prostate carcinoma cell line DU145, PC3, LNCaP and 
22Rv1 cell lines. Furthermore, FILIP1L isoform 203 was up-regulated when HUVECs 
were cultured to senescence and was down-regulated in 5 of 11 prostate tumors 
compared to matched controls. Using a tissue microarray and a FILIP1L specific 
antibody, Desostelle et al. found that FILIP1L levels are 15 to 30 times higher in the 
stroma compared to the epithelium. Furthermore, FILIP1L expression was higher in 
the cytoplasm. In benign samples, there was no significant difference in FILIP1L 
levels in the cytoplasm in both, stroma and epithelium. However, in the nucleus 
FILIP1L levels were significantly lower in nuclei of cancer tissue (highly significant 
(p=0.006) in epithelium, significant (p=0.045) in stroma). FILIP1L expression was 
not associated with Gleason score (level of differentiation), tumor stage or metastasis. 
Using bisulfite treatment and pyrosequencing, it was shown that the promoter CpG 
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island controlling isoform 203 expression (called exon 5 in the publication) is 
hypermethylated in prostate cancer cell lines DU145, PC3, LNCap and 22Rv1, while 
in HPECs the CpG island was mostly unmethylated. The same was true for benign 
prostate tissue and prostate cancer samples. When the effect was quantified, the 
difference, while significant, was below 10% [218]. This could be because the effect 
in tumors was diluted as DNA samples was not taken from pure tumor, and may have 
included large amounts of benign surrounding tissue. 
Another study from the Libutti group was published in 2014, when Kwon et al. further 
investigated the functional significance of FILIP1L in ovarian cancer [219]. Kwon et 
al. previously showed that out of all ovarian cancer cell lines tested, FILIP1L 
expression is lowest in ES2 cells [217]. They generated ES2 cells, that express 
FILIP1LΔC103 and mCherry in a doxycyclin (DOX) inducible manner. Interestingly, 
FILIP1L expression in ES2 cells did not have an effect on proliferation. When these 
cells were injected into ovaries of SCID mice, the mice developed very aggressive 
ovarian cancer. Within 19 days, 90% of mice died with significant ascites by day 17, 
metastasis into the peritoneum, intra-abdominal organs, pelvic lymph nodes and liver 
as well as spontaneous lung metastasis by day 14. Expression of FILIP1L induced by 
DOX did not affect growth of primary tumors, but significantly inhibited metastatic 
spread to the lungs. Cancer metastasis is a multi-step process, requiring cancer cells 
to invade surrounding tissue, intravasation into the blood stream and extravasation as 
well as tumor growth at the secondary site [220]. By injecting ES2 cells in the tail-
vein, Kwon et al. bypassed the initial invasion and extravasation step. FILIP1L 
expression did not affect tumor development in lungs, suggesting that FILIP1L is 
involved in invasion or intravasation and not extravasation. This finding was 
confirmed in vitro with electric cell-substrate impedance sensing. When performing 
in vivo invasion assay in the orthotopic model, it became clear that FILIP1L 
expression inhibits the early invasion steps of ovarian cancer metastasis. Interestingly, 
invasion was completely blocked by using pan-MMP (matrix metalloproteinase) 
inhibitor GM6001 in control cells (not expressing FILIP1L). Expression of MMP3, -
7 and -9 were significantly reduced in FILIP1L expressing tumors. Furthermore, 
gelatine degradation also was significantly lower in tumors expressing FILIP1L. 
Transfection of a MMP9 expression plasmid restored invasive potential in ES2 cells 
expressing FILIP1L in vitro, suggesting FILIP1L inhibits invasion by down-
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regulation of MMPs. MMPs 3, 7 and 9 are transcriptionally controlled by the canonical 
Wingless/Integrated (WNT) signaling pathway [221]. To test, if WNT signaling is 
influenced by FILIP1L expression, Kwon et al. tested expression of several 
components of the WNT signaling pathway. WNT ligands WNT-2, -3A, -4, -5A, -7A 
and -11 were highly expressed in tumors, but not in cultured cells and significantly 
down-regulated in FILIP1L expressing tumors. Expression of WNT receptors frizzled 
(FZD) and low-density lipoprotein receptor-related protein (LRP) were not influenced 
by expression of FILIP1L. Treatment of ES2 cells with WNT3A resulted in induction 
of MMPs but this was significantly reduced in FILIP1L expressing cells. The WNT 
pathway can be induced by either WNT agonists of by inhibiting glycogen synthase 
kinase (GSK) -3β. WNT activity was significantly reduced in ES2 cells that express 
FILIP1L compared to controls when WNT signaling was activated. Canonical WNT 
signaling relies on transcriptional activation via β-catenin, that normally is repressed 
by N-terminal phosphorylation that marks it for ubiquitination and proteasomal 
degradation. Phospho-β-catenin was reduced by WNT activation, but interestingly 
remained unchanged in FILIP1L expressing cells. Inhibiting proteasomal degradation 
with inhibitor MG132 increased phospho-β-catenin levels regardless or FILIP1L 
expression, suggesting that FILIP1L supresses canonical WNT-signaling by 
proteasome-mediated β-catenin degradation [217]. 
Following up on their 2013 study, Kwon et al. [222]  used an ovarian cancer tissue 
microarray, where clinical outcomes of patients were available, to test the implications 
of FILIP1L expression on ovarian cancer outcome. They found, that FILIP1L levels 
decrease with tumor progression, with a significant difference when comparing 
normal to metastatic tissue. Levels of the WNT mediator β-catenin and epithelial to 
mesenchymal transition (EMT) transcription factor SLUG showed an inverse trend. 
In metastatic tissue, FILIP1L expression was significantly lower than in the primary 
tumor from the same patient. Strikingly, in tumors that were resistant to 
platinum/paclitaxel combination therapy, FILIP1L levels were significantly lower 
compared to sensitive tumors, while SLUG, showed an inverse expression pattern. 
Indeed, FILIP1L levels inversely correlated with β-catenin and SLUG, while β-catenin 
and SLUG positively correlated. Expression of another EMT transcription factor, 
SNAIL, also increased with tumor progression, but did not differ between chemo-
resistant and -sensitive tumors and did not inversely correlate with FILIP1L 
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expression. Patients with high FILIP1L had a significantly improved prognosis and 
did not yet reach median overall and disease-free survival in a 120-month follow-up 
period, while patients with low FILIP1L had an overall survival of 60 month and 
disease-free survival of 16 months. In the Cox proportional hazards model [223], high 
β-catenin or high SLUG in combination with low FILIP1L levels, high β-catenin in 
combination with high SLUG expression or low FILIP1L expression alone were 
independent negative prognostic markers for disease-free survival, suggesting 
FILIP1L expression is a useful prognostic marker for ovarian cancer. Kwon et al. 
engineered ovarian cancer cells OVCA429 and SKOV3 cells that normally do not 
express FILIP1L, to express FILIP1L to similar levels as immortalized normal ovarian 
epithelial cells. When these cells were injected into ovaries of nude mice, there were 
16- (OVCA429 cells) and 7-fold (SKOV3 cells) fewer peritoneal metastasis, 
respectively. Together with previous finding, where similar effects were observed for 
ES2 cells [217], this suggests that FILIP1L is a potent tumor suppressor in ovarian 
cancer. Kwon et al. previously showed, that in ovarian cancer, FILIP1L expression 
negatively correlates with the EMT transcription factor SLUG and is lower in tumors 
that are resistant to platinum and paclitaxel therapy [217]. To test if chemoresistance 
is regulated by FILIP1L, Kwon et al. decreased FILIP1L expression in serous ovarian 
carcinoma cells using siRNA. FILIP1L suppression increased SLUG expression and 
cytotoxicity assay revealed, that cisplatin, paclitaxel and doxorubicin efficacy was 
markedly decreased. Simultaneous siRNA knock-down of SLUG alongside FILIP1L 
rescued the chemosensitive phenotype. Additionally, FILIP1L expression levels in 
ovarian cancer cell lines correlated with chemoresistance. WNT signaling activity can 
be monitored by comparing active (unphosphorylated), inactive (N-terminally 
phosphorylated, marked for degradation) and total β-catenin. Activation of WNT 
signaling by LiCl in OVCA429 and SKOV3 cells increased active and decreased 
inactive β-catenin, while total β-catenin remained relatively constant. Engineered 
cells, expressing FILIP1L, had reduced active and increase inactive β-catenin levels 
compared to parental cells. When proteasomal activity was blocked with MG132, 
inactive β-catenin levels increased independently of FILIP1L expression. Similar 
effects of FILIP1L were observed, when FILIP1L was knocked down in HEY and 
OVCAR8 cells that express high levels of FILIP1L, suggesting that FILIP1L controls 
the canonical WNT signaling pathway, by mediating β-catenin availability upstream 
of the proteasome.  
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Previously, Kwon et al. detected FILIP1L at centromeres, which serve as proteolytic 
centres. In OVCA429 and SKOV3 cells expressing FILIP1L, FILIP1L co-localized 
with inactive β-catenin, proteasomes and the centromere marker γ-tubulin, suggesting 
FILIP1L facilitates proteasomal degradation of phospho-β-catenin at centromeres, 
thus blocking WNT signaling.  
A key feature of EMT is the loss of epithelial markers (e.g. E-cadherin) and induction 
of mesenchymal transcription factors (e.g. SLUG), MMPs and adhesion molecules 
[224]. As EMT is controlled by WNT in ovarian cancer, Kwon et al. tested if WNT 
activation leads to differential expression of EMT markers in FILIP1L+ and FILIP1L- 
cells. Before WNT activation, FILIP1L- cells (OVCAR429 and SKOV3) expressed 
high levels of mesenchymal markers N-cadherin and vimentin as well as SNAIL, but 
low levels of epithelial marker E-cadherin. FILIP1L+ cells expressed more E-cadherin 
and less N-cadherin, vimentin and SLUG. Activation of WNT with LiCl in FILIP1L-
cells induced mesenchymal markers and repressed epithelial markers. The effects of 
LiCl were abrogated in FILIP1L+ cells, suggesting that FILIP1L supresses EMT 
through down-regulation of WNT signaling.  
In mouse xenograft tumors from FILIP1L+ cells, mesenchymal markers were 
decreased, and E-cadherin was increased compare to tumors from FILIP1L- cells. The 
FILIP1L+ tumors trended towards EMT inhibition, but there was no consistent 
correlation with data from cultured cells. When FILIP1L was knocked down in HEY 
and OVCAR8 cells (high FILIP1L), mesenchymal markers increased, and E-cadherin 
decreased. SLUG was consistently up-regulated when FILIP1L was knocked down or 
WNT was activated. Furthermore, FILIP1L knockdown changed cell morphology to 
a more mesenchymal phenotype and interestingly, this could be rescued by additional 
knockdown of SLUG. Taken together, these findings suggest, that loss of FILIP1L 
leads to an increase in WNT signaling, thereby promoting tumor progression by 




Figure 10: The proposed role of FILIP1L in regulating WNT signaling and cancer metastasis 
according to Kwon et al.: Activation of the WNT signaling pathway by WNT ligands inhibits binding 
of β-catenin to the destruction complex (purple), which under inactive conditions phosphorylates 
β-catenin and marks it for proteasomal degradation. Unphosphorylated β-catenin transitions to the 
nucleus and, in concert with TCF/LEF transcription factors, induces gene expression of EMT promoting 
transcription factors and MMPs. While MMPs facilitate cancer cell invasion, activation of EMT aids 
cancer metastasis and chemoresistance. The exact mechanism how FILIP1L enhances β-catenin 
degradation is unclear. Proposed mechanisms are either inactivation of the β-catenin destruction 
complex (e.g. GSK3β), recruitment of phospho-β-catenin to centromeres or facilitating poly-




Most of the functional data on FILIP1L comes from ovarian cancer, but FILIP1L has 
been demonstrated to be down-regulated in other cancer entities as well. Park et al. 
[225] investigated the role of FILIP1L in colorectal cancer. First, they tested FILIP1L 
protein levels in various human colorectal cancer cell lines (SW480, DLD1, DKO1, 
HCT116, HT29 and COLO205). Levels were highest in COLO205 cells and lowest 
in HCT116. For further experiments, they overexpressed FILIP1L in HCT116 cells 
and knocked-down expression in COLO205 cells using siRNA. In COLO205 cells, 
FILIP1L knock-down reduced migration and invasion and increased expression of 
MMP-2 and -9. Conversely, FILIP1L overexpression in HCT116 cells decreased 
migration and invasion and decreased MMP-2 expression, while MMP-9 expression 
did not change. Furthermore, FILIP1L overexpression increased apoptosis, cleaved 
caspase-3 and -7 and induced sub-G1 cell cycle arrest in HCT116 cells, while FILIP1L 
knock-down had the opposite effect on COLO205 cells. Park et al. used conditioned 
medium (CM) from either HCT116 cells overexpressing FILIP1L or FILIP1L knock-
down COLO205 cells to evaluate the effects of FILIP1L on angiogenesis. When 
HUVECs were cultured using CM from FILIP1L knock-down COLO205 cells, 
HUVEC invasion was significantly increased in comparison to CM from control 
COLO205 cells. Vice-versa, CM from FILIP1L overexpressing HCT116 cells 
reduced HUVEC invasion in comparison to CM from control HCT116 cells. 
Angiogenic inducers VEGF-A and HIF-1α were up-regulated and angiogenic inhibitor 
angiostatin was reduced in FILIP1L knock-down COLO205 cells, while in FILIP1L 
overexpressing HCT116 cells expression of VEGF-A and -D was reduced and 
expression of angiostatin and endostatin was increased. Park et al. tested if FILIP1L 
mediates WNT signaling in colorectal cancer, and indeed, FILIP1L expression (either 
knock-down or overexpression) correlated with levels of phospho-β-catenin and 
negatively correlated with levels of phosphorylated AKT and GSK3β levels. In fixed 
colorectal cancer tissues (n=354), FILIP1L was primarily located in the cytoplasm and 
expression was lower in colorectal cancer compared to colorectal epithelial cells. 
TUNEL assay revealed, that apoptotic index (AI) did not correlate with FILIP1L 
expression. However, proliferation (as measured by Ki-67 staining) and angiogenesis 
(CD34) were significantly reduced in FILIP1L positive tumors. Furthermore, FILIP1L 
positive tumors were significantly smaller, more differentiated, showed less 
lymphovascular invasion, were lower in cancer stage, had a lower depth of invasion 
and less lymph node metastasis. Patients with FILIP1L positive tumors had 
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significantly longer overall survival than patients with FILIP1L negative tumors. The 
Cox proportional hazard model revealed, that low FILIP1L expression was 
independently associated with poor overall survival, suggesting FILIP1L may have an 
important role in colorectal cancer [225].  
Unrelated to the function of FILIP1L in cancer, FILIP1L was found by Liu et al. [226] 
when they examined the effect of melatonin on pig granulosa cells. Exogenous 
melatonin promotes the maturation of oocytes by granulosa cells (GCs) as in pigs, low 
melatonin doses cause GCs to produce estradiol. Using transcriptome sequencing, 
they found 78 differentially expressed genes when pig GCs were treated with 
melatonin. Among those genes, FILIP1L was upregulated. When Liu et al. knocked 
down FILIP1L using siRNA, estradiol production in GCs was reduced [226]. 
Pan et al. [227] found that circular RNA (circRNA) Filip1l is expressed in spinal cords 
of mice with chronic inflammation pain. CircRNAs arise from alternative splicing and 
are highly stable. Several different modes of action have been proposed for circRNAs, 
including regulation of micro RNAs (miRNAs), e.g. the interaction of ciRS-7 and 
miRNA-7 in cancer [228]. When chronic inflammatory pain was induced by 
subcutaneous injection of carrageenan- and complete Freund's adjuvant (CFA), 
circRNA-Filip1l was induced in spinal cords after 1 day, peaked at 3 days and came 
down to baseline levels after 14 days. Circ-Filip1l was located in spinal nuclei. 
Expression of circ-Filip1l in mouse spinal cords using lentivirus mimicked the 
nociception-like behaviour. As miRNAs have been shown to influence circRNA 
expression, Pan et al. used the miRBase (http://www.mirbase.org/) miRNA database 
to search miRNAs that could bind circ-Filip1l and identified miRNA-1224 as a 
potential regulator. Indeed, CFA decreased miRNA-1224 expression in spinal cords 
from 2 h to 7 d after injection. Expression of miRNA-1224 in spinal cords decreased 
levels of circ-Filip1l expression and miRNA-1224 inhibitor had the opposite effect. 
Interestingly, both treatments had no effect on precursor circ-Filip1l. Injecting 
miRNA-1225 mimics into spinal cords also attenuated nociceptic effects of CFA. 
Regulation of circRNAs has been shown to be Ago2 dependant manner. Using AGO2 
antibody, Pan et al. were able to pull down both, pre-cic-Filip1l and miRNA-1224. 
Silencing of Ago2 in mouse spinal cords did significantly upregulate circ-Filip1l 
following CFA treatment, but did not have an influence on prec-circ-Filip1l, 
suggesting circ-Filip1l is controlled by miRNA-124 in an Ago2 dependant manner. 
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They used in silico prediction to identify genes that could be regulated by circ-Filip1l 
and found ubiquitin protein ligase E3 component η-recognin (Ubr5) as a potential 
target. Ubr5 is associated with neuronal plasticity and pathological processes of the 
central neural system. Indeed, Ubr5 was upregulated in spinal cords of CFA treated 
mice and circ-Filip1l overexpression also induced Ubr5. The nociceptic effects of circ-
Filip1l overexpression were significantly reduced when Ubr5 was silenced using 
siRNA. Taken together, this results suggest a model, in which pre-circ-Filip1l splicing 
is prevented by miRNA-1244 in an Ago2 dependant manner under normal conditions, 
but under conditions of inflammatory pain, due to miRNA-1244 down-regulation, pre-
circ-Filip1l is spliced into circ-Filip1l that in turn promotes Ubr5 expression and 
downstream signaling [227]. 
1.4.3 FILIP1L as novel tumor suppressor gene 
Although the number of studies on FILIP1L is limited, the fact that this novel tumor 
suppressor gene is consistently down-regulated in many cancers, correlates with tumor 
grade and the risk of metastasis in ovarian and colorectal cancer, and is an independent 
prognostic marker for survival, highlights that FILIP1L is an important mediator of 






















0.45 µm syringe filter  Thermo Scientific  
96 Well MicroampTM Optical 96-Well Reaction Plates Thermo Scientific  
ABsolute qPCR Plate Seals Thermo Scientific  
Cell Scrapers  Sarstedt  
Coolcell® Cell Freezing Container   Biocision  
Coverslip  Marienfeld  
Cryotubes  Nunc  
Eppendorfs  Sarstedt  
Falcons  Corningcentristar  
Flask  Thermo Scientific  
Petri Dish  Thermo Scientific  
Qiashredder   Qiagen  
Tips (20, 100 and 1000 µl)  Starlab  
Tissue culture plates (6, 12, 96 well) Thermo Scientific  
  
2.1.2 Chemicals 





2-Propanol VWR  
Acetic Acid  Bio Rad  
Acrylamide–Bis-Acrylamide Stock  Invitrogen  
Agarose  Sigma  
Ammonium Persulfate  Sigma  
Ampicillin Sigma 
Bovine Serum Albumin  Chemometec  
Bromophenol Blue Sigma 
Chloroform Sigma 
DNA Gel Loading Dye  Sigma 
DTT   Sigma 
EDTA  Sigma  
Ethanol VWR  
Fugene HD Transfection Reagent   Promega  
Gelatin porcine skin   Sigma  
Glycerol  VWR  
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Glycine  Fisher Biolegends  
Guanidine Hydrochloride Sigma 
HEPES Sigma 
Membrane Amersham Protran Supported 0.45µm  GE Healthcare Life  
Methanol   VWR  
MgCl2   Sigma  
MOPS Running Buffer   Invitrogen  
NaCl  Sigma  
NaOH  Sigma  
Non-fat milk powder  Marvel  
Nupage™ 4-12% Bis-Tris Protein Gel  Novex, Life  
PBS Tablets  Oxoid  
Ponceau S Solution   Sigma  
Potassium chloride VWR  
Puregene Proteinase K Qiagen 
SDS  Sigma  
Seeblue Pre-Stained Protein Standard   Invitrogen  
Sodium Azide  Sigma  
Sybr Safe  Invitrogen  
T4 DNA Ligase & buffer  NEB  
TaqmanTM Universal PCR Master Mix   Thermo Scientific  
TEMED  Sigma 
TRI Reagent Sigma 
Tris Base  Sigma  
Tris-HCL   Sigma  
Triton X-100  Merck  
Tween 20  Sigma  
  
2.1.3 Kits 




AllPrep DNA/RNA/Protein Mini Kit Qiagen  
Maxiprep   Qiagen  
Miniprep Kit   Qiagen  
Omniscript Reverse Transcriptase  Qiagen  
Pierce™ BCA Protein Assay Kit   Thermo Scientific  
RNAse-Free DNAse Set   Qiagen  






2.1.4 Tissue Culture 




Dulbecco’s Modified Eagle Medium (DMEM)  Gibco  
Ham’s F-12 Nutrient Mix  Gibco  
Keratinocyte-SFM Gibco 
Keratinocyte-SFM Medium Kit Gibco 
RPMI 1640  Gibco  
Opti-MEM Media  Gibco  
AlamarBlue cell viability reagent Thermo 
Cholera Toxin  Sigma  
Fetal Bovine Serum  Labtech  
Human Keratinocyte Growth Supplement (HKGS)  Gibco  
Hydrocortisone  Sigma  
Insulin  Sigma  
Lipofectamine RNAiMAX reagent  Invitrogen  
Mycoalert® Mycoplasma Detection Kit  Lonza  
Penicillin-Streptomycin (10,000 U/mL)  Gibco  
Plenticrispr V2   Addgene  
pMD2.G  Addgene  
Polybrene  Santa Cruz  
psPAX2  Addgene  
Puromycin   Santa Cruz  
Recombinant Mouse EGF   Gibco   
Transferrin  Sigma  






2.2.1 10x PBS  
100 PBS Tablets 
Sodium Chloride 137 mM   
Phosphate Buffer 10 mM   
Potassium Chloride 2.7 mM (pH 7.4)  
dH2O up to 1 L  
 
2.2.2 1x PBS 
100 mL of 10x PBS  
900 mL of dH2O   
Autoclaved  
2.2.3 RM- Medium 
2 mg Cholera toxin 
1 g hydrocortisone 
500 mg insulin  
500 mg transferrin   
100 mg 3,3’5-Triiodo-L-thyronine sodium salt  
100 mL of Ham’s F12 nutrient mixture  
300 mL of DMEM (Dulbecco’s Modified Eagle Medium)  
40 mL of FBS (Fetal bovine serum) 
2.2.4 RM+ Medium 
2 mg Cholera toxin  
1 g hydrocortisone 
500 mg insulin 
500 mg transferrin   
100 mg 3,3’5-Triiodo-L-thyronine sodium salt  
1 mg mouse Epidermal Growth factor  
100 mL of Ham’s F12 nutrient mixture  
300 mL of DMEM   
40 mL of FBS   
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2.2.5 Protein wash solution 
0.3 M guanidine hydrochloride 
In 95% ethanol 
 
2.2.6 2x SDS protein buffer 
100 mM Tris-HCl 
4% SDS (w/v) 
20% glycerol (v/v) 
50 mM EDTA 
10% β-ME (added after protein quantification) 
Bromophenol blue (added after protein quantification) 
 
2.2.7 BCA Protein Assay Reagent B 
4 g copper (II) sulphate pentahydrate   
100 mL dH2O  
 
2.2.8 Subcellular Fractionation (SF) buffer 
20 mM HEPES pH 7.4 
10 mM KCl 
2 mM MgCl2 
1 mM EDTA 
1 mM EGTA 
 
2.2.9 10 x Transfer Buffer 
30.3 g Glycine  
144 g Tris Base  






2.2.10 1x Transfer Buffer 
200 mL of methanol  
100 mL of 10x Transfer buffer 
0.1 % SDS 
dH2O up to 1 L 
 
2.2.11 10x TBS 
24.23 g Tris-HCL   
80.6 g NaCl   
dH2O up to 1 L  
Adjust pH to 7.6 using HCl 
 
2.2.12 1x TBS and TBS-T 
100 mL 10x TBS 
900 mL dH2O 
1 mL Triton X-100 for TBS-T 
 
2.2.13 Ampicillin (stock 100 mg/ml)  
1 g Ampicillin dH2O up to 10 
mL  
Filter, aliquot and freeze at -20 °C  
 
2.2.14 Ampicillin LB Agar 
LB Agar 






2.2.15 50x TAE Buffer 
242 g Tris base  
57.1 mL Glacial 
Acetic Acid 100 
mL 0.5M EDTA 
dH2O up to 1 L  
Adjust pH to 8.0 
 
2.2.16 1x TAE Buffer 
20 mL 50x TAE buffer 
980 mL dH2O 
 
2.2.17 Agarose gels 
1x TAE buffer 
x g Agarose/L (where x is the percentage of gel) 
 
2.2.18 Stripping Buffer 
334.4 g Guanidine Hydrochloride (7 M) 
1.88 g glycine (50 mM) 
0.05 mM EDTA 
20 mM β-ME 
3.73 g KCl (0.1 M) 
dH2O up to 500 mL 
pH adjusted to 10.8 using NaOH 
 
2.2.19 Cell culture freezing medium 
FBS 
5% v/v DMSO 
Freezing medium was prepared fresh before usage 
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2.2.20 2x NTERT freezing medium 
9 mL DMEM 
9 mL Ham’s F12 nutrient mixture 
2 mL FBS 
Sterile filtrate with a 0.2 µm filter 
2 mL DMSO 




2.3 DNA, RNA and Protein Isolation  
DNA for reduced representation bisulphite sequencing (RRBS) was isolated prior to 
the start of this project using the protocol described in [59]. In brief, mouse skin tumors 
were harvested and snap frozen in liquid N2. Tumor tissue was enriched using laser 
capture microdissection and genomic DNA was isolated using the QIAmp DNA micro 
kit (Qiagen) according to the manufacturers protocol. Genomic DNA was then used 
for RRBS library preparation as described in Section 2.4.1. 
For all following experiments, DNA, RNA and protein were isolated from fresh 
frozen tissue or cell pellets using a combination of TRI reagent (Sigma Aldrich) and 
the Qiagen AllPrep DNA/RNA kit. The manufacturers’ protocol was modified in 
order to increase DNA and RNA yield and quality as well as meeting the requirements 
to the usage of TRI reagent. All used buffers were obtained from Qiagen.  
2.3.1 Tissue processing and DNA, RNA, Protein separation  
Fresh frozen samples were pulverized using a mortar. Sample integrity was ensured 
by pre-cooling the mortar and pestle with liquid N2 and the sample was cooled 
throughout pulverization using liquid N2. If DNA, RNA or protein was isolated from 
cell lines, cells were first pelleted using a microcentrifuge. Cell pellets were then 
washed using cold PBS and pelleted again before isolation. Cell suspensions and 
pellets were placed on ice throughout harvest. 
For isolation, 20 – 50 mg of tissue powder or cell pellets were lysed with 500 µL RLT 
Plus buffer, supplied with 1% v/v β-mercaptoethanol (β-ME). After complete lysation, 
samples were centrifuged (3 min, 10000 rpm) in order to remove non-soluble 
components. For DNA binding, residual liquid was transferred to an AllPrep DNA 
spin column and flow through was collected in 2 mL reaction tubes. AllPrep DNA 
spin columns were washed with 500 µL buffer AW1 in order to remove β-ME and 
DNA isolation was carried out as described in Section 2.3.2. 
In order to separate RNA and protein, 1 mL of TRI reagent was added to the flow 
through from the previous step, followed by vortexing. After incubation for 5 min at 
RT, 200 µL chloroform were added followed by vortexing and incubation for 15 min 
at RT. Phase separation was achieved by centrifugation (15 min, 13000 rpm, 4 °C). 
The colourless, aqueous phase, containing the RNA, was transferred to a new 2 mL 
reaction tube and incubated for 15 mins at RT after addition of 500 µL 2-propanol and 
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used for RNA isolation as described in Section 2.3.3. The red, organic phase was used 
for protein isolation following the protocol in Section 2.3.4. 
2.3.2 DNA isolation  
DNA was bound to AllPrep DNA spin columns as described in Section 2.3.1. 
Columns were inverted during initial washing with 500 µL buffer AW1 in order to 
remove β-ME completely. DNA was eluded from columns in 40 µL PBS and 10 µL 
RNAse (Plasmid Maxi kit, Qiagen) was added. RNA was digested for 30 min at 56 °C 
before the eluate was transferred to the AllPrep DNA spin column again, following 
RNAse on-column digestion for additional 15 min at 56 °C. Columns were washed 
using buffer AW1 and flow though was pipetted on the columns again in order to 
ensure complete DNA binding. Protein was digested on-column using 20 µL 
proteinase K solution (Qiagen) mixed with 60 µL buffer AW1 for 30 min at RT. 
Columns were washed twice with buffer AW1 before two final washing steps with 
buffer AW2. Columns were inverted during both washing steps in order to remove 
residual contaminates from buffer AW1. Columns were dry centrifuged (5 min, 
13000 rpm) and DNA was eluted using 50 µL buffer EB. The eluate was pipetted 
back on the column in a second elution step in order to concentrate DNA.  
DNA concentration and purity were measured using the NanoDrop ND-1000 
Spectrophotometer and DNA was stored at 4 °C with tubes being sealed with parafilm 
to prevent evaporation. 
2.3.3 RNA isolation  
All centrifugation steps for RNA isolation were carried out at 4 °C. The RNA 
containing aqueous phase was handled as described in Section 2.3.1. Protein 
digestion was achieved by adding 15 µL proteinase K solution (Qiagen) to every tube 
and incubation for 15 min at RT. In order to ensure RNA binding to columns, 400 µL 
buffer RW1 was added and mixed briefly by inverting the tubes. AllPrep RNA spin 
columns were primed using 200 µL buffer RW1. The entire solution then was 
transferred to spin columns in steps of 700 µL using a vacuum manifold. After 
washing the columns with 400 µL buffer RW1, remaining DNA was digested on 
column using 10 µL DNAse I in 70 µL buffer RDD (RNAse-free DNAse Set, Qiagen) 
for 15 min at RT. Columns were washed using 500 µL buffer RW1 and flow through 
was pipetted on the spin columns again in order to ensure complete RNA binding. 
Columns were washed twice with buffer RPE and inverted in both washing steps to 
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ensure removal of residual contaminations from buffer RW1. Columns were dry 
centrifuged (5 min, 13000 rpm) and RNA was eluted using 30 µL RNAse-free water. 
The eluate was pipetted back on the column in a second elution step in order to 
concentrate RNA.  
RNA concentration and purity were measured using the NanoDrop ND-1000 
Spectrophotometer and RNA was stored at -80 °C. 
2.3.4 Protein isolation  
Protein was precipitated from the red, organic phase from Section 2.3.1 by adding 
1 mL 2-propanol and incubation for 1 h at RT. Protein was pelleted by centrifugation 
(10 min, 13000 rpm, 4 °C). Protein pellets were washed twice using 1 mL wash 
solution (Solution 2.2.5) for 20 min. Between washing steps, washing solution and 
protein pellets were centrifuged for 5 min at 13000 rpm at 4 °C.  
After the final washing step, protein pellets were stored in washing solution at -20 °C.  
For usage in further experiments, protein pellets were resuspended in 2 x SDS buffer 
(Solution 2.2.6). To ensure complete lysis, protein was heated to 50°C and 
temperature was increased to 100°C in a shaking heat block. Once heated to 100°C, 
proteins were boiled for 5 mins and then sonicated (2x 10 s, 20% amplitude, Ultrasonic 
processor, Cole-Parmer instruments, Illinois, USA). Protein was boiled for an 
additional 5 mins in a shaking heat block. 
Protein concentration was measured in triplicates using BCA protein assay (Thermo 
Scientific) using albumin standard (Thermo Scientific). Protein samples were diluted 
1:10 with water and 10 µL of dilution was mixed with 200 µL of BCA solution, 
previously prepared by mixing Reagent A with 1:50 volumes of Reagent B. After 
incubation for 30 mins at room temperature on a shaker, absorbances were measured 
using the Spectromax M2 microplate reader (Molecular devices) at 562 nm. Protein 
concentration was determined according to BSA standards and protein subsequently 
was diluted to a suitable concentration and reducing agent 10% β-ME v/v and 




2.4 Analysis of global DNA methylation in solar simulated UV induced 
mouse cutaneous squamous cell carcinoma 
The goal of this study was to examine DNA methylation in cutaneous squamous cell 
carcinoma (cSCC) in mice and the feasibility to use solar simulated UV (ssUV) 
induced mouse cSCC as a model for the human disease. Therefore, we studied global 
methylation in 7 mouse cSCC tumors, alongside matching control samples from 
ventral skin of the same mouse, that has not been exposed to UV radiation. A technical 
replicate was included for one of the controls as well as one of the tumor samples. 
Additionally, two independent dorsal skin control samples were obtained from mice 
of the same age as the study group, living under the same conditions, but not exposed 
to UV-treatment. All samples were subjected to (oxidative) reduced representation 
bisulphite sequencing ((ox)RRBS). 
RRBS was performed at the Ghent University NXTGNT sequencing facility, Belgium. 
Data was analysed in collaboration with the group of Professor Tim de Meyer (Cancer 
Research Institute Ghent, Belgium). 
2.4.1 Library preparation and Sequencing 
DNA for library preparation was isolated following the protocol described in 
Section 2.3. Library preparation and sequencing were performed by NXTGNT. Upon 
arrival, DNA samples were subjected by Quant-iT™ PicoGreen™ dsDNA Assay Kit 
(P7589, ThermoFischer) for quality assessment. No aberrations were detected, and 
1 µg DNA was used for MSP1 digestion. Digestion was performed overnight for 16 h 
at 37°C in a volume of 30 µL and stopped with 5 µL 0.5 M EDTA. Subsequently, the 
digestion product was purified with the GeneJET PCR Purification Kit (K0701, 
ThermoFischer), eluted in 50 µL elution buffer and quality was checked again on E-
Gel™ EX Agarose Gels, 1% (G401001, ThermoFischer). NEBNext Ultra DNA 
Library Prep Kit for Illumina (E7370, New England Biolabs) and TrueMethyl seq kit 
(Feb 2015, Cambridge Epigenetix) were used for library preparations. For both kits, 
the protocol was followed according the manufacturers recommendations. Samples 
were split into two aliquots (each 275 ng) of which one was oxidized for oxRRBS. 
After bisulfite conversion and subsequent clean up reaction, polymerase chain reaction 




Table 9: PCR protocol for amplification of (ox)RRBS libraries. 
Name Temp  Time  Cycles 
Denaturation 95°C 1 min 1 
Cycling 
95°C 15 sec 
15 
61°C 30 sec 
72°C 1 min 
Final 
Extension 72°C 7 min 1 
Hold 4°C ∞   
 
Agencourt AMPure XP Bead Clean-up 1:1 (E6260) was performed for cleanup and 
DNA fragment length selection. Finally, a DNA high sensitivity chip on the 
Bioanalyzer (Agilent technologies) and measurements of qPCR quantification 
according to the Illumina protocol (“qPCR quantification protocol guide”) concluded 
the last quality control steps. 
Sequencing was performed on the NextSeq500 using 7 dark cycles on single read 
fragments with a length of 76 bp. A concentration of 1.8 pM was loaded with a 15% 
PhiX spike-in.  
The Mouse reference genome as provided by Ensembl (GRCm38/mm10) was used 
for mapping of (ox)RRBS sequencing reads. Quality control and filtering of low-
quality reads was performed using “Trim Galore!” (Babraham Bioinformatics). 
Quality control indicated no major problems, so Bismark (v.0.16.3, Babraham 
Bioinformatics) was used in Bowtie2-mode [229], for mapping. Seed length, 
mismatches and interval during multiseed alignment were set to the default values.  
2.4.2 Differential methylation analysis 
The differential methylation analysis was performed in R (v. 3.3.1) using 
Bioconductor (v. 2.34.0). The aligned data was imported using the BiSeq-package 
(v. 1.14.0) in R. Comparison between average methylation percentages of different 
states (e.g. cases vs controls) was performed using anova analysis and subsequent 
Tukey post hoc analysis if more than two groups were compared. Additionally, for 
correlation calculations, Pearson correlation was performed. 
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The raw counts were used to calculate methylation percentages per CpG (β-values, 
(1)) and subsequently M-values (2), with constant equal to 0.01. M-values were 
demonstrated to have superior statistical properties for Infinium HumanMethylation 
BeadArray data [230], but can also be applied on methylation sequencing data [231], 
and yield more appropriate data to be used with the R Bioconductor limma package 
(v. 3.30.13).   
 
𝛽 =  
 # 𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑒𝑑 𝑟𝑒𝑎𝑑𝑠
# 𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑎𝑑𝑠
      (1)       
𝑀 =  log2 (
𝛽 + 𝐶𝑡𝑒
1 − 𝛽 + 𝐶𝑡𝑒
)     (𝐶𝑡𝑒 = 0.01)     (2) 
 
The calculation of β- and M-values implies intrinsic normalization (i.e. biases are 
largely equal for methylated and unmethylated reads), therefore no additional 
normalization between samples was performed. Data was however filtered to improve 
quality: (i) all loci that have a minimal coverage lower than 8x were considered 
insufficiently informative and were removed from the dataset, (ii) a minimum of 6 
methylated reads over all samples was required to be retained in the dataset for further 
analysis (i.e. at least some methylation should be present). Finally, after statistical 
analysis with limma (per CpG), the Benjamini-Hochberg procedure was used to 
calculate false discovery rates (FDR), and set at a threshold of 10% to indicate 
significance. 
For analysis of differentially methylated regions. the clusterSites function of the BiSeq 
package was used to search for agglomerations of CpG sites. A minimum of 15 CpGs 
in maximum 200 bp found in at least 75% of all samples are considered a potential 
differentially methylated region (DMR). The BiSeq package uses beta binomial 
regression to estimate p-values for each potential DMR [232].  
2.4.3 Comparison with independent data 
To evaluate the relevance of the mouse model in a human context, results were 
compared with human cSCC Infinium HumanMethylation BeadArray data created by 
Rodriguez-Paredes et al. [190]. The data were downloaded via the ArrayExpress 
database (accession: EGAS00001002670) and imported using the wateRmelon 
package (v. 1.18.0). Data was analysed using the same strategy that previously was 
used to analyse the RRBS data from mouse cSCCs, i.e. linear models of the M-values 
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by means of limma. Due to the high sample size (n=46), and thus more power, 
compared to the RRBS dataset (n=16) a more conservative FDR cutoff (5%) was 
consider for the human dataset. Next to assess differentially methylated loci, we also 
evaluated the identification by Rodriguez-Paredes et al. of stem-cell like and 
keratocyte like tumor samples. The authors kindly provided sample annotation with 
respect to both tumor groups. 
Finally, genes were coined to be of major relevance when they were found in both, 
murine RRBS data and human Infinium data, and contained at least two significantly 
differentially methylated CpGs (RRBS) or probes (Infinium) with at least a 20% 
difference in average methylation between tumor vs. control. 
2.4.4 Human-mouse orthologs 
For establishing a human-mouse ortholog gene set the biomaRt package (v. 2.30.0) 
for R was used. Ensembl annotation is broadly used and contains homology 
information to be used for paralog or ortholog identification. The human genome, 
assembly GRCh37, was used in combination with the latest reference genome for 
mouse (assembly GRCm38/mm10), since this version is the most complete for gene 
symbol annotation [233]. BiomaRt gives an indication whether there is a high or low 
likelihood of two genes (one human, one murine) being orthologous. In case multiple 
genes with a high likelihood were found, the gene with the highest degree of homology 
was selected. Also, in case no gene with a high likelihood was found, the gene with 
the highest percentage of homology was selected. For both cases, if homology 
percentages were equal, genes with an identical gene symbol were preferred over their 
fellow candidates. If the latter still resulted in redundant candidates, all were kept as 
candidate human-mouse orthologs.  
2.4.5 Building UCSC bed tracks 
For visualization, results were compiled as a BedGraph file 
(https://genome.ucsc.edu/goldenpath/help/bedgraph.html). For all significant probes, 
the methylation percentage is displayed as a positive value (between 0 and 1) whereas 
for non-significant probes, the methylation percentage is displayed as a negative value 
and in a different colour. Significance of a probe is defined as was mentioned before 
(RRBS: FDR<0.10; Infinium: FDR<0.05). This definition for significance is retained 
respectively for both analyses throughout this manuscript.  
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2.4.6 Clustering  
Clustering was achieved by using the 10,000 most variant loci over all samples, 
thereby excluding noise and low informative loci. As a measure for the equality of 




2.5 Generation of FILIP1L isoform 203 expression vector 
To investigate the effect of overexpressing FILIP1L isoform 203 (referred to just 
FILIP1L) in cell lines that have low expression, FILIP1L isoform 203 coding sequence 
was cloned into the mammalian expression vector pcDNA 3.1 V5/His A.  
2.5.1 FILIP1L coding sequence amplification 
FILIP1L coding sequence (CDS) was amplified from genomic DNA isolated from 
NTERT immortalized human keratinocytes using KOD Hot Start DNA polymerase 
(Merck) using the primers depicted in Table 10. Each 50 µL PCR contained the 
following reagents: 5 µL 10x Buffer, 3 µL MgSO4 (25 mM), dNTP Mix (5 mM each, 
Invitrogen), primer mix (10 µM forward and reverse each), 200 ng genomic DNA, 1.5 
µL DMSO (Thermo), 1 µL KOD Hot Start polymerase and water to a final volume of 
50 µL. PCR was performed with an  initial denaturation and enzyme activation step at 
95°C for 2 min, 40 cycles of 95°C (20 s), 59°C (10 s) and 70°C (1 min 20 s), followed 
by a final elongation step at 70°C for 10 min. PCRs were run on a 0.7% agarose gel 
in TAE buffer (see Solution 2.2.15). DNA of the correct size (2814 bp) was cut out 
and isolated from the agarose gel using the NEB Monarch DNA gel extraction kit 
using the manufacturers protocol. 
Table 10: Primers used for FILIP1L CDS amplification. Primer annealing sequence in bold, 
restriction enzyme cutting sequence (purple) as well as spacer and overhang (grey) were added in the 
PCR amplification. 
PRIMER SEQUENCE ENZYME 
   
FILIP1L_203_FOR CGCCGC GGATCC AAG  
TGATGGTGGTGGATGAACAG  
BamHI 







2.5.2 FILIP1L CDS expression vector cloning  
Both, FILIP1L CDS (insert) and pcDNA 3.1 V5/His A (vector), were digested with 
BamHI and XhoI in Fast digest buffer (Thermo). Either 1 µg of insert or vector were 
mixed with 2 µL 10x Fast Digest buffer, 1 µL BamHI, 1 µL XhoI and water in a total 
volume of 20 µL and digested for 30 min at 37°C. Restrictions were run on a 0.7 % 
agarose gel and DNA of the correct size (insert 2801 bp, vector 5441 bp) were cut out 
and isolated from the agarose gel using the NEB Monarch DNA gel extraction kit 
using the manufacturers protocol. 
Expression plasmid was created by mixing 60 fmol of insert and 20 fmol of vector 
with T4 ligation mix (4 µL 5x T4 buffer, 1 µL T4 ligase (1 U/µL), water to 20 µL) 
and incubated at room temperature over-night. Ligations (5 µL) were transfected in 
competent E. coli DH5α. Bacteria were plated on LB agar plates containing 
100 µg/mL ampicillin and allowed to grow at 37°C over-night. Colonies were picked 
and used to inoculate 5 mL of LB ampicillin medium and were grown over night at 
37°C. Bacterial plasmid DNA was then isolated using the QIAprep Spin Miniprep kit 
applying the manufacturers protocol. In order to ensure the FILIP1L expression vector 
contained the correct insert, 1 µg of plasmid DNA was digested with BamHI and XhoI 
and digestion was analysed on a 0.7 % agarose gel. Plasmids that showed the correct 
DNA fragment sizes (insert 2801 bp, vector 5441 bp) were sequenced with the help 
of the Tayside Centre for Genomic Analysis using the primers listed in Table 10 and 




2.6 Tissue culture 
Human cells, primary and cell lines, were cultured under sterile condition in flasks and 
maintained at 37°C in a humidified incubator with 5% CO2 (HERAcellTM incubator). 
Cells were ensured to be free of mycoplasma contamination by routine testing using 
MycoAlert® Mycoplasma Detection Kit (Lonza).    
2.6.1 Cutaneous squamous cell carcinoma cells 
Cutaneous Squamous Cell Carcinoma cells (cSCC) were isolated from tumour tissue 
obtained from patients after written and informed consent. Details for the human cSCC 
cell lines as well as references for cell line isolation can be found in Table 11. 
Before plating, cell stocks were rapidly thawed in a 37 °C water bath, suspended in 
10 mL warm RM- medium (see Solution 2.2.3), centrifuged at 1000 rpm for 3 mins 
and resuspended in warm RM- medium to remove DMSO. Cells were cultured for 
24-48 h in RM-  until all cells adhered to culture flasks. After that, medium was 
changed to RM+ (see Solution 2.2.4). Culturing and all subsequent experiments were 
performed in RM+ medium. 
The cSCC cell lines contain a population of feeder fibroblasts that are required during 
first passages after cell isolation. Fibroblast population was kept as low as possible 
during all experiments by removing fibroblasts during cell passaging. Cells were first 
washed with PBS and then incubated with 1:3 0.05% Trypsin in EDTA in PBS at 
37 °C until fibroblasts detached. Fibroblast were aspirated, and cells were washed with 
PBS. cSCC cells were removed from flask by incubation with 0.05% Trypsin in EDTA 
for a further 3-4 mins at 37 °C. Trypsin was inactivated by adding fresh RM+ medium 
and removed by centrifugation of cell suspension for 3 mins at 1000 rpm. Cells were 
resuspended in fresh RM+ medium and plated in a new flask. cSCC cells were splitted 
to a maximum of 1:5 and maintained to a maximum passage of 30. 




Table 11: Origin and characteristics of cSCC cell line panel. 
 
Category  Age Sex Tumour site  Tumour 
histology  
Ref.  
       







77 M Right 
preauricular 




MET1  Renal transplant 
progression series: 
primary tumour   






MET2  Renal transplant 
progression series: 
recurrence tumour   







MET4  Renal transplant 
progression series: 
metastasis tumour   
56 M Left axillary 
lymph node  
Metastasis  [83,
234] 
T9  Renal transplant 
progression series: 
unrelated primary 
tumour   
55 M Right hand  Well 
differentiated  
[83] 
IC8  Immuno-competent  51 F Buttock   Poorly 
differentiated, 
spindle cells  
[83] 
IC12  Immuno-competent   87 F Left calf  Poorly 
differentiated  
[83] 
IC18  Immuno-competent   81 M Right ear  Moderately 
differentiated  
[83] 
IC19  Immuno-competent   81 M Scalp  Well 
differentiated  
[83] 
T2  Immunosuppressed: 
Cardiac transplant  
66 M Hand  Well 
differentiated  
[83] 
T8  Immunosuppressed: 
Renal transplant 
67 M Ear  Poorly 
differentiated  
[83] 
T10  Immunosuppressed: 
Renal transplant 
60 M Left Shin  Moderately 
differentiated  
[83] 
T11  Immunosuppressed: 
Renal transplant 
48 M Back  Poorly 
differentiated  
[83] 
       
 
2.6.2 NTERT immortalized keratinocytes 
NTERT cells are human keratinocytes, that have been immortalized by telomerase 
activity [235]. NTERT cells were maintained in Keratinocyte serum free medium 
(K-sfM, Gibco), supplied with ½ volume bovine pituitary extract (Keratinocyte kit, 
Gibco), 0.2 ng/ml of human EGF (GIBCO) and 0.4 mM of CaCl2, at 37°C in 5% CO2. 
EGF was added to K-sfM fresh before use. NTERT cells were passage by washing 
cells 3x with PBS, before incubation with 0.05% Trypsin EDTA at 37 °C until cell 
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detached. Trypsin was inactivated by adding fresh K-sfM and removed by 
centrifugation of cell suspension for 5 mins at 400 rpm. Cells were resuspended in 
fresh K-sfM and plated in a new flask. NTERTs were splitted to a maximum of 1:5 
and maintained to a maximum passage of 40. 
2.6.3 A431 epidermoid carcinoma cells 
A431 human epidermoid carcinoma cells were used in establishing siRNA knock-
downs and initial experiments. 
A431 cells were cultured in DMEM supplied with 10% FBS. For passaging, cells were 
washed with PBS and then incubated with 0.05% Trypsin in EDTA at 37 °C until all 
cells detached. Trypsin was inactivated with fresh DMEM medium and removed by 
centrifugation (1000 rpm, 3 min). Cells then were resuspended in fresh DMEM 
medium and plated with a maximum dilution of 1:5 and maintained to a maximum 
passage of 40. 
2.6.4 Kera308 mouse keratinocyte cells 
Mouse keratinocyte cell line Kera308 were maintained in DMEM supplied with 10% 
FBS. For passaging, cells were washed trice with PBS and then incubated with 0.05% 
Trypsin in EDTA at 37 °C until all cells detached. Trypsin was inactivated with fresh 
DMEM medium and removed by centrifugation (1000 rpm, 3 min). Cells then were 
resuspended in fresh DMEM medium and plated with a maximum dilution of 1:5 and 
maintained to a maximum passage of 40. 
2.6.5 Generation and storage of cell stocks 
In order to store cells, cell stocks were generated using the following protocol. Cells 
were first detached from flasks and trypsin was removed using the same procedure 
that was used during passaging. Cells (with the exception of NTERT cells) were then 
resuspended in freezing medium (see Solution 2.2.19). NTERT cells were 
resuspended in K-sfM and mixed 1:1 with 2x NTERT freezing medium (see Solution 
2.2.20). Cells were stored over-night in cryotubes (Nunc) at -80 °C in a CoolCell® cell 
freezing container to ensure a standardised controlled freezing rate of -1°C/minute. 
The next day, cell vials were transferred to liquid nitrogen tanks for long-term 
preservation.   
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2.6.6 Knockdown using siRNA 
Reverse transfection with siRNA was used to achieve gene knockdowns. Alongside 
each knockdown, a negative control using non-targeting siRNA was performed, using 
the maximum amounts of siRNA and transfection reagent used in the experiment. 
Optimal amounts of RNAiMAX and siRNA were determined in preliminary 
experiments and were based on knockdown efficiency determined by immunoblot and 
RT-qPCR. 
 Lipofectamine RNAiMAX mix for 6 well plate: 
 2-7µl/well of Lipofectamine RNAiMAX (Invitrogen) in 100 µl/well of 
Opti-MEM (Life Technology)  
siRNAs mix for 6 well plate: 
 10-40 nM of siRNA in 100 µl/well of Opti-MEM (Life technology) 
Lipofectamine RNAiMAX mix for 96 well plate: 
0.1-0.2 µl/ well Lipofectamine RNAiMAX (Invitrogen) in 9.8 µl/well of 
Opti-MEM 
siRNAs mix for 96 well plate: 
 10-40 nM/well of siRNA in 9.8 µl/well of Opti-MEM 
Lipofectamine RNAiMAX and siRNA mix were incubated at room temperature for 
5 minutes before being combined and vortexed. For 96 well plates, 80 µL cell 
suspensions containing 1.5 x 103 cells or 1800 µl containing 2 x 105 cells for 6 well 
plates were plated, respectively. Cells were maintained under normal growth 
conditions before analysis. 
Isoform specific siRNAs were designed using the RNAi design tool from integrated 
DNA technologies (https://eu.idtdna.com/Scitools/Applications/RNAi/RNAi.aspx). 
siRNA specificity was ensured using BLAST algorithm (see 
https://blast.ncbi.nlm.nih.gov/Blast.cgi). 




Table 12: Isoform specific siRNAs designed to perform isoform specific knock-down of FILIP1L 
in cells lines. 
NAME SPECIES ISOFORMS SEQUENCE 
    
Hs_FILIP1L_iso201/2_1 human 201 / 202 GCUCAGUAUGGGUUUGUCA 
Hs_FILIP1L_iso201/2_2 human 201 / 202 CACACAGUGGUAAUGGCCA 
Hs_FILIP1L_iso201/3_1 human 201 / 203 CUAACUGUUGCCUGCAUAG 
Hs_FILIP1L_iso201/3_2 human 201 / 203 UUGACUGCAACUUGUCUUG 
Hs_FILIP1L_iso203_1 human 203 UCGCAUUGUUCGGGCGACU 
Hs_FILIP1L_iso203_2 human 203 CUCGCAGCGCGGCACUACA 
Hs_FILIP1L_iso202/6_1 human 202 / 206 CCACUUCUUCUGCCUCAUU 
Mm_Filip1l_iso201/3_1 mouse 201 / 203 CCAAUGAAUGAGUUGGAUA 
Mm_Filip1l_iso201/3_2 mouse 201 / 203 AGACCUCUCAAGAGAUGAC 
Mm_Filip1l_iso202/3_1 mouse 202 / 203 CAAGAATGCTACTCTCTGA 
Mm_Filip1l_iso202/3_2 mouse 202 / 203 GAGAAGATGTACAGTGTAA 
    
 
Table 13: Purchased siRNA pools. 
DESCRIPTION REFERENCE SUPPLIER 
   
ON-TARGETplus Non-targeting Pool D-001810-10-50 Dharmacon 
ON-TARGETplus Human FILIP1L siRNA - SMARTpool L-019458-00-0005 Dharmacon 
   
2.6.7 Overexpression using plasmid vectors 
Overexpression experiments were used in order to restore expression in non-
expressing cells. 
Optimal concentrations of Lipofectamine and expression plasmid were determined in 
preliminary experiments. Alongside each overexpression experiment, a negative 
control using empty vector was performed, using the maximum amounts of plasmid 
and transfection reagent used in the experiment 
Cells were seeded in 6 well plates one day before transfection at a concentration of 
2 x 105 cells per well. Cell confluency was checked, and transfections were only 
performed, if confluency was between 70-90%. Cell medium was replaced with 
1.7 mL fresh medium and Lipofectamine mix was prepared by mixing 150 µL 
Opti-MEM with 2-15 µL Lipofectamine 3000 and DNA mix was prepared by mixing 
150 µL Opti-MEM with 1-10 ng/well of plasmid. After mixing, both solutions were 
combined, briefly vortexed and incubated at room temperature for 5 min. 
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DNA-Lipofectamine mixture (300 µL total volume) was dropwise added to cells and 
incubated at 37 °C. Transfection medium was replaced with fresh medium 6 h after 
transfection and effects of overexpression were analysed using RT-qPCR and 
immunoblotting. 
2.6.8 Cell viability assay 
Cell viability was measured using alamarBlueTM cell viability reagent (Thermo). Cells 
were harvested as described before and plated into 96 well plates at either 1500 or 
3000 cells/well. Cells were treated with siRNA (reverse transfection at time of plating, 
see Section 2.6.6) or overexpressing plasmid (the day after plating, see Section 2.6.7). 
As controls, a corresponding number of cells were plated into 6 well plates and treated 
with the same transfection mix used for the 96 well plates. At the end of the 
experiment, treatment efficacy was controlled by harvesting cells from 6 well plates, 
isolating protein and RNA and checking expression levels via RT-qPCR and 
immunoblotting. 
At time of measurement, cell medium was aspirated and replaced with fresh medium 
supplied with 10% (v/v) alamarBlue reagent. Cells were incubated for 4 h at 37 °C 
and absorbance was measured using the Spectromax M2 microplate reader (Molecular 
devices) at 570 nm. All samples were normalized to control wells containing no cells. 
2.6.9 Cell proliferation 
Cell proliferation was measured using the IncuCyte Live-Cell Imaging System 
(Sartoris). In brief, cells were plated at appropriate densities in 6 well plates. Cells 
were transfected using the protocols described in Sections 2.6.6 and 2.6.7. Images of 
cells were taken every 24 h for 96 h, with 16 images per well per time point. 
Confluency analysis with performed using the IncuCyte Zoom Software. Confluency 
masks were controlled manually in order to ensure all cells were correctly identified 
and false positive signals (e.g. debris) were minimal. Mean confluency measurements 
of all 16 images of a well were taken as the readout and used for subsequent analysis. 
As an independent measurement, additional 6 well plates were set up in the same way 
as described above. Cells were harvested after 96 h, while great care was taken to 
ensure all cells were removed from plates. Cells were counted using the Countess II 
automated cell counter (Thermo). 
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Efficacy of overexpression or knockdown were controlled by treating cells with the 
same transfection mix used in the experiment, isolating RNA and protein and checking 
expression levels via RT-qPCR and immunoblotting. 
2.7 Nuclear-cytoplasmic separation 
Nuclear cytoplasmic separation was achieved by first washing cells twice with ice cold 
PBS before resuspension in 1 mL subcellular fractionation buffer (SF buffer, see 
Solution 2.2.8). Cells were pushed through a 27G needle 20 to 25 times using a 2 mL 
syringe. To ensure complete lysis, 10 µL of cell suspension was mixed with 10 µL of 
trypan blue and lysis was checked using a light microscope. Additional lysis using the 
syringe and needle was performed if lysis was incomplete.  
Lysed cells were incubated on ice for 20 min. Nuclei were pelleted by centrifugation 
at 720 g for 5 min. The supernatant, containing the cytoplasmic fraction, was 
transferred to a fresh tube and placed on ice. Nuclei were washed by resuspending the 
nuclear pellet in 1 mL SF buffer, incubated for 5 min on ice and pelleted again by 
centrifugation at 720 g for 5 min. Supernatant was discarded and pellet was directly 
dissolved in an appropriate amount of 2x SDS sample buffer, sonicated and boiled at 
100°C for 5 min. Protein concentration was measured using BCA assay. 
Cytoplasmic fraction was centrifuged again at 720 g for 5 min to remove remaining 
nuclear particles. Supernatant was mixed with 2 mL TRI reagent. Protein and RNA 





Protein samples were prepared using the protocol described in Section 2.3. 
Proteins were separated using precast polyacrylamide (10% or 4-12%) Bis-Tris gels 
(Invitrogen), and MOPS (Invitrogen) as running buffer. Suitable amounts of protein 
were loaded on the gel alongside 3 µL of Seeblue protein standard (Invitrogen). 
Stacking was achieved by gel electrophoresis at 100 V for 15 mins and separation was 
carried out at 120 V and run until samples reached the end of the gel. 
Proteins were transferred to a 0.45 µm supported nitrocellulose membrane (Amersham 
– GE Healthcare Life Sciences). Transfer was completed in 1x Transfer buffer 
(Solution 2.2.10), supplied with 0.1 % SDS at 100 V for 90 mins using a wet transfer 
system. An ice pack was kept inside the transfer tank and buffer was constantly stirred 
using a magnetic stirrer to avoid overheating. To ensure that protein was completely 
transferred, membranes were stained with Ponceau S solution (Sigma). Excess 
solution was washed off using dH2O and ponceau S was washed off after transfer 
quality assessment using PBS.  
Membranes were blocked using 5% non-fat milk in 1x TBS-T (Solution 2.2.12) for 
1 h at room temperature. Primary antibodies were prepared in 0.1 % non-fat milk in 
1x TBS-T in appropriate dilutions and incubated with the membrane on a roller at 4 °C 
over-night. Membranes were washed 3 times for 15 mins using 1x TBS-T. Secondary 
antibodies were diluted 1:15,000 in 0.1 % non-fat milk in 1x TBS-T and incubated for 
1 to 2 h at room temperature. Excess secondary antibody was washed off as described 
before.  
Imaging analysis was done using the Odyssey® CLx image system and Image Studio 
software (LI-COR). 




Table 14: Primary antibodies used in immunoblotting, including manufacturer, host and dilution 
used. 
Antibody  Manufacturer  Reference Clone  Host  Dil. 
      
Axin2  Abcam  Ab1093307  EPR2005(2)  Rabbit  1:500  
cMyc  Abcam  Ab32072  Y69  Rabbit  1:2000  
Cyclin D1  Cell Signaling  2978 92G2  Rabbit  1:500  
E-cadherin  Santa Cruz  Sc52327  5H9  Mouse  1:1000  
FILIP1L Sigma  SAB2105835 Polyclonal  Rabbit  1:1000 
FILIP1L Sigma  HPA043133 Polyclonal  Rabbit  1:2000 
FILIP1L Aviva ARP52360 
_P050 
Polyclonal  Rabbit  1:500 
FILIP1L Thermo 
scientific 
PA5-32021 Polyclonal  Rabbit  1:1000 
Keratin 10  Abcam  Ab76318  EP1607IHCY  Rabbit  1:1000  
Keratin 14  Abcam  Ab51054  EP1612Y  Rabbit  1:1000  
Keratin 8  Abcam  Ab53280  EP1628Y  Rabbit  1:1000  
Active β-catenin  
  (Non-phospho 
  Ser33,37,          
^Thr41) 
Cell signaling  8814 D13A1  Rabbit  1:1000  
Total β-catenin  Cell signaling  9562 Polyclonal  Rabbit  1:1000  
Total β-catenin  BD bioscience  610153 14/Beta-
Catenin 
Mouse  1:1000 
α-tubulin  Sigma  T9026  DM1A  Mouse  1:2000  
β-actin Sigma  A5316 AC-74 Mouse  1:5000 
GAPDH  Cell Signaling  2118s  14C10  Rabbit  1:2000  
H2A.X (Ser139)  Cell signaling  2577 20000 Rabbit  1:500  
      
 
Table 15: Secondary Antibodies used for immunoblotting. All secondary antibodies were 
purchased from LI-COR. 
Antibody Reference    Host  Reactivity Dilution  
      
IRDYE® 800CW  
  GOAT ANTI-MOUSE 
  IGG (H + L) 
926-32210  Polyclonal  Goat Mouse 1:15000  
IRDYE® 680RD  
  GOAT ANTI-MOUSE 
  IGG (H + L) 
925-68070  Polyclonal  Goat Mouse 1:15000  
IRDYE® 800CW  
  GOAT ANTI-RABBIT 
  IGG (H + L) 
926-32211  Polyclonal  Goat Rabbit 1:15000  
IRDYE® 680RD  
  GOAT ANTI-RABBIT  
  IGG (H + L) 
925-68071  Polyclonal  Goat Rabbit 1:15000  
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2.9 Quantitative real time PCR 
Quantitative real time PCR (qRT PCR) was performed on the Quantstudio 5 Real time 
PCR system from ThermoFischer Scientific. Universal master mix and assays were 
purchased from Applied Biosystems and if available, exon spanning assays were 
chosen. For FILIP1L isoform expression analysis, custom assays were designed as 
described below. 
2.9.1 Assay design 
In order to distinguish between different FILIP1L isoforms, custom assays were 
designed using Primer Quest online tool from Integrated DNA technologies (see 
https://www.idtdna.com/PrimerQuest) and sequence specificity was ensured by 
BLAST algorithm against the host genome and transcripts (see 
https://blast.ncbi.nlm.nih.gov/Blast.cgi).   Assays were diluted prior to usage and final 
concentrations were: 18 µM primer (each, forward and reverse) and 5 µM probe. 
Assay efficiency was tested using samples of cDNA (serial dilutions from 1:1 to 
1:10,000). Assays for isoform specific qRT PCR are listed in Table 16 and Table 17. 
Table 16: Isoform specific assay design for mouse Filip1l. Fo: forward primer, Re: reverse Primer, 
Pr: probe. Probes were fluorescently labelled with 5’ FAM as fluorophore and 3’TAMRA as quencher. 
Name Isoforms Sequence length TM 
     
Mm_Filip1l_1_Fo 201 GAGAGATGCTTTTCAAGCAAA 21 54 
Mm_Filip1l_1_Re   TCCGCCTGTGAGATTCTTTATG 22 58.4 
Mm_Filip1l_1_Pr   CAGGAGGACATCTATGAGAAACCAATG 27 63.4 
  
Amplicon length 109 
 
     
Mm_Filip1l_2_Fo 202 CCGCAGCTCAGATTAAAGAAAC 22 62 
Mm_Filip1l_2_Re   CTTCAGGGTCTTGATCCTCTTC 22 62.1 
Mm_Filip1l_2_Pr   GATCAAGAAACTGCGTCCCAGGAAAAGA 28 68.6 
  
Amplicon length 93 
 
     
Mm_Filip1l_3_Fo 203 CACAAAGAATATATGAAGAAGAG 23 53.5 
Mm_Filip1l_3_Re   TCCTTCTTTTCCTGGGACGCA 21 59.8 
Mm_Filip1l_3_Pr   TGAATTCATAAACTTATTGGAGCAGGA 27 58.9 
  






Table 17: Isoform specific assay design for human FILIP1L. Fo: forward primer, Re: reverse 
Primer, Pr: probe. Probes were fluorescently labelled with 5’ FAM as fluorophore and 3’TAMRA as 
quencher.  
Name Isoforms Sequence length TM 
     
Hs_FILIP1L_3/6_Fo 203 / 206 GGCAGTTCAGATTAAAGAAGCT
AAT 
25 61.8 
Hs_FILIP1L_3/6_Re   GCTTGGTCAGCTCCTCTTT 19 61.9 




Amplicon length 108 
 
     





Hs_FILIP1L_2/6/9_Re   TGAGTTCAATGAGGCAGAAGA
A 
22 62 




Amplicon length 104 
 
     
Hs_FILIP1L_1/3_Fo 201 / 203 ACCAATAAAGTCACCAGCAGT
A 
22 62 
Hs_FILIP1L_1/3_Re   GGTGAGCGTGGTCAGTTAT 19 62 




Amplicon length 102 
 
     
Hs_FILIP1L_3_Fo 203 CATTGTTCGGGCGACTCT 18 62 
Hs_FILIP1L_3_Re   CTTCTCCTCCTGAGACTTGATTT 23 62 




Amplicon length 147 
 
     
Hs_FILIP1L_1/2/4_Fo 201 / 202 
/ 204 
CAGCATTCTGGAGGGAGAAC 20 62 
Hs_FILIP1L_1/2/4_Re   TTTGGAGTGACAAACCCATACT 22 62 










2.9.2 cDNA Synthesis 
RNA was isolated using the protocol described in Section 2.3. cDNA was generated 
using the Qiagen Omniscipt RT kit with a modified version of the manufacturers 
protocol. Each cDNA reaction contained 2 µL 10x buffer RT, 2 µL dNTP mix 
(5 mM each), 0.5 µL RT enzyme, 0.33 µL random hexamers (50 µM, Invitrogen), 
4.67 µL water and 10 µL RNA at a concentration of 100 ng/µL. cDNA conversion 
was carried out for 90 mins at 37 °C. Before qRT PCR, cDNA was diluted 1:40 with 
water. 
2.9.3 qRT PCR 
All reactions using the same assay were set up in one mix to ensure reproducibility. 
Each reaction contained: 4.5 mL master mix, 4.75 µL water and 0.75 µL assay. For 
each reaction, 5 µL of cDNA were pipetted in one well of a 386 well plate and 10 µL 
of master mix were added. Plates were then run using standard qPCR program (50 °C 
for 2 min, 95 °C for 10 mins, 40-times 95 °C for 15 s and 60 °C for 1 min). Each 
reaction was carried out in triplicates. 
2.9.4 Data analysis  
CT values were calculated using the Design and Analysis Application on the Thermo 
Fischer Cloud (https://www.thermofisher.com/de/de/home/cloud). CT values were 
exported, and all triplicates were checked for possible pipetting errors. Values that 
were clear outliers were excluded from further analysis and CT means of triplicates 
were taken for further analysis. Data was normalized to reference genes and relative 
expression was calculated using the following formula: 
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−𝐶𝑇 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 
For certain experiments, fold change was calculated using the following formula: 
𝑓𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 2−(𝐶𝑇 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡−𝐶𝑇 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) 




2.10 Methylation analysis: MassARRAY 
In order to validate differentially methylated regions, that were previously identified 
in the analysis of oxRRBS data, we utilized the Sequenome MassARRAY technology 
in collaboration with the Division of Epigenomics and Cancer Risk Factors of the 
German Cancer Research Center (DKFZ) in Heidelberg, Germany.  
2.10.1 Bisulphite conversion of DNA 
During bisulphite conversion, cytosines in the DNA get deaminated to uracil. Because 
5-methyl-cytosine (5mC) is protected from this deamination, these cytosines continue 
to behave as cytosines in subsequent PCR applications, while converted cytosines 
(now uracils) behave like thymines, allowing to distinguish methylated from 
unmethylated input DNA. 
Bisulphite conversion was carried out using the EZ DNA methylation kit (Zymo 
Research) using a modified version of the manufacturers protocol. CT conversion 
reagent was prepared by adding 750 µL water and 210 µL M-dilution buffer to one 
aliquot of CT conversion reagent. DNA samples were prepared by adding 5 µL 
M-dilution buffer to 45 µL DNA (1 µg) and incubated at 37°C for 15 mins. Bisulphite 
conversion was achieved by adding 100 µL of previously prepared CT conversion 
reagent and incubation for 16 h at 50°C in the dark. Samples were placed on ice for 
10  min before being mixed with 400 µL M-binding buffer and transferred to a Zymo-
Spin IC column.  DNA was bound to columns by centrifugation (10,000 g, 30 s) and 
then washed with 100 µL M-wash buffer and bisulphite conversion was completed by 
desulphonation with 200 µL M-desulphonation buffer on column for 15 mins at RT, 
followed by centrifugation (10,000 g, 30 s). Bisulphite converted DNA was washed 
twice with 200 µL M-wash buffer and, after dry centrifugation at 10,000 g for 3 min, 
eluded in two steps with 25 µL 1:1 mixture of M-elution buffer and water each. 
Converted DNA, which will be referred to as bt (bisulphite treated) DNA from now 
on, was stored at -20°C. 
2.10.2 MassARRAY primer design 
In order to design MassARRAY primers, DNA sequences first were in silico BS 
converted using a Microsoft Word macro, kindly provided the Division of 
Epigenomics and Cancer Risk Factors of the German Cancer Research Center (DKFZ) 
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in Heidelberg, Germany (see Section 5.1). Primers were designed using the Agena 
Bioscience Epidesigner online tool (https://www.epidesigner.com/start3.html). 
Primers performance was tested by PCR using HotStar-Taq polymerase (Qiagen). 
Each 20 µL reaction contained: 1 µL 1:1 diluted BT DNA, 2 µL 10x PCR buffer, 
0.16 µL dNTP mix (10 mM each), 0.5 µL primer mix (10 µM each primer), 0.16 µL 
HotStar-Taq and 15.18 µL water. PCR was performed with the following steps: initial 
denaturation and enzyme activation for 15 min at 95°C, 45 cycle of denaturation at 
95° for 30 s, primer annealing at 52°C, 56°C or 60 °C for 30 s, elongation at 72°C for 
1 min and a final elongation step at 72°C for 10 min. PCRs were analysed on a 1.5% 
agarose gel and the best performing annealing temperature (either 52°C, 56°C or 
60°C), that reliably produced a single PCR product of the expected size, was used for 
generation of DNA for further usage. 
As controls, PCRs were also performed on mouse and human DNA standards of 
known methylation percentage (100%, 80%, 60%, 40%, 20%, 0%).  These controls 
were handled in parallel to the other samples. 
Table 18: Primers used to generate DNA amplicon for further methylation analysis using 
MassARRAY 
































MassARRAY amplicons were generated using the same PCR as mentioned in Section 
2.10.2 using the best determined primer annealing temperature and the best 
performing primers (see Table 18). PCRs were again checked on a 1.5% agarose gel 
to ensure specificity of reactions. 
Unincorporated dNTPs were dephosphorylated by adding 2 µL of SAP (shrimp 
alkaline phosphatase) to 5 µL PCR product from the previous step. Dephosphorylation 
was achieved by incubation at 37°C for 20 min, followed by enzyme deactivation for 
5 min at 85°C.  
Amplicons were converted to RNA and cleaved using RNase A, by mixing 2 µL SAP 
treated PCR product with 5 µL in vitro transcription (IVT) mix (containing 3.21 µL 
water, 0.89 µL 5x T7 buffer, 0.22 µL T cleavage mix, 0.22 µL DTT, 0.4 µL T7 and 
0.06 µL RNase A). IVT was carried out at 37°C for 180 min. 
As samples need to be salt free to ensure correct flying in the mass spectrometer, 
samples were treated with Clean Resin. Resin was spread into a dimple plate and dried 
for 10 min. In the meantime, 16 µL of water was added to IVT products and dried 
resin was added to each well. Desalting was achieved by rotating the plate with IVT 
product and resin for 15 min. Resin was pelleted at the bottom of the wells by 
centrifugation at 3200 g for 5 min. 
Samples were dispensed to a SpectroCHIP array using the MassARRAY 
nanodispenser (Agena Biosciences) and analysed using the MassARRAY analyser. 
Methylation standards for all primers were analysed to ensure that previous steps were 
successful in generating fragmented RNA and expected methylation percentages were 
measured. Fragments with low or high mass that do not produce reliable data were 
excluded. Furthermore, fragments with more than one silent methylated or silent non-
methylated peaks, where a fragment without analytical value has the same mass than 
the analysed fragment and therefore adds to either a methylated or non-methylated 

















3.1 Studies preceding this work 
The goal of this study was to characterize the global DNA methylation landscape in 
cSCC and to determine if the mouse model of cSCC, which was recently developed 
in our lab, reflects the methylation landscape of the human disease. The development 
of the solar-simulated UV induced murine cSCC (ssUV cSCC) model will be 
discussed below. 
3.1.1 A new preclinical model of cutaneous squamous cell carcinoma 
As discussed in the introduction (see Section 1.2.3.6), existing models to investigate 
cSCC may have deficits in accurately mapping human cSCC. For example, 
DMBA/TPA induced tumors are almost exclusively papillomas and UVB-induced 
tumors do not factor in UVA radiation which is a critical carcinogen, especially in 
immunosuppressed individuals. 
In an effort to investigate the effects of transcription factor NF-E2 p45-related factor 
2 (Nrf2), the master regulator of the oxidative stress response, on skin carcinogenesis 
our lab has developed a new murine model for cSCC. The aim was to mimic human 
cSCC development as closely as possible. The main difference between other UV-
induced models and the ssUV cSCC model is the usage of UVA-340 lamps. These 
lamps emit UV radiation, that closely mimics the energetic portion of the solar UV 
radiation spectrum (see Figure 3). Furthermore, relatively low doses of radiation and 
a longer exposure period were chosen to allow tumor development. The aim was to 
simulate exposure to UV radiation early in life, followed by development of cSCC 
over the course of adulthood. 
 
Figure 11: Histopathology of tumors forming in the ssUVR induced mouse cSCC model. Tumors 
range from pre-malignant epidermal hyperplasia, to well- and moderately differentiated tumors as well 
as poorly differentiated and invasive cSCCs. Figure taken from Knatko et al. 2015 [60]. 
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SKH-1 hairless mice that were subjected to chronic irradiation with ssUVR, showed 
a “field change”, also known as “field cancerisation”, that is typical for human cSCCs. 
This suggests that, similar to humans, irradiated mice develop multiple cSCCs in close 
proximity that arise from dysplastic epithelium. The histopathological spectrum of the 
ssUV cSCC tumors includes well-, moderately- and poorly-differentiated tumors that 
histopathologically were very similar to human cSCCs (see Figure 11) [60,135]. 
Thus, by mimicking the carcinogenic process that is known to occur in humans, the 
resulting mouse tumors are a good model to investigate human cSCC. 
3.1.2 Mouse ssUVR induced cSCC resembles the mutation spectrum of human 
cSCC 
As mentioned before, human cSCC is the most highly mutated human cancer, making 
it difficult to identify drivers of carcinogenesis that could potentially be therapeutically 
targeted. Having established that the ssUVR-induced mouse tumors are 
histopathologically similar to human cSCC, our lab aimed to further validate the 
model using whole exome sequencing. Knatko et al. performed sequencing of 18 
microdissected tumors, ranging from severely dysplastic actinic keratosis to invasive 
cSCC. They found a high single nucleotide polymorphism (SNP) rate of 155 mutations 
per Mb (low of 12 and high of 279), which is even higher than the rate observed in 
humans (an average of 30 per Mb). The vast majority (78.6 %) of these SNPs were 
C.G to T.A transitions, consistent with a characteristic UVR mutation signature. Most 
of these transitions (81.6 %) occurred following a pyrimidine base. Insertion and 
deletion (INDEL) rate was 23.5 per case, with some cases having no INDELs, and 




Figure 12: Mutation signature of ssUV induced mouse cSCC and comparison to human cSCC. 
Top left: SNP distribution occurring in mouse cSCC (mcSCC). The overwhelming majority of SNPs 
were C.G to T.A transitions, consistent with a typical UV induced mutation signature. Top right: 
Comparison of SNP distribution between mcSCC and human cSCC (hcSCC). The mutation signature 
observed in mcSCC is very similar to the one present in hcSCC. Bottom: The trinucleotide context in 
which mutations occur in mcSCC is very similar to hcSCC. Figure from Knatko et al. 2016 [59]. 
The observed mutation spectrum is remarkably similar to human cSCC. For example, 
Pickering et al., South et al. and Inman et al. reported that the primary mutation in 
human cSCC are C.G to T.A transitions, the same mutation as in the mouse ssUV 
cSCCs. Furthermore, there is a correlation between the observed trinucleotide context 
in ssUV cSCC and human cSCC. Pickering et al. and South et al. both reported C>T 
mutations predominantly occurring in a Y(C>T)N context (Y=pyrimidine, N= A/T/G) 
[58,83,101]. While regions with genes that undergo copy number gains in human 
cSCC showed significant overlap with ssUV cSCC, regions of loss did not show 
overlap. 
Because of the massive mutation burden in human cSCC, there are a plethora of 
mutated genes. The most frequently mutated gene is TP53. Mutations of the Trp53 
mouse gene were observed in 15 out of 18 samples (83%), similar to the reported 90% 
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in humans [58]. Most mutations of the Trp53 gene were located in the DNA binding 
domain of the protein, suggesting loss of function. NOTCH family genes have been 
shown to be frequently mutated in cSCC [58], with mutations typically being located 
in the EGF repeat domain. In the mouse cSCCs, genes of the Notch family were 
mutated in 10 out of 18 samples (~ 55%), with 7 out of 16 mutations located in the 
EGF repeat domain.  
3.1.3 The mouse ssUVR induced cSCC model is closely representing human 
cSCC 
Thus, mouse cSCC, which are induced by chronic intermittent exposure to ssUVR, 
are histopathologically very similar to human cSCC. Furthermore, the complex 
genetic landscape of human cSCC is represented in the mouse ssUV cSCC, as 
highlighted by the similarities in frequency, type and context of mutations, as well as 
the mutations in key tumor suppressor genes. We therefore can conclude, that the 
model is suitable to investigate the biology and possible treatment strategies for human 
cSCC.  
The whole-exome sequencing revealed frequent mutations in Tet genes, which encode 
Tet proteins that facilitate DNA demethylation. As discussed before, DNA 
methylation is an important process in cell homeostasis that plays a crucial role in 
cancer. To further validate our murine model for cSCC, we next aimed to investigate 
the ssUV cSCC’s methylome, to compare it to human cSCC and to identify 




3.2 Analysis of global DNA methylation in mouse ssUVR induced cSCC 
The first goal was to investigate if the methylation landscape of the mouse ssUVR-
induced cSCC reflects the methylation changes occurring in human cSCC. 
Furthermore, we aimed to identify differentially methylated regions (DMRs) that may 
lead to aberrant gene regulation. In order to achieve this, we used reduced 
representation bisulphite sequencing (see Section 2.4). Because of the initial finding 
of mutations in Tet genes, that are responsible for active DNA demethylation, a special 
RRBS protocol, termed oxidative RRBS (oxRRBS) was used that not only allows to 
investigate DNA methylation, but also DNA hydroxymethylation. 
3.2.1 oxRRBS data processing 
OxRRBS data was analysed as described in Section 2.4.2. Figure illustrates the data 
processing pipeline and the retained CpG sites. Results will be discussed in the 
following sections. 
 
Figure 13: Schematic illustration of oxRRBS data processing. Boxes indicate the filtering steps 
and the retained CpG loci. oxRRBS yielded information on 34,895,989 loci (Raw data) and 
Clustering was performed on the 10,000 most variable loci. In an Initial filtering step, only loci were 
retained that were sequenced in all samples and showed a minimum of 6 methylated reads per site, 
therefore removing loci with low informatic value (85,508 sites). Further filtering (Filtered data) to a 
minimum coverage of 8 resulted in 31,899 sites. Significance testing for Significant individual CpGs 
resulted in 4,940 CpGs, 134 of which remained After FDR correction. We further identified 201 
Potential DMRs, 78 of with were Significant DMRs. Results for differential methylation will be 




3.2.2 Quality control of technical replicates 
We began by studying duplicate samples for one tumor and one matched control 
sample as technical replicates. The goal was to have technical replicates that would 
allow us to evaluate the degree of variance caused by the sequencing reaction. 
Clustering analysis was performed on all samples for the top 10,000 most variant loci, 
using the Euclidian distance based on the covariance of the methylation percentages 
as a measure of equality between samples. After import, the data were filtered by 
shared regions and coverage. Only those CpGs were included, which (i) were 
sequenced in all samples and (ii) showed a minimum coverage (number of reads) of 
8. These criteria were met by a total of 86,508 CpGs.  
The cluster analysis revealed that there was a high degree of similarity between the 
technical replicates (see Figure 14). We therefore concluded that there were no major 
technical biases present in our data. In order to increase coverage and the number of 
sequenced CpGs in the technical replicates, the reads were merged over both replicates 





Figure 14: Clustering of sequenced samples based on the 10,000 most variable loci. T and C are 
tumor and control samples respectively, the number indicates the animal of origin and finally technical 
replicates are indicated by an “*”. Tumor and control samples cluster separately, indicating profound 
methylation changes between the two groups. Technical replicates cluster closely together, suggesting 
no major biases in the sequencing reaction. Technical replicates were therefore merged and treated as 
a single sample in all further analyses.  
3.2.3 Hydroxymethylation cannot be distinguished from noise in mouse skin and 
ssUV cSCC 
After the initial finding, that Tet genes were frequently mutated in ssUV cSCC, we 
were especially interested in hydroxymethylation. Tet proteins facilitate active DNA 
demethylation by oxidizing methylated cytosine (5mC) to hydroximethylated cytosine 
(5hmC), which subsequently is exchanged for cytosine through active or passive 
mechanisms (see Figure 5 in Section 1.3.2). We hypothesised, that mutations and 
possible functional impairment of Tet proteins would lead to changes in the 5hmC 
content in the DNA. Classic RRBS detects both, 5mC and 5hmC while, by utilizing 
an additional oxidisation step, in oxidative RRBS (oxRRBS) 5hmC is converted to 
5fC which is not detected as a methylated cytosine (see Figure 6). Therefore, by 
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subtracting methylated reads from oxRRBS tracks from classic RRBS tracks, the 
positions of 5hmC can be analysed. 
 
 
Figure 15: Histogram of frequency of percentage of hydroxymethylation. The vast majority of 
analysed loci show no hydroxymethylation (see x-axis: 0). Few loci are lowly hydroximethylated. Some 
loci show negative hydroxymethylation (see x-axis: < 0). This is biologically impossible. The 
distribution of hydroxymethylation appears to a Gaussian distribution around zero, indicating that 
hydroxymethylation is not distinguishable from noise. 
We therefore filtered oxRRBS data by shared regions (reads present in 100% of 
samples) and minimum coverage (minCov=8), as well as a minimal methylated read 
count of at least 6 over all samples. This resulted in a total of 31,899 CpGs. 
Considering the difference between the result for the oxidative and regular RRBS, it 
became apparent that 5hmC levels were extremely low and essentially 
indistinguishable from noise. Additionally, negative values for hydroxymethylation 
should be treated as noise and distribution of values is virtually symmetrical, further 
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suggesting hydroxymethylation levels are so low, that they are indistinguishable from 
noise. A histogram of the distribution of 5hmC levels at all analysed CpGs is shown 
in Figure 15. 
Therefore, we cannot draw any conclusions on the effects of mutations in Tet genes 
on global 5hmC content in ssUV cSCC. The low levels of 5hmC suggest that the 
removal of methylation by means of Tet proteins is either not playing a role in mouse 
skin, is only of relevance for very few loci, or the exchange of 5hmC to unmethylated 
cytosine is happening so rapidly, that we are not able to detect it with the used 
methodology. 
Since hydroxymethylation was not distinguishable from noise, the regular (full) RRBS 
data was used for all subsequent methylation analysis. 
3.2.4 General features of the ssUV cSCC methylome 
RRBS analysis yielded information on 34,895,989 CpG’s, leading to 31,889 variables 
upon filtering for minimal coverage and a minimal degree of methylation (as overall 




Table 19: Mapping statistics. Columns represent id, coverage (amount of sequenced paired-end 
fragments), number and fraction of mapped fragments, and final amount of CpGs covered, used for 
limma-voom statistical analysis. *Technical replicates, replicates with lowest coverage were not 
considered for statistical analysis (therefore “NA” for library size) 
Sample Coverage Mapped Efficiency Amount of CpGs 
B16 50246099 35897072 71.44% 148478473 
B168 31208553 11846587 37.96% 20976502 
B35 47506596 31168402 65.61% 32953329 
B352 59062762 40558384 68.67% 112782255 
B44 46671525 37466609 80.28% 214756352 
B444 46261104 31338931 67.74% 76641707 
B45 52869383 39235006 74.21% 129918624 
B54 25497793 15890153 62.32% 55121366 
B545 46097634 32793211 71.14% 157000982 
B56 55635840 40540911 72.87% 303053855 
B56* 34434081 28434250 82.58% NA 
B562 50611092 34949961 69.06% 152969508 
B562* 40463535 28614975 70.72% NA 
B77 51857150 41406489 79.85% 203128198 
B85 47469589 38480384 81.06% 182230279 
B851 49190255 33340159 67.78% 83772331 
B87 49688142 32715118 65.84% 52517052 
B874 58596499 41893348 71.49% 161520850 
 
3.2.4.1 Average methylation  
The methylome of most cancers is characterized by large stretches of non-coding 
regions of hydroximethylated DNA, while CpG island methylation, especially those 
that are associated with tumor suppressor gene expression, become hypermethylated. 
Globally, this results in a decrease in overall methylation. However, there is some 
evidence that in cSCC, global DNA methylation levels could increase, rather than 
decrease. For example, Nandakumar et al. reported an increase in global methylation 
after they irradiated SKH-1 hairless mice with UVB radiation as well as in human 
cSCC samples compared to control skin samples (see Section 1.3.4) [172].  
We calculated the means of methylation levels across all tumor samples and compared 
them to the mean methylation levels of matched controls and independent healthy skin. 
This was done on the 31,889 CpGs as described in Section 3.2.4. 
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Average methylation in ssUV cSCC was significantly higher compared to matched 
control skin (pairwise t-test, p=0.007, see Figure 16). Due to the low number of 
independent healthy skin samples (n=2) no statistical analysis was performed for this 
group, but methylation percentage was similar to dorsal skin. A trend for correlation 
between average methylation and sequencing depth was observed (p=0.0724), but 
sequencing depth did not differ between control and tumor samples (p=0.314). 
Although this result is consistent with previously published data, it is important to note 
that we only analysed a subfraction of the approximately 22 million CpGs present in 
the murine genome (GRCm38/mm10 assembly). Furthermore, RRBS methodologies 
enrich for sequences with medium to high CpG density and therefore CGIs, but 
relatively ignore the parts of the genome that undergo hypomethylation in cancer. We 
therefore cannot conclude that global methylation increases in ssUV cSCC, but we 
could say that there might be a trend towards hypermethylation, a pattern that has been 






Figure 16: Average methylation is 
significantly higher in mouse ssUV cSCC 
compared to matched controls.  Average 
methylation levels are based on the results 
from 31,899 CpGs. The total number of CpGs 
in the mouse genome is approximately 22 
million CpGs. As only 31,899 CpGs were 
analysed (< 0.15% of all mouse CpGs), this 



















3.2.5 Visualization of methylation levels in the UCSC genome browser 
UCSC tracks were built as described in Section 2.4.5. Tracks for both, RRBS and 










3.3 Analysis of differential methylation between ssUV cSCC and normal 
skin 
As discussed before, DNA methylation is a critical process in regulating gene 
expression and genome stability. DNA methylation patterns can differ massively 
between cancerous and benign tissue and regulates silencing of tumor suppressor 
genes and up-regulation of oncogenes. Individual CpGs, even when in a region with 
multiple other CpGs, can have a profound impact on the ability of transcription factors 
to bind [236]. On the other hand, some regions are recognised by specialised methyl 
CpG binding domain (MBD) proteins where the methylation status of all CpGs in the 
region impacts the regulatory effect [237]. In order to address both, methylation of 
individual CpGs and methylation across CpG islands (CGIs), two separate analyses 
were performed. 
3.3.1 Differential methylation of individual CpGs 
The methylation status of individual CpGs can influence the ability of transcription 
factors and other regulatory elements to bind specific regulatory regions of DNA and 
supress gene expression. The RRBS data were filtered by shared regions (100% of 
samples) and coverage (minCov=8). After exclusion of CpGs not passing the 
threshold for minimum average methylation (loci that are unmethylated across all 




After significance testing and false discovery rate (FDR) correction, we found 134 
differentially methylated CpGs in 87 different genes and 10 intergenic CpGs, of which 
four clustered together in a region on chromosome 17 (36,231,447-36,231,471). All 
significant CpGs were hypermethylated in tumors, consistent with the fact that regions 
of medium to high CpG content (that are predominantly picked up by RRBS) become 




Table 20: Methylation levels of all CpGs at the Filip1l locus. Position: Position on chromosome 16, 
iHS: independent healthy skin, adj. p-Value: p-value after FDR correction. Significantly differentially 
methylated CpGs are highlighted in bold. 
position  tumor  ventral skin  iHS adj. p-Value 
57391482 0.0784 0.1603 0.0908 0.383665339 
57391492 0.0859 0.1613 0.0960 0.367049289 
57391494 0.1153 0.2144 0.1091 0.295194978 
57391498 0.1185 0.2110 0.1439 0.23858672 
57391502 0.1033 0.1432 0.0790 0.321105505 
57391517 0.0228 0.0386 0.0142 0.569014216 
57391520 0.4816 0.0285 0.0100 0.027515586 
57391522 0.5369 0.0441 0.0197 0.027515586 
57391524 0.5227 0.0574 0.0223 0.027515586 
57391525 0.4965 0.0401 0.0170 0.027515586 
57391528 0.4196 0.0475 0.0156 0.032013265 
57391529 0.4559 0.0335 0.0132 0.027515586 
57391533 0.5847 0.0460 0.0119 0.027515586 
57391534 0.5048 0.0292 0.0105 0.027515586 
57391538 0.7234 0.0835 0.0320 0.027515586 
57391539 0.6259 0.0773 0.0318 0.027515586 
57391546 0.5436 0.0519 0.0252 0.027515586 
57391547 0.5724 0.0445 0.0221 0.054320133 
57391552 0.5907 0.0663 0.0253 0.032447585 
57391553 0.6377 0.0492 0.0255 0.038106479 
57391555 0.5577 0.0583 0.0291 0.027515586 
57391556 0.6157 0.0534 0.0274 0.032447585 
57391571 0.5074 0.0436 0.0173 0.032013265 
57391572 0.5528 0.0349 0.0140 0.054320133 
57391584 0.4891 0.0383 0.0160 0.027515586 
57391585 0.3797 0.0199 0.0049 0.063242775 
57391592 0.0221 0.0382 0.0222 0.909063251 
57391593 0.2390 0.0456 0.0958 0.681628775 
57391596 0.1366 0.0431 0.0369 0.379501469 
57391617 0.1010 0.0437 0.0315 0.107375253 
57391622 0.1026 0.0638 0.0332 0.152881156 
57391625 0.1005 0.0504 0.0339 0.111199584 
57391632 0.1269 0.0986 0.0689 0.322642769 
57391636 0.0670 0.0405 0.0225 0.24123848 
57391649 0.0714 0.0282 0.0210 0.261554549 
57391651 0.0642 0.0324 0.0278 0.322642769 
57391655 0.0621 0.0300 0.0155 0.231940497 
57391657 0.0847 0.0314 0.0168 0.228728963 
57391674 0.0759 0.0226 0.0147 0.132937668 





Interestingly, 17 of the differentially methylated CpGs clustered in an intronic region 
of the Filip1l gene (and the Cmss1 gene that is coded on the opposite DNA strand). 
The CpGs in this region showed one of the highest percentages of differential 
methylation. The methylation levels of the CpGs at the Filip1l locus are summarized 
in Table 20 and Figure 17. The locus will be discussed in more detail in Section 3.4.1. 
Methylation changes in individual CpGs are profound in mouse cSCC. In the 
following sections, we will further analyse differences in methylation and compare 
these changes with data from human cSCC cases. 
 
Figure 17: Graphical representation of methylation levels of CpGs at the Filip1l locus. The locus 
is located on chromosome 16. A cluster of 20 CpGs are hypermethylated in tumors compared to 
matched controls, 17 of which display significantly higher methylation. 
3.3.2 Regions of potential differential methylation  
Methylation at CpG islands (CGIs) is associated with inactivation of promoters or 
other regulatory elements CGIs are frequently differentially methylated in cancer.  
A total of 201 regions were found as potential DMRs. Using the BiSeq package and 
binominal regression, we estimated the p-values for each of those regions. After 
statistical analysis, 78 DMRs were found to be significantly differentially methylated. 
The differences in methylation between controls and tumors ranged from -13% 
to -40% (positive values indicate increased methylation in tumors). Hypermethylation 
in tumors occurred in 76 DMRs, which was expected, since CGIs tend to become 
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hypermethylated in cancer. The methylation difference between ventral skin controls 
and tumors of the 78 significantly differentially methylated regions can be found in  
Figure 18. 
 
Figure 18: Methylation differences between ventral skin controls and tumors of the 78 
significantly differentially methylated regions. A positive methylation difference indicates 
hypermethylation in tumors compared to ventral skin controls. Methylation differences range from 40% 
to -13%. The majority of DMRs (76 of 78) are hypermethylated in tumors, consistent with the 
observation, that average methylation is significantly increased in tumors. The region with the highest 
difference in methylation is the previously discussed Filip1l locus (indicated by the black arrow). 
From a biological point of view, DMRs with a high difference in methylation are most 
likely to be of relevance, whereas very high significances are not as important. We 
therefore searched for DMRs that showed a high methylation difference between 
controls and tumors and significant p-values. One region of particular interest is 
located on chromosome 16, position 57,391,482-57,391,657. The medium 
methylation difference was -40% (hypermethylation in tumors), making this region 
the most differential methylated one that we detected. The region overlaps with two 
genes on opposite strands, Filip1l and Cmss1. 
Selected regions of differential methylation will be discussed in the following section.  
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3.4 Regions of differential methylation are often associated with 
regulatory elements 
In our previous analysis, we identified 78 significantly differentially methylated 
regions of which 76 were hypermethylated and 2 were hypomethylated in ssUV cSCC 
compared to controls. Next, we aimed to investigate genomic features of these regions.  
Using the bed tracks built for the UCSC genome browser (https://genome.ucsc.edu/) 
we visualized methylation at the identified regions. Furthermore, the following tracks 




2. Position on chromosome 
 
 
3. GENCODE annotation, Harrow et al. 2006 [238] 
Gene annotation for protein coding and RNA genes 
Annotated genes are displayed as blue arrowed lines (introns) and blue 
rectangles (exons) 
 
4. Baseline methylation levels in mouse keratinocytes, He et al. 2014 [239] 
A reference for DNA methylation in normal mouse keratinocytes, mainly 
indicating the position of all CpGs in the displayed region 
 
5. UCSC bed tracks showing methylation in controls and tumors (see Section 
2.4.5) 
 
Methylation levels in tumors and controls. Scale from (-)1 (100% 
methylation) to 0 (0% methylation). 
Positive values indicate significantly differentially methylated CpGs, 
negative values indicate non significantly differentially methylated CpGs. 
VS_CTL: Methylation in ventral skin controls 




6. EPD viewer hub, displaying promoters and CAGE sequencing, FANTOM 
Consortium and the RIKEN PMI and CLST (DGT) and Dreos et al. [240] 
CAGE seq measures transcriptional activity and is used to map 
transcription start sites and gives an indication on the regions regulatory 
relevance. 
 
7. FANTOM5 TSS activity in adult skin, Noguchi et al. 2017 [241] 
Transcriptional activity at the region. 
 
8. JASPAR 2018 Transcription factor binding sites, Khan et al. 2018 [242]. 
Predicted transcription factor binding sites, supports the regulatory 




3.4.1 Filip1l intronic DMR 
The Filip1l intronic DMR that was detected at the Filip1l locus ( 
Figure 19) and is located in the intron between exon 1 and 2. It is 176 bp long and 
contains 38 individual CpGs (GC content: 76%). The medium methylation in controls 
is 34 %, while methylation in tumors is 76%. 
In both analyses, i.e. individual CpGs and DMRs, the CpG cluster appeared as the top 
hit, showing both a highly significant methylation difference and a large difference in 
methylation percentages.  
With 153,140 bps, the intron in which the DMR resides is unusually long. The DMR 
is located approximately 38,000 bp downstream of exon 1. Out of 39, 17 CpGs were 
identified as significantly differentially methylated and were hypermethylated in 
tumors compared to controls (see Section 3.3.1, Figure 17 and Table 20). 
Furthermore, the region shows both, a high median methylation difference as well as 







Figure 19: Intronic DMR at the Filip1l locus. The DMR is 176 bp long and contains 39 individual 
CpGs. Median methylation level in the controls is 34% while it is 76% in the tumors, a methylation 
difference of almost 42% between the groups making it the most differentially methylated region we 
detected. The methylation difference between controls and tumors is also highly significant (median 
p=0.00014). EPD predicted a promoter sequence at the locus, and FANTOM5 CAGE seq peaks indicate 
that this region is of regulatory relevance (see All CAGE tracks). Furthermore, FANTOM5 TSS activity 
(SkinAdult tracks) show transcriptional activity at the intronic region. We suspect this transcriptional 
activity is due to transcription of enhancer RNAs, strongly indicating that the DMR co-localizes with 
an enhancer [243]. This is further confirmed by clustering of multiple predicted transcription factor 
binding sites (TFBS, JASPAR CORE), a common occurrence at enhancer regions [244,245]. 
We suspected that this region could be an enhancer. The region is almost 200,000 bp 
upstream of the promoter of Filip1l isoform 202, providing sufficient physical space 
to allow for regulation of this promoter. Interestingly, mouse isoform 202 is the 
ortholog of human isoform 203, which has been shown to play an important role in 
various cancers, most notably in ovarian carcinoma. 
Investigation of the DMR shows that there is transcriptional activity at the region. As 
the DMR is far away from any known protein coding sequence, it is possible, that they 
are enhancer RNAs. The function of enhancer RNAs is unknown, but their expression 
is a common occurrence near enhancer regions [243]. Furthermore, predicted 
transcription factor binding sites are clustering in this region, a common feature of 
enhancer regions [244,245]. Therefore, strengthening the hypothesis that the region is 
indeed an enhancer, possibly controlling expression of Filip1l isoform 202. 
As shown in  
Figure 19, the DMR co-localizes with a proposed Filip1l promoter (see EPDnew 
(v003) promoter track). This finding further suggests a regulatory role of methylation 
changes at the Filip1l DMR. 
Although DNA methylation is known to regulate human FILIP1L expression, the 
human differentially methylated regulatory region is located upstream of exon 5 at the 
promoter and transcription start site (TSS) of FILIP1L isoform 203, the ortholog of 
mouse Filip1l isoform 202. The Filip1l DMR we detected is not conserved in humans, 
suggesting that in mice, there could be additional epigenetic mechanisms regulating 
Filip1l. 
We will investigate the role of Filip1l in cSCC in further detail later in this thesis. 
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3.4.2 DMR #2 
DMR #2 is located on chromosome 3 at position 5,860,619 to 5,860,741. It is 123 bp 
long and contains 30 individual CpGs. Methylation in controls skin samples is 25% 
while the CGI is hypermethylated in tumors with 58% average methylation. The CGI 
is of unknown function, but the presence of CAGE seq peaks and RNA transcripts in 
this non-coding region as well as the presence of multiple potential transcription factor 
binding sites hint at a possible enhancer function. The closest genes of known 
functions are Pex2 (approximately 250 kb upstream) and Zfhx4 (500 kb upstream). 
Pex2 (peroxisomal biogenesis factor 2) is involved in peroxisome biogenesis and has 
been demonstrated to be essential for survival of liver cancer cells [246]. The Human 
Protein Atlas (https://www.proteinatlas.org/) lists Pex2 as moderately expressed in 
human skin, but with low to no expression in skin cancer [247]. Zfhx4 (Zinc finger 
homeobox 4) is highly expressed in both skin and skin cancer, making it an unlikely 






Figure 20: DMR #2 is 123 bp long and contains 27 individual CpGs. Median methylation is 25% in 
controls and 58% in tumors. Although the region is of unknown function, FANTOM5 CAGE seq peaks 
indicate that this region is of regulatory relevance (see All CAGE tracks). Furthermore, FANTOM5 
TSS activity (SkinAdult tracks) show transcriptional activity at the intronic region. We suspect this 
transcriptional activity is due to transcription of enhancer RNAs, strongly indicating that the DMR co-
localizes with an enhancer [243]. This is further confirmed by clustering of multiple predicted 




3.4.3 Gm26917 DMR 
The Gm26917 DMR is the 2nd largest DMR we identified. It spans 838 bp and contains 
123 individual CPGs. This intergenic region contains the coding sequence of 
Gm26917, a long intergenic non-coding RNA (lincRNA) gene of unknown function. 
Similar to long non-coding RNAs (lncRNA), lincRNAs are involved in a multitude of 
cellular processes, including metabolism, growth, cell maintenance and regulation 
[248–251]. LincRNAs are conserved across mammalian species and may have 








Figure 21: The Gm26917 DMR is 838 bp long and contains 123 individual CpGs.  It is the 2nd 
largest DMR identified in our analysis. The region codes for the lincRNA Gm26917. Methylation level 
in controls is 14.5% while it is 31.2% in tumors. Multiple CAGE seq peaks and transcription factor 
b8inding sites suggest the presence of multiple transcription start sites in the area, but there seems to 
be only negligible RNA transcription in skin.  
Interestingly, the Gm26971 DMR contains multiple CAGE seq peaks, suggesting 
multiple transcription start sites. As nothing is known about the Gm26971 lincRNA, 
the significance of this is unclear. However, there is almost no transcriptional activity 




3.4.4 Cdk8 intronic DMR 
Cyclin dependant kinase 8 (Cdk8) is an important factor of the mediator complex, 
facilitating the interaction between transcription factors and RNA polymerase II and 
may be an oncogene, depending on the cell context [253,254]. We detected a DMR 
approximate 1.7 kb upstream of exon 2 of the Cdk8 gene. The DMR is 136 bp long 
and contains 24 individual CpGs. Methylation levels are 8.4% in controls and 21.8% 
in tumors. 
The DMR does not co-localize with any known regulatory element. There are no 
promoters and transcription is minimal at this region, which is expected for an intronic 
region. Although there are transcription factor binding sites at the area of the DMR, 
binding sites do not cluster at the DMR to the same extend as they do for other loci 
(for example see  
Figure 19).  
Intronic methylation has been identified as a regulator of translational retention 
[255,256]. Most transcripts are spliced co-transcriptionally, meaning splicing occurs 
at the same time as transcription [257]. This opens up the possibility of DNA 
methylation to regulate alternative splicing as DNA methylation can influence 
chromatin structure and therefore the elongation rate of RNA polymerase II. 
Alternatively, methyl CpG binding protein 2 (MeCP2) can bind methylated DNA and 
recruit RNA binding factors that regulate splicing [256,258].  
Indeed, Cdk8 has multiple splice variants with some retaining introns [259]. It is 
possible, that in cSCC differential DNA methylation is influencing alternative splicing 
of Cdk8, therefore altering the proteins function. Differential intronic methylation of 
the Cdk8 gene in murine cSCC may lead to alternative splicing and altered Cdk8 




Figure 22: Cdk8 intronic DMR. The DMR is 136 bp long and contains 24 individual CpGs. 
Methylation levels are 8.4% in controls and 21.8% in tumors. There are no annotated promoters in the 
area and transcription is minimal. Transcription factor binding sites do not cluster at the area. We are 
not able to draw direct conclusions on the relevance of the region. However, it is possible, that 
intragenic methylation may reduce the rate of transcription and therefore alter splicing of the Cdk8 gene 
[255].   
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3.4.5 DMR #12 
DMR #12 is located in an intergenic region on chromosome 11 at position 109,011,629 
to 109,012,044. The DMR is 277 bp long and contains 37 CpGs. While medium 
methylation across the region is 17.1% in controls, medium methylation is 31.6% in 
tumors. 
The region is of unknown function, but the presence of multiple predicted transcription 
factor binding sites and CAGE seq peaks suggests the CGI could have an enhancer 
function. Furthermore, transcriptional activity at this intergenic DMR could be due to 
enhancer RNA transcription. The absence of other CAGE seq peaks or transcriptional 
activity in the proximity of the CGI (within 25 kb of the DMR), further strengthens 
this hypothesis. 
The nearest gene (50 kb upstream) is Axin2, which plays a crucial role in controlling 
β-catenin stability in the Wnt signalling pathway. This pathway is not classically 
associated with cSCC, but has been proposed to be a potential therapeutic target in 
human cSCC [260]. However, based on the available data, we cannot conclude that 








Figure 23: DMR #12 is 277 bp long and contains 37  individual CpGs. Median methylation is 17.1% 
in controls and 31.6% in tumors. Although the region is of unknown function, FANTOM5 CAGE seq 
peaks indicate that this region is of regulatory relevance (see All CAGE tracks). Furthermore, 
FANTOM5 TSS activity (SkinAdult tracks) show transcriptional activity at the intronic region. We 
suspect this transcriptional activity is due to transcription of enhancer RNAs, strongly indicating that 
the DMR co-localizes with an enhancer [243]. This is further confirmed by clustering of multiple 
predicted transcription factor binding sites (TFBS, JASPAR CORE), a common occurrence at enhancer 
regions [244].  
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3.5 Comparison of methylation in mouse ssUV cSCC with human cSCC 
There is a surprisingly small number of studies investigating DNA methylation in 
human cSCC. Furthermore, most studies have only focussed on a single or only few 
regions of differential methylation. In addition, these studies only use qualitative or 
semi quantitative methods. 
One study by Yang et al. [171] investigated global DNA methylation in both, 
DMBA/TPA- and UVB-induced mouse tumors, but found very little overlap between 
the two models, again highlighting the need for an adequate preclinical model. More 
recently, Rodriguez-Paredes et al. [190] have published their detailed analysis of the 
methylome of 16 human AK and 18 cSCC cases. This provides an excellent 
opportunity to test if the ssUVR induced mouse cSCC model, is a good model for the 
human disease in terms of DNA methylation, in addition to histopathology and 
genetics. 
3.5.1 Methylation of keratin clusters differentiates two subtypes of human cSCC 
One of the most important findings from the study by Rodriguez-Paredes et al. was 
that there seem to be two cSCC subtypes. Methylation at keratin gene clusters clearly 
differentiated that one AK and cSCC subclass was related to healthy epidermis, while 
the other one was related to cancer. When we examined the corresponding keratin 
cluster region in the mouse data (chr15:101,343,355-102,046,669), the region was not 
covered with sufficient detail to perform a subtype analysis. Therefore, we are unable 
to draw any conclusions if there are any subtypes in the murine ssUV cSCC. 
3.5.2 Global methylation levels are higher in stem cell like human cSCC 
In the murine ssUV cSCC, the average levels of methylation were significantly higher 
than in control samples. Although this is in contrast to the hypomethylation pattern in 
most cancers, this effect has been reported for human cSCC and some skin cancer cell 
lines.  
In order to investigate the global levels of methylation, we performed a similar 
analysis on the Infinium HumanMethylation BeadArray data from Rodriguez-Paredes 
et al. Cluster analysis of global levels of methylation supported the presence of 
different subtypes, as the stem cell like tumor samples (as identified by Rodriguez-





Figure 24: Cluster plot: HSo and HSy are control samples, cSCC and AK are tumor samples; for 
the latter K and S indicate whether the samples is respectively a keratinocyte like or stem cell like 
cancer sample. The majority of stem cell like AK and cSCC samples cluster together, indicating that 
they indeed for a separate subclass. 
However, as shown in Figure 25, when we compared the average methylation levels 
between controls, AK samples and cSCC samples, there was no difference between 
the groups. As the publication by Rodriguez-Paredes et al. suggests, in terms of DNA 
methylation, there are striking similarities between AK and cSCC. We regrouped the 
samples in controls and keratinocyte-like as well as stem cell-like AK and cSCC 
samples and analysed average methylation. Here, the control- and keratinocyte-like 
samples showed no difference in methylation. Differences in global methylation levels 
between keratinocyte-like samples were higher, which is not surprising since those 
samples include cSCC samples that are more heterogeneous than the normal skin 
control samples that are also included in this group (Figure 25 A). Interestingly, stem 
cell-like samples showed significantly higher average methylation levels than both 
keratinocyte-like (p=0.002) and control (p=0.010) samples (Figure 25 B). This 
suggests that in addition to methylation at keratin clusters, global methylation levels 




Figure 25: A: Average methylation of human skin samples (control), AK and cSCC. No difference 
in average methylation between the groups was detected. B: Average methylation of control samples 
and AK and cSCC samples, identified as keratinocyte like of stem cell like. Average methylation is 
significantly higher in stem cell like samples compare to both, control and keratinocyte like samples. 





3.5.3 Differentially methylated regions overlap between human cSCC and mouse 
ssUV cSCC 
In the analysis by Rodriguez-Paredes et al., out of 859,515 Infinium probes 378,190 
(= 44%) were found to be differentially methylated between control and tumor 
samples (including both, AK and cSCC). The Infinium 850k array covers 31,047 
annotated genes, of which at least one differentially methylated probe was found in 
26,703 genes (= 86%).  
Starting from our RRBS data, we found 214 mouse genes that have at least one 
differentially methylated CpG. Using Ensemble annotation and the R package 
biomaRt (as described in Section 2.4.4), we found that out of the 214 mouse genes, 
153 appear to have a human ortholog. Remarkably, 150 out the 153 (= 98%) mouse 
genes with a human ortholog were differentially methylated in both, our RRBS mouse 
data and the human data by Rodriguez-Paredes et al. This remarkable overlap suggests 
that methylation changes in mouse ssUV cSCC reflects the processes in human cSCC. 
When we further filtered the gene list to contain at least two differentially methylated 
probes (Infinium) or CpGs (RRBS) and show a difference in methylation of at least 
20%, seven genes were identified: Tspan9, Cmss1/Filip1l, Abr, Drd2, Nrros, Mdga2 




3.6 Investigation of methylation of the regulatory elements of FILIP1L in 
human and mouse cSCC  
In collaboration with the German Cancer Research Center, we used MassARRAY 
(Agena Biosciences) to validate the previously detected DMR in mouse ssUV cSCC. 
Unfortunately, we were not able to create a PCR product of sufficient quality from the 
DMR between exon 1 and 2 of the mouse Filip1l gene. Therefore, no robust data could 
be generated for this region. 
In the following section, I will compare methylation at the FILIP1L promoter of 
human cSCC cell lines with expression of FILIP1L in those cell lines. Results for 
FILIP1L expression can be found in Section 3.8.2. 
 
Figure 26: DNA methylation levels in HOSE and ES2 cell lines, NTERT cells and 8 human cSCC 
cell lines. Results represent the mean of three technical replicates. The FILIP1L promoter is 
hypermethylated in ES2, T10 and IC8 cancer cells and hypomethylated in the normal cell lines HOSE 
and NTERT, as well as the cSCC cell lines T2, T8, IC1, IC12, IC19 and Met1. 
In humans, FILIP1L expression is controlled by promoter methylation. This promoter 
is located at an alternative transcription start site upstream of FILIP1L exon 5. For 
example, the promoter is hypomethylated in HOSE cells that express high levels of 
FILIP1L, while it is hypermethylated in ES2 ovarian cancer cells that express no 
FILIP1L (see [215,261]). We first tested, if this promoter is differentially methylated 






























expression. DNA from human cSCC cell lines was BS converted and the 
MassARRAY protocol was followed as described in Section 2.10. As a control, we 
included DNA from HOSE and ES2 cells (kindly provided by the laboratory of Dr. 
Gillian Smith), where promoter methylation status is known. The results are displayed 
in Figure 26. As expected, the promoter region is almost un-methylated in HOSE 
cells, while ES2 cells show methylation levels of over 40%. In NTERT cells, the 
region is also un-methylated, as expected in a non-cancer cell line with high FILIP1L 
expression, In T2, T8, IC1, IC19, IC12 and Met1 cells, the promoter region also shows 
low methylation levels. However, methylation in T10 and IC8 cells is similar to ES2 
cells. The high methylation levels in T10 cells correlate well with low FILIP1L 
expression in the cell line, but IC8 has both, a hypermethylated FILIP1L promoter and 
high FILIP1L expression. In the cell lines with hypomethylated promoter regions, 
methylation levels also do not inversely correlate with FILIP1L expression. For 
example, FILIP1L expression is high in T2 cells and low in T8 cells although both 
cell lines have similarly low promoter methylation. This suggests, that there are 
unknown regulatory mechanisms other than DNA methylation controlling FILIP1L 
expression in human cSCC. Table 21 summarizes DNA methylation levels at the 
FILIP1L promoter and FILIP1L expression in the tested cell lines. 
Table 21: FILIP1L promoter methylation and FILIP1L expression levels of the tested cell lines. 
There is no clear inverse correlation between methylation and expression in human cSCC cell lines. 
Inverse correlations between FILIP1L promoter methylation and expression are highlighted in bold. 
Cell line FILIP1L promoter methylation FILIP1L expression 
HOSE low high 
ES2 high low 
NTERT low high 
T2 low high 
T8 low low 
T10 high low 
IC1 low normal 
IC8 high high 
IC12 low high 
IC19 low low 





Figure 27 shows the FILIP1L promoter methylation levels in 14 human cSCC 
samples. In all but one sample (cSCC2) methylation levels were < 10%, suggesting 
that methylation at the FILIP1L promoter is not a common feature of human cSCC. 
 
Figure 27: FILIP1L promoter methylation in 14 human cSCCs. Results represent the mean of 
three technical replicates. Although the promoter controls FILIP1L expression in multiple cancers 
and is hypermethylated in these cancers compared to controls, the promoter region is almost 
unmethylated in all tested human cSCC samples. 
Using BLAST search, we identified the mouse region that corresponds to the human 
FILIP1L promoter, located upstream This region is also a CGI and may be involved 
in regulation of mouse Filip1l. Figure 28 shows the average methylation levels of the 
mouse Filip1l promoter in ventral and dorsal skin controls as well tumors and the 
mouse keratinocyte cell line Kera308. Methylation levels are < 0.02 % across all tested 
samples. Furthermore, there are no differences between normal skin and tumors, 
suggesting that the Filip1l promoter, similar to human cSCC, does not play a role in 






























Figure 28: Methylation at the mouse Filip1l promoter in ventral skin, dorsal skin, tumors and the 
mouse keratinocyte cell line Kera308.. Ventral Skin: matched controls; Dorsal Skin: Chronically 
irradiated but benign skin; Tumors: mouse cSCC. Results represent the mean and standard deviation of 
18 VS, DS and Tumor samples and three technical replicates of Kera308 DNA. The promoter shows 



























3.7 Filip1l in murine cutaneous squamous cell carcinoma 
As previously described, we detected a differentially methylated region (DMR) within 
an intronic region of the Filip1l gene. This DMR showed the biggest difference in 
average methylation between the tumors and the normal skin tissue that we detected 
in our dataset. Furthermore, inspection of genomic features at the detected DMR 
suggests that the region is of regulatory relevance. More precisely, we suspected the 
region could represent an enhancer, possibly controlling the expression of Filip1l 
isoform 202. 
Since there is no published information about the role of Filip1l in the skin, we next 
characterized the Filip1l isoform composition, the expression of Filip1l in the mouse 
skin and cSCC, and its functional significance. 
3.7.1 Filip1l isoform 202 is the main expressed isoform in mouse skin 
Murine Filip1l has three known isoforms (see Figure 8). There is nothing known about 
which isoforms are expressed in mouse skin or if there is any tissue specific expression 
pattern. Furthermore, it is unknown if the individual Filip1l isoforms may have 
different cellular functions.  
Filip1l isoform 201 contains the shorter exons 1 to 4, isoform 202 has an alternative 
exon after regular exon 4 and also contains the long and main exon 5, while isoform 
203 contains all exons (1 to 5). Exon spanning primers in exons 3 and 4 amplify the 
mRNA transcripts of isoforms 201 and 203. Isoform 203 is amplified by primers 
spanning exon 4 and 5, while a forward primer in isoform 202s alternative exon and 
exon 5 amplify only isoform 202. 
We used isoform specific qPCR to determine the expression pattern of different Filip1l 
isoforms in healthy mouse skin and skin tumors, as well as in the mouse keratinocyte 
cell line Kera308. The results are shown in Figure 29 and Figure 30. In these figures, 
VS refers to non-irradiated ventral skin, DS refers to chronically irradiated, but benign 
dorsal skin and T refers to mouse cSCC tumors, while numbers indicate animals and 
tumor numbers (e.g 1.10 T1 is tumor 1 of animal 1.10). 
In mouse ventral skin (VS), the expression of the full-length isoform 203 is minimal, 
while the expression of isoforms 203 and 201 combined is slightly higher. The 
expression of isoform 202 is 15- to 37-fold higher than the expression of the other 
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isoforms. This clearly shows that isoform 202 is the main expressed isoform in mouse 
ventral skin (see Figure 29).  
 
Figure 29: Isoform-specific qPCR for Filip1l in mouse ventral skin (VS). Results represent the mean 
of three technical replicates. The expression of isoforms 201 and 203 is minimal compared to the 
expression of isoform 202. We therefore conclude, that isoform 202 is the main expressed isoform in 
mouse VS. 
Similar to VS, Filip1l isoform 202 is the main expressed isoform in dorsal skin (DS) 
and tumors. In DS, the expression ratio between isoforms 202 and 201+203 are in a 
similar range as in VS (18-fold, isoform 202 compared to the other isoforms 
combined). This is also the case for the isoform composition in the mouse keratinocyte 
cell line Kera308, where isoform 202 is the main isoform, and the ratios between 






































Figure 30: Isoform specific qPCR for Filip1l in mouse dorsal skin (DS) and the mouse 
keratinocyte cell line Kera308. Results represent the mean of three technical replicates. Similar to VS, 
isoform 202 is the main expressed isoform in chronically irradiated dorsal mouse skin (DS), Tumors 
(T) and the Kera308 cell line. 
Having determined the expression of Filip1l in mouse skin and Kera308 cells, we 
assessed the protein levels of Filip1l in Kera308 cells by immunoblotting and 
confirmed the observed isoform expression using isoform-specific siRNAs. We 
designed siRNAs to target either isoforms 201 and 203 or isoforms 202 and 203 (see 
Table 12). As shown in Figure 31, under these experimental conditions, the Filip1l 
protein appears as a band at 110 kDa in control cells (i.e. cells transfected with a non-
targeting siRNA pool). siRNA knock-down of all isoforms (using a combination of 
all siRNAs) completely abolishes the Filip1l protein expression at both 24- and 
48-hours post-transfection. Treatment with siRNAs targeting isoforms 201 and 203 
does not reduce Filip1l protein, while siRNAs targeting isoforms 202 and 203, similar 
to treatment with all siRNAs, supresses Filip1l protein expression. Furthermore, 
treatment with siRNAs targeting Filip1l isoforms other than 202, appears to increase 
Filip1l isoform 202 expression (see Figure 31, si 201/203). Treatment with siRNAs 
targeting isoform 202 is sufficient to compensate for this effect. This could be a 
compensatory mechanism in response to Filip1l isoform 201 and 203 knock-down, 
despite both isoforms being expressed at a low level. 
This experiment further confirms that, in Kera308 cells, isoform 202 is the main 



































Figure 31: Protein levels of Filip1l after siRNA treatment at 24- and 48-hours post-transfection. 
The used siRNAs target two isoforms, either 201 and 203, or 202 and 203. si 201/203 and si 202/203 
experiments use two siRNAs each, si 201/202/203 use the combination of 4 siRNAs. The combination 
of siRNAs targeting all Filip1l isoforms completely abolishes Filip1l protein expression, while siRNAs 
targeting isoforms 201 and 203 do not. Treatment with siRNAs targeting isoforms 202 and 203 also 
supress Filip1l expression. This confirms the finding from the mRNA analysis that Filip1l isoform 202 
is the main expressed isoform in Kera308 cells. 
We therefore conclude that Filip1l isoform 202 is the main expressed isoform in mouse 
skin, and in the keratinocyte cell line Kera308. Interestingly, the mouse Filip1l isoform 
202 is very similar to the human isoform 203 (compare Figure 8), which seems to be 
the functional isoform in humans. From this point onwards, we refer to the mouse 
Filip1l isoform 202 as simply Filip1l, unless otherwise indicated. 
3.7.2 Comparison of Filip1l expression in mouse tumors vs. healthy skin is 
inconclusive 
Having established the isoform composition and a methodology to investigate Filip1l 
expression, we aimed to determine if Filip1l expression is altered in murine cSCCs 
compared to normal skin. Using the same isoform-specific primer, we utilized RT-
qPCR to test the Filip1l expression in tumors as well as matched ventral and dorsal 
skin samples collected from 18 animals. The results are displayed in Figure 32, 





We first used 18S as a reference gene and found, that compared to VS, the expression 
of Filip1l is significantly lower in DS (p=0.013) and is further reduced in tumors 
(p<0.001) (Figure 32). However, the expression of 18S varied across samples. When 
the expression analysis was repeated using the genes encoding actin, Gapdh and Hprt1 
as reference genes, the expression of Filip1l showed a different pattern. There were 
no significant differences detected between VS and DS, while expression of Filip1l 
increased in tumor samples (significant when normalized to actin, p=0.003) as shown 
in Figure 33 and Figure 34. 
 
Figure 32: Expression of Filip1l in ventral skin (VS), dorsal skin (DS) and tumors, normalized to 
18S. Results represent the means and standard deviations of 18 ventral skin, dorsal skin and tumor 
samples. Expression is significantly lower in DS and tumors in comparison with VS. The expression of 
the reference genes displayed considerable variance. Significance is indicated by asterisks (* p<0.05, 





Figure 33: Expression of Filip1l in ventral skin (VS), dorsal skin (DS) and tumors, normalized to 
Actin. Results represent the means and standard deviations of 18 ventral skin, dorsal skin and tumor 
samples. Expression is significantly lower in DS and tumors in comparison with VS. The expression of 
the reference genes displayed considerable variance. Significance is indicated by asterisks (* p<0.05, 
** p<0.01, *** p<0.001). 
 
 
Figure 34: Expression of Filip1l in ventral skin (VS), dorsal skin (DS) and tumors, normalized to 
Gapdh and Hprt1. Results represent the means and standard deviations of 18 ventral skin, dorsal skin 
and tumor samples. Expression is significantly lower in DS and tumors in comparison with VS. The 
expression of the reference genes displayed considerable variance. Significance is indicated by asterisks 




Similar to 18S, there was a considerable variance in the expression of actin, Gapdh 
and Hprt1. Using linear regression, it became apparent that the expression of the 
chosen reference genes did not display sufficient correlation to be able to determine 
which reference genes should be used for qPCR normalization (Figure 35). Therefore, 
these qPCR results are not conclusive with regard to potential differences in 
expression of Filip1l between normal and tumor tissue. 
 
 
Figure 35: Correlation of CT values between 18S, actin, Gapdh and Hprt1. Correlation between 





3.7.3 Filip1l protein levels are reduced in murine cSCC tumors 
The alterations in the expression levels of Filip1l in tumors vs. control skin could not 
be conclusively determined using RT-qPCR due to variance in reference gene 
expression. In order to determine the levels of Filip1l protein in mouse cSCC tumors 
and control skin, immunoblotting was used. A total of 54 samples from 18 animals 
(three samples per animal: VS, DS and tumor, numbers above this indicate animal 
designations) were analysed as shown in Figure 36. Using fluorescence detection 
immunoblotting (LiCOR), we were able to quantify the Filip1l protein levels in all 
samples using α-Tubulin as a loading control. The Filip1l protein levels were 
significantly reduced in chronically-irradiated DS compared to non-irradiated VS 
(paired t-test, p=0.03). Furthermore, in murine cSCC tumors, the Filip1l protein levels 





Figure 36: Filip1l protein levels in VS, DS and tumors of SKH-1 hairless mice that had been 
chronically exposed to UV radiation. A: Representative immunoblot for 4 out of 18 animals. 
Filip1l is detected as a band at 110 kDa, consistent with its molecular weight of 98 kDa. Filip1l appears 
as a double band in murine skin. B: Quantification of Filip1l protein levels in all 18 animals. Filip1l 
protein levels are significantly reduced in DS compared to VS and further reduced in tumors compared 
to VS. Significance is indicated by asterisks (* p<0.05, ** p<0.01, *** p<0.001). The numbers on the 
top indicate individual animals. 
Surprisingly, the Filip1l protein appeared as a double band in the SKH-1 mouse skin 
samples. As this had not been previously reported, SKH-1 mouse samples were 
analysed side-by-side with Kera308 samples using different Filip1l antibodies (see 
Figure 37). While the presence of the second (top) Filip1l band in skin homogenates 
from SKH-1 mice was confirmed irrespective of the antibody used, it was absent in 
Kera308 cell lysates. Interestingly, the second (top) band was markedly weaker in the 




Figure 37: The second (top) Filip1l band was confirmed in SKH-1 mouse samples using different 
Filip1l antibodies. In Kera308 samples, Filip1l only appears as a single band. The identity of the 
second band is unknown. 
3.7.4 Is Filip1l controlling Wnt signalling in mouse cSCC? 
We have observed a reduction in Filip1l protein levels in murine cSCC, possibly 
through changes in DNA methylation affecting its gene expression. The role of Filip1l 
is largely unknown, but the strongest evidence of its cellular function has been 
provided by the laboratory of Steven K. Libutti. In multiple publications, Libutti and 
co-workers established, that human FILIP1L is a tumor suppressor in various cancers. 
Their data indicate, that Filip1l is involved in regulating β-catenin stability and thus 
affecting the canonical WNT/β-catenin signalling pathway [200,215,222,261], 
although the precise mechanism is unknown.  
Using immunoblotting and antibodies against either total β-catenin or non-
phosphorylated β-catenin (Ser33, Ser37, Thr41), the active form of β-catenin, we 
aimed to determine Wnt/β-catenin signalling activity and possibly correlate it to 




Active Wnt-signalling would be indicated by an increase in the ratio between active 
(non-phosphorylated) and total β-catenin. In tumors from 5 out of 18 animals (28%), 
the ratio between active and total β-catenin was increased in comparison to VS 
controls, indicating enhanced Wnt/β-catenin signalling. In contrast, tumours from 12 
out of 18 animals (67%) showed the opposite trend, and one animal (6%) did not show 
changes in β-catenin ratio. 
  
 
Figure 38: Ratios between active and total β-catenin. Active Wnt/β-catenin signalling would be 





Figure 39: Quantification of the immunoblots shown in Figure 38. The ratio between active and 
total β-catenin does not differ between VS controls and tumors. 
Having previously established, that the Filip1l protein levels are down-regulated in 
murine cSCC tumors compared to VS controls, we can conclude that, although, as 
published research suggests,  Filip1l may have a role in controlling Wnt/β-catenin 
signalling in other tumor types, there is no correlation (see Figure 40) between active 
β-catenin and Filip1l protein levels in murine cSCC, suggesting that in this tumor type, 
Filip1l does not regulate Wnt/β-catenin signalling 
 
Figure 40: Correlation analysis between Filip1l protein levels and active to total β-catenin ratio. 
There is no inverse correlation between the tested parameters, suggesting that in murine cSCC tumors, 
Filip1l does not regulate Wnt-signaling or other factors play a more pivotal role. 
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3.8 FILIP1L in human cutaneous squamous cell carcinoma 
FILIP1L was initially discovered as down-regulated in ovarian cancer 1 (DOC1) and 
its role in ovarian cancer has been described. To this date, FILIP1L has never been 
described in a skin context and its role in cSCC is completely unknown. After having 
established that down-regulation of Filip1l is common in murine cSCC, we aimed to 
investigate the role of FILIP1L in human cSCC cell lines.  
3.8.1 The isoform expression in human cSCC is more complex compared to 
mouse 
While mouse Filip1l has three known isoforms, of which only isoform 202 is 
expressed in murine skin and tumors, in humans, there are eight known isoforms. 
Similar to mouse, it is unknown if the different isoforms serve distinct cellular 
functions. Everything that is known about the function of FILIP1L focuses on isoform 
203 and an artificially created truncation mutant lacking 103 amino acids at the C-
terminus (FILIP1LΔC103) that is based on isoform 203. 
We first wanted to examine the expression levels of the different FILIP1L isoforms in 
a panel of 15 cSCC cell lines and 3 cultures of primary human keratinocytes. Similar 
to the experiments carried out in mouse samples (see Section 3.7.1), isoform specific 
qPCR probes were designed in order to distinguish between expression of the eight 
isoforms. Due to the more complex nature and greater overlap between human 
compared to mouse isoforms, most probes unfortunately target multiple isoforms. A 
list of primer target sites can be found in Table 22. 
Table 22: Primer binding sites for human FILIP1L isoform specific primers. 
TARGETED ISOFORMS BINDING SITE 1 BINDING SITE 2 
   
201, 202, 203, 206, 210 Exon 5 Exon 5 
203, 206 alternative TSS 203/206 Exon 5 
210 alternative TSS 210 Exon 5 
202, 206, 209 Exon 5 Exon 6 
204 Exon 4 alternative end 204 
209 alternative TSS 209 Exon 5 
Exon 5 Exon 5 Exon 5 





Figure 41 shows the means of expression of different FILIP1L isoforms in 15 human 
cSCC cell lines and 3 primary cultures of normal human keratinocytes (NHK). The 
main detected isoforms are isoforms containing exon 5 (exon 5 probe, isoforms 201, 
202, 203, 206, 210), isoforms 203 and 206 (iso 203/206 probe) and isoforms 201 and 
203 (iso 201/203 probe). As indicated by the low expression values of their respected 
probes, isoforms 210 (iso 210 probe), isoforms 202, 206 and 209 (iso 202/206/209 
probe), isoform 209 (iso 209 probe) and isoform 204 (iso 204 probe), only show 
marginal expression in the tested cell lines. As expression of isoform 206 is marginal, 
we can conclude, that CT values of the iso 203/206 probe are a good approximation 
of isoform 203 expression. 
We therefore can conclude, that FILIP1L isoforms 201 and 203 are the main expressed 
isoforms in human cSCC cell lines and NHK primary cultures. 
 
Figure 41: Means of expression of different Filip1l isoforms in 15 human cSCC cell lines and 3 
primary cultures of normal human keratinocytes (NHK).Error bars indicate the variance 
between the different cell lines. Expression of isoforms 210, 202, 206, 209 and 204 are negligible. 
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Isoform specific qPCR results are displayed in Error! Reference source not found.. In 
both, normal human keratinocytes (NHK) and all tested cSCC cell lines, FILIP1L 
isoforms 204 and 209 are expressed at either low or undetectable levels. Isoform 210 
is not expressed in most cell lines, but interestingly it is expressed at high levels in 
IC1 met cells. Isoforms 202, 206 and 209 are expressed at very low levels in NHK 
cells, but expression is higher in some cSCC cell lines, most notably IC8. As 
expression for isoform 206 is negligible in most cell lines, probes detecting isoforms 
203 and 206, can be considered isoform 203 specific. This isoform, that is most similar 
to mouse Filip1l isoform 202, accounts for the majority of expressed FILIP1L 
isoforms. Isoforms 201, 202, 203, 206 and 210 are all amplified by the Exon 5 probe. 
As we established that isoforms 202 and 206 are lowly expressed, while isoform 210 
is only expressed in IC1 met cells, we can conclude, that the majority of the Exon 5 
probe amplification comes from isoform 201 and 203. 
Having established that isoforms 201 and 203 are the main expressed isoforms in 
human cSCC cell lines and NHKs, we used the same isoform specific qPCR probes to 
determine the expression levels of both isoforms and compare expression in cancer 
cell lines to NHKs. The results are displayed in Figure 42. FILIP1L isoform 203 is 
considered the functional isoform in humans and expression of this isoform is reduced 
in 9 out of 15 cSCC cell lines compared to NHKs (IC18, IC19, IC, Met1, Met4, PM1, 
T8, T10 and T11). Conversely, in 6 out of 15 cSCC cell lines. FILIP1L isoform 203 




Figure 42: Expression of FILIP1L isoforms 201 and 203 in 15 cSCC cell lines (cSCC) and 3 
primary cultures of normal human keratinocytes (NHK). The red line indicates the average 
expression of isoform 201 and 203 in NHKs. Expression of isoform 203 is reduced in 9 out of 15 and 
increased in 6 out of 15 human cSCC cell lines compared to NHKs. 
To our knowledge, this is the first time the FILIP1L isoform composition has been 
determined in human cell lines. Interestingly, in NHK and human cSCC cells, isoform 
203 is the main expressed isoform alongside isoform 201. It is currently unknown, if 
the two different isoforms serve different cellular function. We therefore decided to 
focus on FILIP1L isoform 203, which will be simply referred to as FILIP1L unless 
indicated otherwise. 
3.8.2 FILIP1L protein levels are reduced in some cSCC cell lines 
On the mRNA level, FILIP1L expression is reduced in 9 out of 15 human cSCC cell 
lines compared to NHKs. In order to test if the expression changes translate to a 
reduction in FILIP1L protein levels, we analysed protein samples from 3 NHK 




Figure 43: FILIP1L Protein levels in NHK cultures and human cSCC cell lines. The red line 
indicates the mean FILIP1L protein levels in NHKs. FILIP1L protein levels are reduced in 7 out of 
11 cSCC cell lines compared to NHKs. Protein expression levels correlate with mRNA expression data. 
When comparing FILIP1L mRNA expression with FILIP1L protein levels, the results 
do not necessarily correlate. For example, Ab10 shows higher expression than Ab11, 
yet FILIP1L protein levels are higher in Ab11. Despite that, all cell lines that show 
decreased FILIP1L expression, also have reduced FILIP1L protein levels (IC1, IC18, 
IC19, Met1, T8 and T10). Met4 and T9 cells have low FILIP1L expression but show 
no reduction in protein levels. This suggests, that there could be a post-transcriptional 
control of FILIP1L protein expression. 
Most importantly, FILIP1L protein levels are markedly reduced in 7 out of the 12 
cSCC lines tested (IC1, IC8, IC18, IC19, Met2, T8 and T10), suggesting that, similar 
to murine cSCC, reduced FILIP1L levels are a common feature of human cSCC. 
Therefore, it is important to investigate the role that FILIP1L plays in human skin and 
how reduced FILIP1L levels may benefit tumors. This knowledge will broaden our 
understanding about the complex biology of cSCC and may lead to the development 
of treatment strategies. 
Interestingly, IC1 and IC1 met cells have different levels of FILIP1L protein. The IC1 
cell line has been derived from a primary cSCC tumor, while the IC1 met cell lines 
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comes from a metastasis in the same patient. We choose IC1 and IC1 met cell lines to 
investigate the function of FILIP1L in human cSCC.  
In a parallel study, our lab has found that under standard cell culture conditions, 
primary human keratinocytes have highly active WNT/β-Catenin-signalling (Daniela 
Nobre Salvador, PhD thesis). As we suspect that FILIP1L may influence WNT/β-
Catenin-signalling, we decided to use the immortalized human keratinocyte cell line 
NTERT as a control, where WNT/β-Catenin activity is more uniform. 
3.8.3 The role of FILIP1L in the immortalized human keratinocyte cell line 
NTERT 
As previously discussed, the majority of available data on FILIP1L suggest a role as 
a tumor suppressor by aiding destruction of β-Catenin and suppression of 
WNT/β-Catenin signalling activity (see Figure 10). 
In order to test, if FILIP1L itself may be a target of WNT/β-Catenin signalling, we 
utilized the human keratinocyte cell line NTERT. NTERT cells were either untreated, 
or grown for 2 h, 4 h, 8 h or 24 h in the presence of LiCl. LiCl inhibits glycogen 
synthase kinase 3 β (GSK 3β) activity and therefore the phosphorylation and 
subsequent destruction of β-Catenin. As a control, NaCl treatment was used. The 




Figure 44: FILIP1L levels in NTERT cells treated with 10 mM LiCl, equal amounts of NaCl or 
were left untreated. Results represent the quantification results from immunoblots and three biological 
replicates. UT: Untreated control. LiCl was used to inhibit GSK 3β  FILIP1L levels are up-regulated 
by LiCl treatment after 2 h and are highest after treatment for 24 h. Expression also increases with time, 
possibly due to a response to increased confluency. Significance is indicated by asterisks (* p<0.05, ** 
p<0.01, *** p<0.001). 
In response to treatment with 10 mM LiCl, FILIP1L expression is significantly up-
regulated after 2 h and remains stable at 4 and 8 h timepoints. Expression is highest 
after 24 h treatment. In NaCl-treated control cells, FILIP1L expression is not 
significantly altered (except for the 24 h timepoint compared to untreated controls. 
However, FILIP1L expression increases with time, possibly through increased 
confluency.  
There are few known direct target genes for WNT/β-Catenin activation in skin. We 
investigated the expression of the WNT/β-Catenin target genes AXIN2 [262], CCND1 
(Cyclin D1) [263] and MYC [264] (Figure 45, Figure 46 and Figure 47). The 
expression of AXIN2 is increased in NaCl controls after 2 and 4 h but is significantly 
up-regulated after 8 and 24 h of NaCl treatment in comparison to untreated controls. 
Upon treatment with LiCl, AXIN2 expression is significantly increased compared to 
NaCl controls at all time points. Although AXIN2 is a known target gene of the 
WNT/β-Catenin signalling pathway, we do not have evidence, that this is through this 




Figure 45: Expression of AXIN2 after stimulation of WNT/β-Catenin signalling with 10 mM LiCl. 
Results represent the quantification results from immunoblots and three biological replicates. AXIN2 
expression is not affected by NaCl controls at 2 and 4 h but is up-regulated after 8 and 24 h compared 
to untreated controls. Compared to NaCl controls, expression of AXIN2 is significantly up-regulated 
at all timepoints. This suggests that WNT/β-Catenin activation with LiCl increases AXIN2 expression. 
Significance is indicated by asterisks (* p<0.05, ** p<0.01, *** p<0.001). 
 CCND1 (Cyclin D1) is up-regulated upon WNT/β-Catenin activation in various 
tissues [263]. In NTERT cells, there are no significant changes in CCND1 expression 
after 2 and 4 h of LiCl or NaCl treatment (Figure 46). After 8 and 24 h, CCND1 
expression is significantly increased in NaCl controls compared to untreated control. 
At the 8 and 24 h timepoints, LiCl treatment has no significant effect on CCND1 
expression. There is no clear pattern of CCND1 expression changes after treatment 
with LiCl, suggesting that CCND1 may not be a suitable WNT/β-Catenin reporter 





Figure 46: Expression of CCND1 after stimulation of WNT/β-Catenin signalling with 10 mM 
LiCl. Results represent the quantification results from immunoblots and three biological replicates. 
There is no clear pattern of CCDN1 expression changes in response to LiCl stimulation. At 2 and 4 h, 
no significant changes can be observed, but CCDN1 expression is significantly increased in NaCl 
controls compared to untreated controls after 8 and 24 h. No significant changes between NaCl controls 
and LiCl treatments were detected. Significance is indicated by asterisks (* p<0.05, ** p<0.01, *** 
p<0.001). 
Similar to CCND1, MYC can be used as a WNT/β-Catenin reporter. While there is an 
increase in MYC expression at all timepoints in NaCl controls compared to untreated 
controls, the increase is not significant. LiCl treatment non-significantly reduces MYC 
expression at 2 h and significantly after 4, 8 and 24 h (Figure 47). This suggests, that 





Figure 47: Expression of MYC after stimulation of WNT/β-Catenin signalling with 10 mM LiCl. 
Results represent the quantification results from immunoblots and three biological replicates. 
Expression of MYC is not significantly affected in the NaCl controls compared to untreated controls. 
However, there is a tendency for increased MYC expression at later timepoints. At 4, 8 and 24 h, MYC 
expression is significantly decreased compared to NaCl controls, suggesting WNT/β-Catenin activation 
with LiCl reduces MYC expression. Significance is indicated by asterisks (* p<0.05, ** p<0.01, *** 
p<0.001). 
3.8.4 FILIP1L levels do not correlate with markers of WNT/β-Catenin activity 
It was interesting to see that the expression of FILIP1L and AXIN2 was increased after 
treatment with LiCl (Figure 44). To investigate, if FILIP1L expression influences the 
expression of  the WNT/β-Catenin signalling target genes AXIN2 and MYC, we 
performed FILIP1L siRNA knock-down in NTERT cells and examined the  AXIN2 






Figure 48: Representative blot of markers of WNT/β-Catenin activity in NTERT cells. FILIP1L 
siRNA knock-down decrease FILIP1L protein levels at all timepoints. AXIN2 levels increase at all 
timepoints, while MYC levels appear to be unaffected by FILIP1L knock-down. This suggest, that 
FILIP1L knock-down activates WNT/β-Catenin signalling in NTERT cells, therefore increasing 
expression of target genes, such as AXIN2. 
Unfortunately, we were unable to achieve a complete knock-down of FILIP1L in 
NTERT cells. As shown in Figure 32 and Figure 49 A, the FILIP1L protein levels are 
markedly reduced in siRNA-transfected cells compare to scrambled siRNA-
transfected control cells (CTL) at 24, 48 and 72 h post-transfection. The reduction is 
not statistically significant, most likely due to the small sample size and large 
variations between experiments. The AXIN2 protein levels are increased in siRNA-
transfected cell compared to control cells after 24, 48 and 72 h of transfection (see 
Figure 49 B). Similar to FILIP1L results, the increase is not statistically significant. 
Nonetheless, there is a clear trend in AXIN2 levels increasing when FILIP1l is 
knocked down and cells are treated with LiCl. MYC protein levels do not change with 
FILIP1L siRNA knock-down. Western blots for the above mentioned figures can be 




Figure 49: A: FILIP1L protein levels in NTERT cells after transfection with either non-targeting 
siRNA (CTL) or siRNA pool targeting FILIP1L (siRNA) after 24, 48 and 72 h post transfection. 
FILIP1L protein levels are reduced in siRNA transfected cells, but reduction is non-significant due to 
inter experimental variation. B: AXIN2 and MYC protein levels after transfection with either non-
targeting siRNA (CTL) or siRNA pool targeting FILIP1L (siRNA) after 24, 48 and 72 h post 
transfection. Contrary to FILIP1L, AXIN2 protein levels increase in siRNA transfected cells. Results 
represent the quantification results from immunoblots and three biological replicates. 
3.8.5 FILIP1L knock-down does not affect nuclear levels of β-Catenin in NTERT 
cells 
As shown in Figure 49, siRNA knock-down of FILIP1L induces AXIN2 protein 
expression in NTERT cells, although this effect was not statistically significant. A 
more direct approach to access WNT/β-Catenin signalling activity is to determine the 
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nuclear levels of unphosphorylated β-Catenin, as this is the factor that drives 
transcription with the help of the co-activators T-Cell Factor (TCF) or lymphoid 
enhancer factor (LEF). We performed siRNA knock-down of FILIP1L in NTERT 
cells. The nuclear and cytoplasmic fractions were then separated (as described in 
Section 2.7) and the levels of FILIP1L, unphosphorylated (active) β-Catenin as well 
as nuclear and cytoplasmic loading controls Histone H3 and α-Tubulin were measured 
using immunoblotting. The results are displayed in Figure 50 and Figure 51. 
 
Figure 50: Representative blot of nuclear and cytoplasmic levels of FILIP1L and active β-Catenin. 
FILIP1L protein is predominantly located in the nucleus. Knock-down of FILIP1L using siRNA 
reduces nuclear protein levels but has no effect on the cytoplasmic fraction. As FILIP1L, β-Catenin is 
located in the nucleus. FILIP1L knock-down is slightly increasing nuclear β-Catenin.  
The majority of FILIP1L protein is located in the nucleus and significantly reduced in 
siRNA-treated cells compared to controls, indicating that the siRNA knock-down was 
successful. In the cytoplasm, FILIP1L levels do not change. As expected, active 
β-Catenin is almost exclusively located in the nucleus. In other cell origins, such as 
prostate, ovarian or lung, FILIP1L controls β-Catenin stability by aiding its 
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destruction. In NTERT cells, FILIP1L knock-down does not significantly increase 
nuclear β-Catenin levels.  
 
Figure 51: Quantification of blot shown in Figure 50 and independent repetition of the 
experiment. Results represent the quantification results from immunoblots and three biological 
replicates. FILIP1L protein levels significantly decrease after transfection with siRNA after 48 h in the 
nuclear fraction, but there is no effect on cytoplasmic FILIP1L levels. There is a slight increase in 
nuclear levels of active β-Catenin, but significance was not reached (p=0.1845), suggesting that factors 
other than FILIP1L are more important in controlling WNT/ β-Catenin signalling in NTERT cells. 
Significance testing was performed on 3 individual experiments and is indicated by asterisks (* p<0.05, 





3.8.6 Functional significance of FILIP1L in cSCC cells 
In order to investigate the functional significance of FILIP1L levels, we decided to 
knock-down or re-express FILIP1L in IC1 met and IC1 cells respectively. IC1 met 
cells express FILIP1L at a level similar to NHK cells, while IC1 cells have reduced 
FILIP1L levels. Both cell lines are derived from the same donor. IC1 represents the 
primary tumor, while IC1 met cells come from a metastasis. 
The coding sequence for FILIP1L isoform 203 was cloned into a standard pcDNA 
vector under control of a T7 promoter. The identity of the plasmid and the correct 
sequence and positioning of the FILIP1L insert were confirmed by sequencing with 
the help of the Tayside Centre for Genomic Analysis. As siRNA knock-down of 
FILIP1L in NTERT cells using an siRNA pool was only about 50% effective, we used 
pools of individual siRNAs and additional siRNAs in order to knock-down FILIP1L 
more efficiently IC1 cell line  
3.8.6.1 Overexpression of FILIP1L in IC1 met cells 
Expression and protein levels of FILIP1L are reduced in the human cSCC cell line IC1 
compared to NTERT cells and normal human keratinocytes (see Figure 43). Using 
the protocol described in Section 2.6.7, we aimed to over-express FILIP1L in IC1 
cells. The results are displayed in Figure 52.  Untreated (UT) IC1 cells have low 
FILIP1L levels. However, there is a significant 3-fold increase in FILIP1L protein 
expression after transfection, even in empty vector (EV) controls. Transfection for 
48 h with vector containing FILIP1L significantly increases FILIP1L protein 
compared to EV, with expression being highest when using 2 µg plasmid. Expression 
does not differ between empty vector controls and FILIP1L containing plasmid after 
72 h of transfection. However, FILIP1L protein levels are significantly higher 
compared to untreated control. This suggests, that the transfection procedure by itself 
induces FILIP1L expression. Although FILIP1L levels are further and significantly 
increased when transfection is carried out with FILIP1L expression vector, the 
increase in EV controls disqualifies overexpression of FILIP1L in IC1 cells from 
further investigating the functional significance of FILIP1L in this cell line. Additional 
means of IC1 transfection were tested, however neither resulted in a sufficient 
transfection efficiency while also not causing increased expression of FILIP1L in 




Figure 52: A: Representative blot of FILIP1L overexpression in IC1 cells. FILIP1L protein levels 
are increased in empty vector (EV) controls compared to untreated (UT) control after 48 h. In cells 
transfected with FILIP1L expression vector, FILIP1L levels further increase at the 48 h timepoint. After 
72 h, FILIP1L is increased in EV controls compared to UT controls, but there is no further increase in 
cells transfected with FILIP1L expression vector. B: Quantification of FILIP1L overexpression 
experiments (three biological replicates). Compared to UT controls, FILIP1L levels are significantly 
higher in EV controls after both, 48 and 72 h, suggesting that the transfection procedure alone induces 
FILIP1L expression. Although FILIP1L protein levels significantly increase in cells transfected with 
FILIP1L expression vector after 48 h, the protocol is not suitable to investigate the functional 
significance of FILIP1L in IC1 cells. Significance is indicated by asterisks (* p<0.05, ** p<0.01, *** 
p<0.001). 
3.8.6.2 siRNA knock-down of FILIP1L in IC1 met cells 
The expression and protein levels of FILIP1L in IC1 met cells are comparable to 
NTERT cells and normal human keratinocytes (see Figure 43). FILIP1L was 
knocked-down in IC1 met cells using siRNA, as described in Section 2.6.6. The 
results are shown in Figure 53. FIIP1L siRNA knockdown in IC1 met cells is 
successful, using either siRNA 1 or a combination of siRNAs 2 and 3 from the smart 
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pool. Similar to IC1 cells, treatment with transfection agents up-regulates FILIP1L 
expression (data not shown) in IC1 met cells, suggesting, that FILIP1L expression 
could be a response to agents that weaken cell membranes. Nevertheless, siRNA 
knock-down is sufficient to compensate for the effect. 
 
Figure 53: FILIP1L siRNA knock-down in IC1 met cells. FILIP1L protein levels are markedly 
reduced in FILIP1L targeting siRNA transfected cells compare to non-targeting control (CTL). 
Having established a working protocol to knock-down FILIP1L in IC1 met cells, we 
tested if FILIP1L knock-down in this cell line affects the levels of active and total β-
catenin and therefore WNT/β-catenin signalling activity. The results are displayed in 
Figure 54.  
FILIP1L protein levels are significantly reduced in IC1 met cells after 48 and 72 h of 
transfection with targeting siRNA compared to non-targeting controls (CTL). The 






Figure 54: Representative blot of FILIP1L, Vimentin as well as total and active β-catenin in IC1 
met cell, transfected with siRNA targeting FILIP1L. FILIP1L knock-down was successful. The 
high levels of Vimentin confer that the tested cells are IC1 met cells and not feeder fibroblasts. The 
change in total and active β-catenin appear to very little. 
Total β-catenin levels do not change after 48 h of FILIP1L knockdown compared to 
controls (CTL). However, after 72 h, there is a significant decrease in total β-catenin 
levels. Interestingly, the decrease is more pronounced in IC1 cells transfected with 
siRNA 1 although FILIP1L levels are lower in cells transfected with siRNAs 2 and 3, 
suggesting there is no direct correlation between FILIP1L and total levels of β-catenin. 
In contrast to total β-catenin, active β-catenin levels are significantly reduced in IC1 
met cells after 48 h of FILIP1L siRNA knock-down. This is the opposite of what we 
would expect if FILIP1L would negatively regulate WNT/β-catenin signalling. After 
72 h of FILIP1L knock-down, while total β-catenin levels are significantly reduced, 
active β-catenin levels significantly increase. There is no clear pattern of the 





Figure 55: Quantification of FILIP1L protein levels in IC1 met cells after knock-down of 
FILIP1L after 48 and 72 h. Results represent the quantification results from immunoblots and three 
biological replicates. FILIP1L protein levels are significantly reduced after 48 and 72 h. Significance 




Figure 56: Quantification of total and active β-catenin in IC1 met cells transfected with siRNA 
targeting FILIP1L or non-targeting siRNA control (CTL). Results represent the quantification 
results from immunoblots and three biological replicates. Total β-catenin levels do not significantly 
change after 48 h of siRNA treatment. However, total β-catenin levels are significantly lower after 72 
h of FILIP1L knock-down. In contrast to total β-catenin, active β-catenin levels significantly decrease 
after 48 h of FILIP1L knock-down. This is the opposite of what is expected, if FILIP1L would 
negatively regulate WNT/ β-catenin in IC1 met cells. However, active β-catenin levels significantly 
increase after 72 h of FILIP1L knock-down. There is no clear pattern how or if FILIP1L is influencing 
total and active β-catenin levels in IC1 met cells. Significance is indicated by asterisks (* p<0.05, ** 




Next, we investigated if FILIP1L knock-down has an effect on the behaviour of the 
cells. IC1 met cells were plated into 6 well plates at 5*105 cells/well and reverse 
transfected with either siRNA targeting FILIP1L, non-targeting control siRNA or 
were left untreated. The efficacy of FILIP1L knockdown was ensured in control 
experiment, using the same transfection mix as used in the proliferation experiment. 
Cell confluency was then measured over the course of 96 h using the IncuCyte 
(Satorius) imaging system as described in Section 2.6.9. The results are displayed in 
Figure 57. 
 
Figure 57: Measurement of confluency of IC1 met cells transfected with non-targeting siRNA 
(CTL) of siRNA targeting FILIP1L (siRNA 1 and 2+3) of untreated (UT) cells as a measurement 
of cell proliferation. Results represent the means and standard deviations from three biological 
replicates. No difference in confluency between FILIP1L knock-down and controls was observed. 
Untreated cells tended to have a higher confluency, but the effect was not significant.  
Untreated IC1 met cells show similar percentages of confluency compared to non-
targeting siRNA controls (CTL). Overall, the confluency did not significantly differ 
among any of the treatments. This suggests, that FILIP1L knock-down has no effect 




We next assessed the viability of IC1 met cells after FILIP1L knock-down using 
Alamar Blue reagent. The results are displayed in Figure 58. 
 
Figure 58: Cell viability of IC1 met cells after 24, 48, 72 and 92 h of siRNA mediated FILIP1L 
knock-down. Results represent the means and standard deviations from three biological replicates. Cell 
viability is reduced in transfected cells compared to untreated (UT) cells. FILIP1L knock-down does 
not affect cell viability after 24, 48 and 72 h compared to non-targeting controls (CTL). However, IC1 
met viability is significantly lower in FILIP1L knock-down cells compared to CTL after 96 h. 
Significance is indicated by asterisks (* p<0.05, ** p<0.01, *** p<0.001). 
In contrast to proliferation, as measured by cell confluency (see Figure 57), cell 
viability is significantly reduced in IC1 met cells transfected with siRNA, regardless 
of the FILIP1L expression status. Cell viability is not affected by FILIP1L knock-
down after 24, 48 and 72 h. However, cell viability significantly decreases in FILIP1L 
knock-down cells after 96 h of siRNA knock-down, although the effect is smaller in 
comparison to the much more pronounced decrease in cell viability between untreated 




Taken together, FILIP1L knock-down has no clear effect on WNT/ β-catenin signaling 
in IC1 met cells and no effect on proliferation as measured by confluency. There was 
no effect on IC1 met viability after 24, 48 and 72 h of FILIP1L knock-down. However, 
a significant reduction of cell viability was observed after 96 h of knock-down, but 
this effect was small in comparison to the reduction observed between untreated and 


















4.1 DNA methylation in solar simulated UV induced cSCC 
The first goal of the work presented in this thesis was to characterize the methylome 
of murine cSCC tumors, generated by chronic exposure to solar simulated UV 
radiation. 
There were frequent mutations in Tet genes that facilitate DNA demethylation. This 
led us to hypothesise, that there could be changes in the distribution of 5hmC. 
Therefore, we chose oxidative RRBS, a methodology that allows for analysis of both 
5mC and 5hmC. Unfortunately, during analysis of the oxRRBS data it became clear, 
that the amount of detected 5hmC was not sufficient to distinguish it from data noise. 
Therefore, we cannot draw any conclusions if mutations in the Tet genes have an effect 
on the methylation landscape of mouse ssUV cSCC. Recently, in addition to being a 
by-product DNA demethylation by TET proteins, 5hmC has been shown to regulate 
many cellular and developmental processes (e.g. pluripotency of stem cells and 
tumorigenesis, summarized in [265]). The high turnover of skin cells and therefore 
quick passive removal of 5hmC may be the reason we only detected very low amounts 
of 5hmC. It would be interesting to see how 5hmC levels change in response to the 
mutations in Tet genes in skin. This would require creating e.g. Kera308 cell lines with 
inducible CRISPR and sgRNAs targeting the Tet genes and monitor the changes with 
oxRRBS or pull-down of 5hmC rich DNA using 5hmC antibodies with subsequent 
sequencing. Additionally, the global changes in 5hmC content could be measured 
using a 5hmC ELISA assay. 
It has been suggested, that UVR leads to an increase in global DNA methylation in 
both irradiated mouse skin as well as cell lines. Because the used methodology 
(RRBS) induces bias as the method enriches for regions of medium to high CpG 
density and excludes large parts of the genome (e.g. open sea regions with low CpG 
density), analysis of the global content of 5mC was not possible. Analysis of the 
subfraction of the genome covered by our method, we found that methylation was 
significantly higher in tumors, consistent with previously published data. 
Unfortunately, a colorimetric ELISA assay to determine the global levels of 5mC in 




Analysis of genomic features, such as TSS activity, transcription factor binding sites 
and CAGE seq, at differentially methylated regions revealed that most DMRs 
colocalize with regions of potential regulatory function. This suggests that the 
methylation changes in mouse ssUV cSCC are important for cancer development or 
progression. In cSCC, most mutations do not occur within oncogenes, but within 
tumor suppressor genes. Our findings highlight, that in addition to mutations, changes 
in DNA methylation could have a crucial role in silencing of tumor suppressor genes 
in cSCC. This is supported by the significant increase in average methylation in the 
murine tumors. RRBS enriches for CGI and most CGIs (especially at promoter 
regions) are unmethylated in normal cells. It is possible that the increase in average 
methylation across the analysed CGIs could indicate that the corresponding genes are 
silenced via DNA methylation. The importance of silencing of tumor suppressor genes 
is critical when considering potential therapeutic approaches. Oncogenes often have 
similar functions across all tissues of the body. For example, receptor tyrosine kinases 
are cell surface proteins that sense growth stimulating signals in many cell types. By 
contrast, tumor suppressor genes often have cell-specific roles and may be better 
candidates for treatment, especially in cSCC where many tumor suppressors are 
involved in cancer progression. 
Although we show that DMRs often can be found at regions of potential regulatory 
function, we did not actually investigate if the regions have indeed regulatory function. 
Unrevealing the function of differentially methylated regions can be challenging. We 
do not have sufficient understanding how cells ‘decide’ which CGIs they methylate, 
and which regulatory elements should be silenced by DNA methylation. In the past, 
investigating the function of distinct DMRs involved treating cells with drugs that 
inhibit DNA methyl transferases (DNMT), such as 5- azacytidine, that result in DNA 
demethylation on a genome wide scale and then accessing expression changes of the 
gene of interest (or transcriptome analysis). However, reducing DNA methylation 
using DNMT inhibitors leads to demethylation of a multitude of regulatory elements 
and activation of normally silenced transcription start sites and therefore does not 
allow for functional assessment of a single region. Furthermore, DNA methylation in 
cell lines tends to be rather stable at certain regions. More recently, methods have been 
developed to modulate DNA methylation in a targeted manner. The most promising 
is using the CRISPR-Cas9 system. By fusing a dead Cas9 enzyme with DNMT or 
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TET enzymes, it is possible to methylate or demethylate DNA at a specific locus. 
However, this technology has not been extensively used and it is unsuitable to change 
methylation at larger regions. It would be interesting to change methylation at selected 
regions of proposed regulatory function, especially the Filip1l locus, and observe the 
effects on gene expression. This would allow us to further elucidate the role of DNA 
methylation changes in cSCC.  
A second goal of this work was to compare methylation in the ssUV cSCC with 
methylation in human cSCC. We compared general features of the human and mouse 
cSCC methylome such as average/global methylation. While initially we did not find 
a difference in global methylation between normal and neoplastic human skin, when 
we grouped the data by Rodriguez-Paredes et al. into control, keratinocyte like and 
stem cell like, global methylation was significantly higher in the stem cell like 
samples. The RRBS method we used does not cover the whole genome, therefore we 
were not able to draw conclusions on genome wide DNA methylation levels. The 
Infinium 850K array, used by Rodriguez-Paredes et al., covers a much larger portion 
of the genome and our analysis of the data found a significant increase in global DNA 
methylation in stem cell like cSCCs. We have performed an assay to determine the 
global DNA methylation levels in the murine ssUV cSCCs and controls, the human 
cSCC cell line panel and NHKs as well as human cSCCs and normal skin. 
Unfortunately, this assay did not produce reliable data. Repeating the experiment or 
using an equivalent assay, will be crucial to validate if global methylation levels 
increase in murine ssUV cSCC, as suggested by the RRBS analysis, and allow further 
comparison of the mouse ssUV cSCC model to human cSCCs. 
One of the most important findings by Rodriguez-Paredes et al. was the identification 
of two sub-types of human AK and cSCC, one keratinocyte like and one stem cell like. 
The differentiation was mainly made by analysing the methylation at the keratin gene 
cluster. Unfortunately, the mouse keratin genes were not sufficiently covered by 
RRBS in our dataset. It would be very interesting, if these two subclasses also exist in 
mouse ssUV cSCC. Investigating this would probably include targeted bisulfite 
sequencing of the mouse keratin clusters. Furthermore, including more tumor samples 
as well as chronically irradiated AK-like mouse skin would be crucial. This could 
further validate the ssUV cSCC model. 
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The differences in the method used by Rodriguez-Paredes et al. and us to investigate 
DNA methylation make it difficult to directly compare methylation at specific regions. 
We chose to compare the genes in both datasets, that either contain at least one 
significantly differentially methylated probe (Rodriguez-Paredes et al.) and at least 
one significantly methylated CpG (oxRRBS). In our data, these criteria were met by 
214 genes, 153 of the genes had a human ortholog. A staggering 150 of those genes 
(98%) were also differentially methylated in human cSCC. The remarkable 
similarities in the methylomes of human and ssUV cSCC suggest that the ssUV cSCC 
model, in addition to histopathology and genetics, is similar to human cSCC on the 
DNA methylation level and may be advantageous over other preclinical models. It 
would be interesting, to analyse the ssUV cSCC in more detail, for example by using 
WGBS instead of RRBS. This would allow for a more detailed comparison of the 
ssUV cSCC methylome to the human cSCC methylome. Rodriguez-Paredes et al. used 
the Infinium 850k array and ideally, the same methodology should be used in order to 
allow for the best possible comparison. Unfortunately, the Infinium arrays are 
designed for humans and usage for murine samples is limited. 
4.2 Filamin A interacting protein 1 like 
The top hit in our CpG and DMR analyses was an intronic region of the Filip1l gene. 
Filip1l is an interesting new tumor suppressor gene that has never been investigated 
in skin. In mice, the Filip1l gene encodes for 3 isoforms.  
Unfortunately, we were not able to validate the Filip1l intronic methylation in an 
independent sample set using MassARRAY because we were not able to amplify the 
region with sufficient quality. Design of new primers, possibly at the minus strand, 
could solve the amplification problems. However, MassARRAY revealed, that 
although in human, methylation at the FILIP1L promoter CGI controls FILIP1L 
expression, the promoter is virtually unmethylated in mouse control skin as well as 
tumors. 
For the first time, we have shown that Filip1l isoform 202 is the main expressed 
isoform in the murine skin. Remarkably, Filip1l isoform 202 is very similar (91% 
identity) to human isoform 203, the functional isoform in humans. Our first efforts to 
compare Filip1l expression in murine skin and cSCC tumors by qPCR was not 
successful due to problems with finding a suitable reference gene. However, the 
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analysis of the Filip1l protein levels by immunoblotting revealed that the protein is 
significantly down-regulated in murine cSCC tumors compared to VS control tissue. 
The function of Filip1l is incompletely understood. The strongest evidence points to a 
role in regulating β-catenin stability and Wnt/β-catenin signalling. To test if Wnt/β-
catenin signalling is dysregulated in the mouse cSCC, we examined the ratios between 
the active form of β-catenin and the total β-catenin levels. These ratios were lower in 
the majority of tumor samples compared to VS controls (12 out of 18 animals, 67%) 
and higher in 5 animals (28%), while no correlation between Filip1l levels and 
β-catenin ratios could be detected. While down-regulation of Filip1l is a common 
feature of UV radiation-induced murine cSCC, up-regulation of the Wnt/β-catenin 
signalling is not. This suggests, that in contrast to other tumor types, Filip1l does not 
regulate Wnt/β-catenin signalling in murine cSCC. 
In humans, the FILIP1L gene encodes for 8 isoforms. It is assumed, that isoform 203 
is the main isoform. Nothing is known about the FILIP1L isoform expression pattern 
and if different FILIP1L isoforms serve different biological function. The majority of 
functional data on FILIP1L has focused on its role in modulating the WNT/β-catenin 
signalling pathway. FILIP1L has been shown to facilitate the destruction of β-catenin 
and therefore supress canonical WNT/β-catenin signalling, but the exact mechanism 
remains unknown. 
In various cancers, such as ovarian, prostate and pancreatic cancer, FILIP1L 
expression is controlled by promoter methylation, with hypermethylation silencing 
FILIP1L expression in the cancers. We tested 8 human cSCC cell lines and found 
promoter hypermethylation in 2 using MassARRAY. However, there was no clear 
inverse correlation between promoter methylation and FILIP1L expression levels. 
Furthermore, the promoter was lowly methylated in 14 human cSCC samples. 
Together this suggests, that unknown factors other than promoter methylation control 
FILIP1L expression in human cSCC. 
We investigated both the levels of FILIP1L and its isoform composition in a panel of 
15 human  cSCC cell lines as well as normal human keratinocytes (NHK). We found 
that FILIP1L isoform 203 is the main expressed isoform in all cell lines with other 
isoform’s expression varying between cell lines. Furthermore, FILIP1L expression 
was reduced in 9 out of 15 cSCC cell lines compared to NHKs. For the first time, we 
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have shown that FILIP1L isoform 203 is the main expressed isoform in human skin. 
In fact, this thesis, to our knowledge, is the first investigation if FILIP1L in skin.  
We chose the immortalized keratinocyte cell line NTERT to investigate the function 
of FILIP1L in human skin. Both the levels and the isoform composition of FILIP1L 
were similar in NTERT cells compared to NHK cultures. When we treated NTERT 
cells with LiCl, a GSK3β inhibitor, this resulted in induction of FILIP1L expression 
and induced expression of the WNT/β-catenin target gene AXIN2. However, we do 
not have evidence that this induction is through activation of the WNT/β-catenin 
pathway. Knock-down of FILIP1L using siRNA did not induce AXIN2 expression in 
NTERT cells. Furthermore, FILIP1L knock-down did not affect the levels of active 
β-catenin in the nucleus, but the efficiency of the knock-down was only about 50% 
and the variation between repetitions of experiments was high. Establishing a better 
knock-down, a more reliable supply of cells and reducing variations would be required 
to draw definitive conclusions. 
We chose to investigate the role of FILIP1L using the human cSCC cell lines IC1 and 
IC1 met. While IC1 was derived from a primary tumor and FILIP1L expression is low 
(compared to NHKs) in this cell line, IC1 met is from a metastasis of the same patient 
and has normal levels of FILIP1L expression. We cloned the coding sequence for 
FILIP1L isoform 203 into a pcDNA3.1 expression vector. Unfortunately, when we 
transfected IC1 cells with the pcDNA vector, FILIP1L expression was significantly 
induced in empty vector controls, suggesting, that the transfection procedure alone is 
inducing FILIP1L expression. This is supported by the fact, that transfection of IC1 
met cells with siRNA is also slightly inducing FILIP1L. While reducing the amount 
of transfection reagent (Lipofectamine 3000) did reduce FILIP1L induction, 
transfection efficiency was not sufficient. We also tested other transfection reagents, 
but the results were similar. 
Knock-down of FILIP1L in IC1 met cells was successful and efficiency was higher 
than in NTERT cells (90% compared to 50%). However, FILIP1L knock-down did 
not lead to a significant increase in the levels of active β-catenin in IC1 met cells. This 
suggests, that FILIP1L does not control WNT/β-catenin signalling in skin or that other 
factors have a bigger role. 
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Last, we tested the effect of FILIP1L knock-down on the proliferation of IC1 met cells, 
using confluency measurements with the IncuCyte imaging system. FILIP1L knock-
down had no effect on IC1 met proliferation, suggesting that in contrast to e.g. ovarian 






In this study, we present a comprehensive analysis of DNA methylation in mouse 
cSCC and propose, that the most significant changes occur at regions of regulatory 
importance. Remarkably, the changes in the methylome of murine cSCC show high 
degrees of similarity to human cSCC in terms of both general features and the genes 
affected. Therefore, we conclude that the murine cSCC model developed in our lab 
recapitulates human cSCC, as shown by the remarkable similarities in histopathology, 
mutation spectrum and DNA methylation. The model may be advantageous over other 
currently used preclinical models. 
FILIP1L is a novel tumor suppressor gene that is potentially involved in 
WNT/β-catenin signalling. Especially in ovarian cancer, FILIP1L is an important 
regulator of aggressiveness and an independent prognostic marker. We found the 
Filip1l gene to be differentially methylated in ssUV cSCC, and the Filip1l protein to 
be down-regulated in the tumors compared to control skin. Furthermore, FILIP1L 
expression and protein levels are reduced in 9 out of 15 of the tested human cSCC cell 
lines. However, we did not find evidence, that FILIP1L regulates WNT/β-catenin 
signalling in skin. Further investigation will be necessary to determine if down-
regulation of FILIP1L is important in human cSCC and which pathways are involved. 
Evidence is increasing that in cSCC, inactivation of tumor suppressor genes plays a 
major role. The mutation burden of completely normal appearing skin can exceed that 
of aggressive cancers in other tissues, suggesting that skin is especially resilient to 
mutations in oncogenes. Silencing of tumor suppressor genes is frequently mediated 
by DNA hypermethylation of tumor suppressor promoters and other regulatory 
elements. In this work, we provide evidence that tumor suppressor genes, e.g. 
FILIP1L, can be silenced by DNA methylation in cSCC. Epigenetic regulation of gene 
expression plays a major role in cSCC. For example, cSCC cells are very sensitive to 
drugs that target histone deacetylase and histone demethylase [266]. Targeting DNA 
methylation in cSCC may have similar effects and could provide new approaches for 














5.1 In silico bisulfite conversion macro for word 
The in silico BS conversion macro includes a clean-up function to remove unnecessary 
characters and line breaks. It was kindly provided by the Division of Epigenetics and 
Cancer Risk Factors of the German Cancer Research Center. 
Sub AUTOEXEC() 
    Set MYBAR = CommandBars _ 
    .Add(Name:="CpG", Position:=msoBarFloating, TEMPORARY:=True) 
    MYBAR.Visible = True 
    MYBAR.Left = 1000 
    MYBAR.Top = 130 
     
    Set CLEANUPBUTTON = MYBAR.Controls _ 
    .Add(Type:=msoControlButton) 
    CLEANUPBUTTON.OnAction = "CLEANUP" 
    CLEANUPBUTTON.TooltipText = "Clean up sequence" 
    CLEANUPBUTTON.FaceId = 2174 
     
    Set REVCOMPBUTTON = MYBAR.Controls _ 
    .Add(Type:=msoControlButton) 
    REVCOMPBUTTON.OnAction = "REVCOMP" 
    REVCOMPBUTTON.TooltipText = "Reverse complement" 
    REVCOMPBUTTON.FaceId = 1977 
     
    Set BISTREATBUTTON = MYBAR.Controls _ 
    .Add(Type:=msoControlButton) 
    BISTREATBUTTON.OnAction = "BISTREAT" 
    BISTREATBUTTON.TooltipText = "Bisulfite treatment" 
    BISTREATBUTTON.FaceId = 625 
End Sub 
Sub CLEANUP() 
    With Selection.Font 
        .Name = "COURIER" 
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        .AllCaps = True 
    End With 
    Selection.Find.ClearFormatting 
    Selection.Find.Replacement.ClearFormatting 
    With Selection.Find 
        .Text = "^p" 
        .Replacement.Text = "" 
        .Forward = True 
        .Wrap = wdFindStop 
        .Format = False 
        .MatchCase = False 
        .MatchWholeWord = False 
        .MatchWildcards = False 
        .MatchSoundsLike = False 
        .MatchAllWordForms = False 
    End With 
    Selection.Find.Execute Replace:=wdReplaceAll 
    With Selection.Find 
        .Text = "^t" 
        .Replacement.Text = "" 
        .Forward = True 
        .Wrap = wdFindStop 
        .Format = False 
        .MatchCase = False 
        .MatchWholeWord = False 
        .MatchWildcards = False 
        .MatchSoundsLike = False 
        .MatchAllWordForms = False 
    End With 
    Selection.Find.Execute Replace:=wdReplaceAll 
    With Selection.Find 
        .Text = "^#" 
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        .Replacement.Text = "" 
        .Forward = True 
        .Wrap = wdFindStop 
        .Format = False 
        .MatchCase = False 
        .MatchWholeWord = False 
        .MatchWildcards = False 
        .MatchSoundsLike = False 
        .MatchAllWordForms = False 
    End With 
    Selection.Find.Execute Replace:=wdReplaceAll 
    With Selection.Find 
        .Text = " " 
        .Replacement.Text = "" 
        .Forward = True 
        .Wrap = wdFindStop 
        .Format = False 
        .MatchCase = False 
        .MatchWholeWord = False 
        .MatchWildcards = False 
        .MatchSoundsLike = False 
        .MatchAllWordForms = False 
    End With 
    Selection.Find.Execute Replace:=wdReplaceAll 
End Sub 
Sub REVCOMP() 
    Dim STARTSTRING 
    Dim ENDSTRING 
    Dim THISBASE 
    STARTSTRING = UCase(Selection.Text) 
    For BASEPOSITION = Len(STARTSTRING) To 1 Step -1 
    THISBASE = Mid(STARTSTRING, BASEPOSITION, 1) 
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    Select Case THISBASE 
    Case "A" 
    ENDSTRING = ENDSTRING & "T" 
    Case "T" 
    ENDSTRING = ENDSTRING & "A" 
    Case "C" 
    ENDSTRING = ENDSTRING & "G" 
    Case "G" 
    ENDSTRING = ENDSTRING & "C" 
    Case Else 
    ENDSTRING = ENDSTRING & LCase(THISBASE) 
    End Select 
    Next 
    Selection.Text = ENDSTRING 
End Sub 
Sub BISTREAT() 
    With Selection.Font 
        .Name = "COURIER" 
        .AllCaps = True 
    End With 
    Selection.Find.ClearFormatting 
    Selection.Find.Replacement.ClearFormatting 
    With Selection.Find 
        .Text = "CG" 
        .Replacement.Text = "XG" 
        .Forward = True 
        .Wrap = wdFindStop 
        .Format = False 
        .MatchCase = False 
        .MatchWholeWord = False 
        .MatchWildcards = False 
        .MatchSoundsLike = False 
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        .MatchAllWordForms = False 
    End With 
    Selection.Find.Execute Replace:=wdReplaceAll 
    With Selection.Find 
        .Text = "C" 
        .Replacement.Text = "T" 
        .Forward = True 
        .Wrap = wdFindStop 
        .Format = False 
        .MatchCase = False 
        .MatchWholeWord = False 
        .MatchWildcards = False 
        .MatchSoundsLike = False 
        .MatchAllWordForms = False 
    End With 
    Selection.Find.Execute Replace:=wdReplaceAll 
    With Selection.Find 
        .Text = "XG" 
        .Replacement.Text = "CG" 
        .Forward = True 
        .Wrap = wdFindStop 
        .Format = False 
        .MatchCase = False 
        .MatchWholeWord = False 
        .MatchWildcards = False 
        .MatchSoundsLike = False 
        .MatchAllWordForms = False 
    End With 
    Selection.Find.Execute Replace:=wdReplaceAll 





5.2 NTERT FILIP1L siRNA KD Western blots 
 
Figure 59: NTERT cells, FILIP1L siRNA knock-down. Quantifications see Figure 44: FILIP1L 
levels in NTERT cells treated with 10 mM LiCl, equal amounts of NaCl or were left untreated. 
Results represent the quantification results from immunoblots and three biological replicates. UT: 
Untreated control. LiCl was used to inhibit GSK 3β  FILIP1L levels are up-regulated by LiCl treatment 
after 2 h and are highest after treatment for 24 h. Expression also increases with time, possibly due to 
a response to increased confluency. Significance is indicated by asterisks (* p<0.05, ** p<0.01, *** 
p<0.001).Figure 44, Figure 45, Figure 46, Figure 47.  
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5.3 NTERT FILIP1L siRNA knock-down with LiCl treatment blots 
(preliminary) 
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